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  iiiABSTRACT 
Human enterovirus 71 (HEV71) is a member of the Human Enterovirus A species 
within the Family Picornaviridae.  Since 1997, HEV71 has emerged as a major 
cause of epidemics of hand, foot and mouth disease (HFMD) associated with severe 
neurological disease in the Asia-Pacific region.  At the present time, little is known 
about the pathogenesis of acute neurological disease caused by HEV71.  The major 
aim of this study was to generate infectious cDNA clones of HEV71 and use them as 
tools for investigating the biology of HEV71 and molecular genetics of HEV71 
virulence and pathogenesis.  
 
Two infectious cDNA clones of HEV71 clinical isolates, 26M (genotype B3) and 6F 
(genotype C2) were successfully constructed using a low copy number plasmid 
vector and an appropriate bacterial host.  Transfection of cDNA clones or RNA 
transcripts derived from these clones produced infectious viruses.  Phenotypic 
characterisation of clone-derived viruses (CDV-26M and CDV-6F) was performed, 
and CDV-26M and CDV-6F were found to have indistinguishable phenotypes 
compared to their wild type viruses.  
 
Strains HEV71-26M and HEV71-6F were found to have distinct cell culture growth 
phenotypes.  To identify the genome regions responsible for the growth phenotypes 
of the two strains a series of chimeric viruses were constructed by exchanging the 5′ 
untranslated region (5′ UTR), structural protein (P1), and nonstructural protein (P2 
and P3) gene regions using infectious cDNA clones of both virus strains.  Analysis 
of reciprocal virus chimeras revealed that the 5′ UTR of both strains were compatible 
but not responsible for the observed phenotypes.  Both the P1 and P2-P3 genome 
  ivregions influence the HEV71 growth phenotype in cell culture, phenotype expression 
is dependent on specific P1/P2-P3 combinations and is not reciprocal. 
 
In the previous study, in order to investigate the pathogenesis of HEV71 infection, a 
mouse HEV71 model was developed using a mouse-adapted variant of HEV71-26M.  
Mouse-adapted strain MP-26M caused fore- and/or hindlimb paralysis in mice, 
whereas HEV71-26M-infected mice did not develop clinical signs of infection at any 
virus dose or route of inoculation tested.  In this study, the molecular basis of mouse 
adaptation by HEV71 was identified.  Nucleotide sequence analysis of HEV71-26M 
and MP-26M revealed three point mutations in the open reading frame, each 
resulting in an amino acid substitution in the VP1, VP2 and 2C proteins; no 
mutations were identified in the untranslated regions of the genome.  To determine 
which of the three amino acid mutations were responsible for the adaptation and 
virulence of HEV71-26M in mice, recombinant cDNA clones containing one, or a 
combination of two or three mutations, were constructed.  Mouse virulence assays of 
the mutated viruses clearly demonstrated that a non-conservative amino acid 
substitution (G
710→E) in the capsid protein VP1 alone was sufficient to confer the 
mouse virulence phenotype on HEV71. 
 
In addition, a mouse oral infection model was established in this study.  Oral 
inoculation with the mouse-adapted HEV71 virus, MP-26M, induced fore-or 
hindlimb paralysis in newborn mice in an age- and dose-dependent manner.  As oral 
transmission is the natural route of HEV71 infection, this murine HEV71 oral 
infection model will provide a suitable tool for studying HEV71 pathogenesis, for 
  vdefining neurological determinants, and for testing vaccine efficacy and 
immunogenicity in the future. 
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  xxvCHAPTER ONE 
LITERATURE REVIEW 
1.1  The Picornaviridae and the genus enterovirus 
1.1.1  Classification  
The Picornaviridae is a family of small, non-enveloped viruses with a single-strand, 
positive-sense RNA genome.  Based on biological and genetic properties, this virus 
family is classified into eight genera: enterovirus, apthovirus, cardiovirus, 
hepatovirus, parechovirus, erbovirus, kobuvirus and teschovirus, four of which 
contain human pathogens including the Genus Enterovirus, Parechovirus, Kobuvirus 
and Hepatovirus (Fauquet et al., 2005, Pallansch & Roos, 2007) 
(http://www.picornaviridae.com).  Human enterovirus 71 (HEV71), the subject of 
this thesis, is classified as a member of the Genus Enterovirus.    
 
Enteroviruses are acid stable, retaining activity at pH 3 or lower, and replicate 
primarily in the enteric tract (Racaniello, 2007).  The Genus Enterovirus consists of 
more than 100 serotypes (Hyypia et al., 1997, Pallansch & Roos, 2007) 
(http://www.picornaviridae.com).  Of these, approximately 95 serotypes are human 
pathogens, with a few serotypes infecting cattle, swine and non-human primates 
(Hyypia et al., 1997, Pallansch & Roos, 2007) (http://www.picornaviridae.com).   
Human enteroviruses were originally classified as poliovirus (PV), coxsackievirus A 
(CAV), coxsackievirus B (CBV) and echovirus (E) on the basis of human disease 
and their pathogenicity in experimental animals (Hyypia et al., 1997, Pallansch & 
Roos, 2007).  Polioviruses 1-3, the first human enteroviruses to be identified, are the 
causative agents of paralytic poliomyelitis in humans.  Polioviruses only infect non-
  1human primates causing disease resembling human poliomyelitis (Pallansch & Roos, 
2007).  Coxsackieviruses, first isolated from the faeces of two children with paralysis 
during a poliomyelitis outbreak, are classified into subgroups A and B based on 
characteristic diseases produced in newborn mice; CAVs cause flaccid paralysis and 
CBVs cause spastic paralysis (Hyypia et al., 1997, Pallansch & Roos, 2007).  This 
difference is due to the replication of CAVs in skeletal and heart muscle of infected 
mice while CBV infections involve a wide range of tissues, including the central 
nervous system (Hyypia et al., 1997, Pallansch & Roos, 2007).  Echoviruses were 
first isolated after the introduction of cell culture techniques (Robbins et al., 1951).  
These viruses are unable to infect newborn mice and, at the time of their discovery, 
the association of the viruses with human diseases was not known (Pallansch & 
Roos, 2007).  The designated name ECHO stands for enteric, cytopathogenic, 
human, orphan, which refers to the lack of disease association when echoviruses 
were first identified (Pallansch & Roos, 2007).  Individual strains of human 
enteroviruses were further classified into serotypes by cross-neutralization or cross-
complement fixation, and serial numbers were then given according to the order of 
isolation of serologically distinct isolates (Pallansch & Roos, 2007).  There are three 
serotypes of poliovirus (PV1-3), twenty-one serotypes of coxsackievirus A  (CAV 1-
14, 16-17, 19-22 and 24), six serotypes of coxsackievirus B (CBV 1-6) and twenty 
eight serotypes of echovirus (E1-7, 9, 11-21, 24-27, 29-33) (Pallansch & Roos, 
2007).  
 
However, there were frequent difficulties in assigning enteroviruses into subgroups 
based on their pathogenesis in experimental animals and by serotypic differentiation.  
Thus, the more recent isolates of human enteroviruses have been named with a 
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system of consecutive numbers: EV68, EV69, EV70 and EV71 (Melnick et al., 
1974).  Currently, molecular methods have been used for identification of new 
enterovirus isolates that are untypable using existing neutralizing antisera (Oberste et 
al., 1999, Oberste et al., 2005, Oberste et al., 2007, Oberste et al., 2001).  This 
method is based on a comparison of nucleotide and deduced amino acid sequences of 
the complete capsid protein VP1 and/or the capsid P1 region (Oberste et al., 1999, 
Oberste et al., 2005).  VP1 and P1 sequences contain serotype-specific information 
that can be used for enterovirus identification (Oberste et al., 1999, Oberste et al., 
2005).  The numbered enteroviruses EV73-EV101 were identified based on this 
method (Norder et al., 2003, Oberste et al., 2005, Oberste et al., 2007, Oberste et al., 
2001). 
 
Human enteroviruses have been classified into four species: Human enteroviruses A-
D (HEV-A-D) based primarily on genetic properties (Fauquet et al., 2005, Hyypia et 
al., 1997, Pallansch & Roos, 2007).  Amino acid sequence comparison of the capsid 
protein P1 and individual proteins spanning the whole coding region leads to 
grouping of four genetic clusters among human enteroviruses (Pallansch & Roos, 
2007).  HEV71 is classified as a member of the species HEV-A.  The biological 
significance of the current clustering is still unknown.  An overview of the 
classification of human enteroviruses is outlined in Table 1.1. 
1.1.2  Medical significance of human enteroviruses 
Enterovirus infections are very common and cause a high total number of cases of 
disease worldwide, with a billion or more annually, and an estimated 50 million 
annually in the USA alone (Pallansch & Roos, 2007).  Although most enterovirus4 
Table 1.1  Current genetic classification of human enterovirus 
 
 
Species 
 
 
Number of Serotypes 
 
Name of Members 
 
Human enterovirus A 
 
 
17 
 
Coxsackieviruses A2-A8, A10, A12, A14, A16, Human enteroviruses 71, 76, 
89-92 
 
 
Human enterovirus B 
 
 
56 
 
Coxsackieviruses A9, Coxsackieviruses B1-B6, Echoviruses 1-7, 9, 11-21, 
24-27, 29-33, Human enteroviruses 69, 73-75, 77, 78, 79-88, 93, 97, 98, 100, 
101 
 
 
Human enterovirus C 
 
 
15 
 
Polioviruses 1-3, Coxsackieviruses A1, 11, 13, 17, 19-22, 
Human enteroviruses 95, 96, 99 
 
 
Human enterovirus D 
 
 
3 
 
Human enteroviruses 68, 70, 94 
 
 infections are asymptomatic, enteroviruses can cause a wide range of acute, mild or  
severe  diseases, including mild upper respiratory illness (common cold), non-
specific febrile illness, pleurodynia, aseptic meningitis, encephalitis, acute flaccid 
paralysis (paralytic poliomyelitis), myocarditis, neonatal sepsis-like disease, acute 
haemorrhagic conjunctivitis, herpangina and febrile rash (hand, foot and mouth 
disease) (Pallansch & Roos, 2007).  Moreover, enteroviruses may cause severe 
chronic diseases, including myocarditis and dilated cardiomyopathy, type 1 diabetes 
mellitus and neuromuscular diseases (Pallansch & Roos, 2007).  Apart from the 
especially devastating polioviruses, there are no vaccines available for protection 
against enteroviruses. 
1.1.3  Virion Morphology 
Enterovirus virions are small, spherical in shape and have a diameter of about 30 nm 
(Racaniello, 2007).  Virus particles are composed of a protein shell, with no lipid 
envelope, surrounding the RNA genome (Racaniello, 2007).  The viral capsid is 
icosahedral in symmetry and composed of 60 identical units (protomers).  Each 
protomer consists of one copy of four structural proteins: viral proteins 1 through 4 
(VP1-VP4).  Three of these proteins, VP1-VP3, form the external surface of the 
protein shell; VP4, in conjunction with the amino termini of VP1 and VP2, forms an 
inner surface (Hogle, 2002, Racaniello, 2007).  The three external surface proteins 
have no amino acid sequence homology, but nevertheless share a similar folding 
pattern of a wedge-shape structure made up of an eight-stranded antiparallel β-barrel 
with loops connecting the strands (Hogle, 2002, Racaniello, 2007).  The carboxyl 
termini of these proteins are located on the virion surface, and the amino termini are 
located on the inner surface (Hogle, 2002, Racaniello, 2007).  A protein network 
  5formed by the amino termini of these proteins and VP4 contributes significantly to 
the stability of virions.   
 
The high resolution structures of some picornaviruses, including PV and human 
rhinovirus type 14 (HRV14) were determined by X-ray crystallography and 
cryoelectron microscopy (Hogle et al., 1985, Rossmann et al., 1985).  It has been 
shown that the surface of PV has a prominent star-shaped mesa at the 5-fold axis of 
symmetry, surrounded by a deep canyon and another protrusion at the 3-fold axis 
(Hogle et al., 1985, Rossmann et al., 1985).  The canyon has been identified as the 
receptor-binding site of PV (Belnap et al., 2000, He et al., 2000).  A schematic 
diagram of the picornavirus virion is shown in Figure 1.1.  To date, the high 
resolution structure of HEV71 remains undetermined. 
1.1.4  Genomic structure  
The genome of enteroviruses is a single-stranded, polyadenylated, positive-sense 
RNA of approximately 7-8 kb in size.  Genomic RNA is infectious, and the positive-
sense RNA directly encodes the viral proteins necessary for RNA replication.  The 
RNA genome is covalently linked to a virally encoded 22-amino acid protein, VPg, 
at the 5′ terminus of the genome.  The viral genome contains a single open reading 
frame (ORF), encoding a polyprotein of around 2,200 amino acids, which is co- or 
post-translationally cleaved by viral proteases to yield the mature viral proteins.  The 
polyprotein is divided into three regions, P1, P2 and P3.  The P1 region encodes four 
viral structural proteins, VP1-VP4.  The P2 and P3 regions encode seven non-
structural proteins, 2A-C and 3A-D, involved in RNA replication, polyprotein 
processing and shut-down of host cell protein synthesis.  A common coding order of 
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Figure 1.1  Structure of enterovirus.  (A) High resolution x-ray crystallographic 
structure of the Mahoney strain of type 1, poliovirus.  The star-shaped mesas at the 
five-fold axis, the three-bladed propellers at the threefold axis, two-fold axis, and the 
deep canyon are shown.  (B) Schematic diagram representation of the core structure 
eight-stranded beta-sandwich shared by VP1, VP2 and VP3.  Adapted from 
Racaniello 2007. 
 
 
 
  7enterovirus proteins are the structural genes VP4, VP2, VP3 and VP1, followed by 
the non-structural genes 2A, 2B, 2C, 3A, 3B, 3C and 3D.   
 
The ORF is preceded by a 5′ untranslated region (5′ UTR), and followed by a 3′ 
untranslated region (3′ UTR), and a poly-A tract.  The 5′ UTR of enteroviruses is 
relatively long, approximately 700-800 nucleotides in length (10% of the genome), 
and extensively structured.  It contains a cloverleaf structure followed by an internal 
ribosomal entry site (IRES) element.  The 5′ cloverleaf plays an essential role in the 
initiation of negative-strand RNA synthesis (Andino et al., 1990, Parsley et al., 
1997), while the IRES element has a role in the initiation of translation (Ehrenfeld & 
Teterina, 2002).  The 3′ UTR is also structured but much shorter than the 5′ UTR and 
is approximately 50-90 nucleotides in length (1.5% of the genome).  The 3′ UTR is 
required for efficient initiation of negative-strand RNA synthesis (Todd et al., 1997).  
The genome organization of enteroviruses is shown in Figure 1.2.   
1.1.5  Replication cycle   
Enterovirus replication takes place in the cytoplasm of the host cell.  The first step of 
virus replication is attachment of the virus to its cell receptor, a molecule on the 
surface of the cell to which the virus specifically binds and uses for gaining entry 
into the cell.  Binding to the cell receptor leads to capsid structure reorganization, 
resulting in uncoating and release of the RNA genome into the cytoplasm.  The 
positive-stranded viral RNA genome is then used as a template for translation of 
viral proteins essential for genome replication and the production of new virus 
particles.  The first step of genome replication is the synthesis of a negative-stranded 
intermediate from the positive-stranded RNA template, followed by the production 
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Figure 1.2  Genome structure of enterovirus.  The VPg is covalently linked to the 
5′ end.  A single ORF is preceded by a 5′ untranslated region (5′ UTR), and followed 
by a 3′ untranslated region (3′ UTR), and a poly-A tract.  Following translation into a 
single polyprotein, the coding region is cleaved into P1, P2 and P3 regions.   
Intermediate and final cleavage products are shown.  (Adapted from Racaniello, 
2007).    
 
 
 
 
  9of a positive-stranded RNA genome.  The newly synthesized capsid proteins and 
positive-stranded RNA are assembled to form the mature virion.  The time required 
for a single replication cycle varies from 5 to 10 h (Racaniello, 2007).  Enteroviruses
generally generate cytopathic effects and are cytocidal for vertebrate cells 
(Racaniello, 2007).  The replication cycle of enteroviruses is shown in Figure 1.3. 
1.1.5.1  Entry of virus into cells 
Enterovirus infection is initiated when the virus attaches to a specific receptor on the 
surface of host cells.  The receptors for a number of enteroviruses have been 
identified (Evans & Almond, 1998, Mendelsohn et al., 1989, Racaniello, 2007, 
Shafren et al., 1995, Shafren et al., 1997, Triantafilou et al., 2002, Triantafilou et al., 
1999).  A broad range of cellular receptors are used by members of enteroviruses, 
and some are shared among the members (summarized in Table 1.2).  Some 
enteroviruses, such as PV, utilize only one receptor for both attachment and entry to 
the cells (Mendelsohn et al., 1989).  By contrast, many enteroviruses, such as 
CAV12, have been shown to use a cellular receptor only for virus attachment, 
requiring one or more accessory receptors for entry into cells (Shafren et al., 1997).     
 
After attachment to its respective receptor, the virus undergoes receptor-mediated 
conformational transition.  Binding of PV to the poliovirus receptor (PVR; CD155) 
at physiological temperature triggers an irreversible conformation change in the 
native virion (160S particle), resulting in the production of an altered (A) particle 
(135S particle) (De Sena & Mandel, 1977, Fenwick & Cooper, 1962, Gomez Yafal 
et al., 1993).  The A particle has externalized myristoylated capsid protein VP4 and 
the N-terminus of the capsid protein VP1 (Fricks & Hogle, 1990).  Then, the 
externalized peptides insert into membranes and form channels and pores that 
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Figure 1.3  Schematic diagram of enterovirus life cycle.  Enterovirus infection is 
initiated when the virus attaches to its cell receptor, leading to conformational 
changes in the virus that facilitates release of the RNA genome into the cytoplasm 
and subsequent translation and replication.  Taken from Hogle, 2002. 
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Table 1.2  Cell receptors utilized by members of human enteroviruses
a 
 
Species Serotype  Receptor  Type  of 
Receptor 
Co-receptor 
 
Human enterovirus A 
 
 
Coxsackieviruses A2-A8, 10, 12, 14, 16 
 
Human enteroviruses 71, 76, 89-92  
 
 
Unknown 
 
Unknown 
  
 
Human enterovirus B 
 
 
Coxsackievirus A9 
Coxsackieviruses B1-B6 
Coxsackieviruses B1, 3, 5 
Echoviruses 1, 8 
Echoviruses 3, 6, 7, 11-13, 20, 21, 24, 29, 33 
Echoviruses 6, 9 (cell culture adapted) 
Echovirus 22 
 
 
αvβ3, αvβ6 
CAR  
DAF(CD55) 
α2β1 (Vla-2) 
DAF(CD55) 
Heparin sulfate 
αvβ3 (Vibronectin) 
 
 
Integrin 
Ig-like 
SCR-like 
Integrin 
SCR-like 
GAG 
Integrin 
 
 
β2-m, GRP78 
ND 
αvβ6-Integrin 
ND 
β2-m, CD59 
ND 
ND 
 
Human enterovirus C 
 
 
Polioviruses 1-3 
Coxsackieviruses A13, 18, 21 
Coxsackievirus A21 
 
 
PVR (CD155) 
ICAM-1 
DAF(CD55) 
 
 
Ig-like 
Ig-like 
SCR-like 
 
 
ND 
ND 
ICAM-1 
 
Human enterovirus D 
 
 
Human enterovirus 70 
 
DAF(CD55) 
 
 
SCR-like 
 
 
ND 
ND, not determined; β2-m, β2-microglobulin; GRP78, glucose related 78kDa protein; CAR, Coxsackievirus-Adenovirus receptor; Ig, 
immunoglobulin; DAF, Decay-accelerating factor; SCR, short consensus repeat; GAG, glycosaminoglycan; PVR, Poliovirus receptor; ICAM-1, 
intracellular adhesion molecule 1. 
aAdapted from Racaniello, 2007; Evan and Almond, 1998; Triantafilou et al., 1999 and 2002; Shafren et al., 
1995 and 1997.
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facilitate translocation of the viral RNA genome across the plasma or vesicle 
membrane into the cytoplasm (Fricks & Hogle, 1990, Tosteson & Chow, 1997).  An 
altered form of the virus that has lost its RNA sediments at 80S, called the 80S 
particle.  The trigger for switching from 135S particle to the 80S empty particle is 
not clearly known.   
 
Although enterovirus cell entry pathways have been studied extensively, particularly 
in PV, the mechanisms by which enteroviruses gain entry into host cells remains 
unclear.  Earlier studies suggested that PV entered cells via clathrin-mediated 
endocytosis and the viral uncoating was triggered by acidification of early 
endosomes (Madshus et al., 1984, Zeichhardt et al., 1987, Zeichhardt et al., 1985).  
By contrast, subsequent studies showed that blocking the acidification of endosomes 
with bafilomycin A1 and inhibition of dynamin, a GTPase required for 
internalization of clathin-coated vesicles, had no effect on PV replication (DeTulleo 
& Kirchhausen, 1998, Perez & Carrasco, 1993).  These findings suggest that 
clathrin-mediated endocytosis is not essential for poliovirus entry.   
 
Two most recent studies have characterised the PV cell entry pathway using both 
live-cell imaging and biochemical assays.  Brandenburg et al. (2007) found that PV 
entered the cell by a clatrin-, caveolin-, flotillin-, and microtubule- independent, but 
tyrosine kinase- and actin-dependent, endocytosis mechanism after binding to 
receptors on the cell surface.  After internalization, viral uncoating occurred rapidly 
within the cell, and in vesicles located very close (within 100-200 nm) to the plasma 
membrane.  RNA release required energy, an actin skeleton, and the activity of 
tyrosine kinases.  Interestingly, Coyne et al. (2007) found that PV entered human brain microvascular endothelial cells (HBMECs) by dynamin-dependent caveolar 
endocytosis.  Virus entry was promoted by interaction of PV with PVR that induced 
intracellular signaling events.  PVR-induced signals led to rearrangement of the actin 
cytoskeleton, and activation of tyrosine kinase and phosphatase essential for 
dynamin dependent caveolar entry.  Taken together, these findings suggest that PV 
enters different cells by different mechanisms, and utilizes cell’s signaling pathways 
during virus entry. 
 
To date, the cellular receptor of HEV71 has not yet been identified and the 
mechanisms by which HEV71 enters the cells is for the most part unknown.  It has 
been found that the receptor utilized by HEV71 has a major protein component, and 
HEV71 possibly enters the cells by a caveolin-mediated endocytosis (Herrero, 2007).  
1.1.5.2  RNA replication 
After entry into the host cell, the plus stranded RNA genome of enteroviruses must 
first be translated to provide viral proteins that are necessary for RNA synthesis.  
The replication strategy involves transcription of the positive-stranded RNA genome 
into a negative-stranded RNA which is then used as a template for new genomic 
positive-stranded RNA.  The site of synthesis of enterovirus RNA is in the 
cytoplasm of the host cell (Detjen et al., 1978).  Enterovirus RNA replication 
requires membranous vesicles derived from membranes of endoplasmic reticulum 
and the Golgi complex (Bienz et al., 1992, Schlegel et al., 1996).  These 
membranous vesicles are induced by nonstructural proteins 2B, 2C, 2BC and 3A 
(Aldabe & Carrasco, 1995, Cho et al., 1994, Suhy et al., 2000).  The function of the 
membranous vesicles in viral RNA replication is still unclear. It has been 
hypothesized that the membranous vesicles act as scaffold for assembly of the 
  14replication complex and also protect the viral RNA from nucleases (Fogg et al., 
2003).  In addition, the membranous vesicles may act to concentrate the viral 
proteins at the site of RNA synthesis for an efficient RNA replication process (Fogg 
et al., 2003, Tershak, 1984).  
 
Several viral and cellular factors were found to be involved in enterovirus RNA 
replication.  These include all of the nonstructural proteins, cellular RNA binding 
proteins (PCBP, PABP and hnRNP C) and the cis-acting RNA secondary structures 
(the cloverleaf of 5′ UTR, cre and the 3′ UTR-poly (A) tract ) (Paul, 2002, Sean & 
Semler, 2008).  Figure 1.4 shows the current models for negative- and positive-
stranded RNA synthesis.  The viral RNA-dependent RNA polymerase, 3D
pol, plays a 
central role in the synthesis of both negative and positive strands (Paul, 2002, 
Racaniello, 2007).  A virus encoded protein, VPg, is essential for protein-primed 
initiation of the replication of both strands (Paul, 2002, Racaniello, 2007).  The 
initiation of enterovirus RNA replication is regulated predominantly by the 
interaction between RNA template, 3D
pol, and VPg, with the aid of other viral and 
host factors (Paul, 2002, Racaniello, 2007).     
1.1.5.3  Protein synthesis 
Synthesis of enterovirus polyprotein is mediated by an internal ribosomal entry site 
(IRES) element via a cap-independent mechanism (Ehrenfeld & Teterina, 2002).   
Enteroviruses have a type I IRES.  The translation initiation mediated by the type I 
IRES involves internal ribosome binding, followed by ribosome scanning of the 
mRNA to identify a downstream AUG initiation codon (Ehrenfeld & Teterina, 
2002).  During virus infection, a viral proteinase, 2A, expressed by virus has been 
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Figure 1.4  Model for the negative- and positive-strand enterovirus RNA 
synthesis.  Initiation of negative-strand RNA synthesis involves the interaction of 
cellular and viral proteins on the 5′- and 3′- UTRs.  A ribonucleoprotein (RNP) 
complex is formed when PCBP2 and 3CD proteins bind the 5′ cloverleaf.  The RNP 
interacts with the PABP bound to the 3′ poly (A) tract, resulting in a circularised 
genome.  The RNP synthesises the nascent negative-strand RNA beginning at the 3′ 
poly (A) tract of the genomic RNA.  VPg-link precursor (VP-pUpU) synthesised by 
3D
pol using the sequence AAACA of cre as template is serve as primer for 3D
pol 
during the elongation step.  Nascent negative-strand RNA forms heteroduplex with 
the positive-strand RNA template, called replicative form (RF).  Initiation of 
positive-strand RNA synthesis involves the interaction of cellular and viral proteins 
on the negative-strand RNA template.  VP-pUpU synthesised by 3D
pol using the 3′- 
terminal two As of the negative-strand as template is serve as primer for 3D
pol during 
the elongation step.  Up to six nascent positive-strand RNAs are simultaneously 
synthesised on one negative-strand RNA template. (Adapted from Sean and Semler, 
2008, Paul, 2002). 
  16found to cleave the translation initiation factor, elF4G, required for cap-dependent 
translation (Gradi et al., 1998, Liebig et al., 2002).  Thus, the cap-dependent host cell 
translation is inhibited while viral protein expression continues via a cap-
independent mechanism (Gradi et al., 1998, Liebig et al., 2002).   
 
After translation, the polyprotein precursor is rapidly co or post translationally 
cleaved by virus-encoded proteinases.  High molecular weight precursors do not 
accumulate in infected cells because they are processed as soon as the viral proteases 
have been expressed (Racaniello, 2007).  Viral proteases, 2A
pro and 3CD
pro and its 
processing product 3C
pro play a major role in processing of the viral polyprotein 
(Harris et al., 1990, Lawson & Semler, 1991, Toyoda et al., 1986).  The initial 
cleavage of the polyprotein precursors occurs at the site between the P1 and P2 
junction, mediated by 2A
pro, releasing the P1 precursors from the P2-P3 precursors 
(Harris et al., 1990).  Other proteolytic cleavages are largely carried out by 3CD
pro 
and/or 3C
pro, including further processing of P1 into VP0, VP3 and VP1, and 
processing proteins of the P2 and P3 regions (Harris et al., 1990).  However, the 
mechanism of maturation cleavage at the VP4 and VP2 junction is still not known.   
1.1.5.4  Virion assembly 
The morphogenesis of enteroviruses is a multi-stepped process (Racaniello, 2007).  
Firstly, the P1 region is released from the polyprotein precursors after being cleaved 
with 2A protein, and is further processed by proteinase 3CD
pro into VP0, VP3 and 
VP1.  The 5S protomer consisting one copy each of VP0, VP3 and VP1 is then 
formed.  Five protomers then assemble to form a 14S pentamer which then self-
assembles into 80S empty capsids.  The final step of morphogenesis is the cleavage 
of VP0 into VP4 and VP2 by an unknown proteinase.  The encapsidation process of 
  17enteroviruses is still poorly defined.  Two models of viron assembly have been 
suggested (Jacobson & Baltimore, 1968, Nugent & Kirkegaard, 1995).  One model 
involves the insertion of newly synthesized viral RNA into the 80S empty capsids to 
form provirions, in which the VP0 is still not cleaved (Jacobson & Baltimore, 1968).  
However, an x-ray crystallographic structure of the 80S empty capsid showed no 
evidence for an opening for viral RNA to gain entry (Basavappa et al., 1994).   
Another model involves assembly of the 14S pentamers with viral RNA to form the 
provirions.  This model is supported by the finding that the 14S pentamers are stored 
in 80S empty capsids in infected cells (Nugent & Kirkegaard, 1995). 
1.1.6  Mature viral protein 
Structural capsid proteins 
The structural capsid proteins (VP1, VP2, VP3 and VP4) form the icosahedral 
structure of virus.  The viral protein VP0 is cleaved into VP4 and VP2 in the final 
stages of virion assembly (Racaniello, 2007).  VP1-VP3 proteins are approximately 
30 kDa in size (Racaniello, 2007).  The amino acid sequences of VP1, VP2 and VP3 
are not obviously similar, but all three proteins have similar topology of an eight-
stranded, antiparallel β-barrel (Racaniello, 2007).  The β-barrel domain is a wedge-
shaped structure composed of two antiparallel β-sheets.  Packing of the β-barrel 
units of structural proteins to form a capsid protein shell is strengthened by a 
network of protein-protein contacts on the interior of the capsid.  This network is 
formed by the N-terminal extensions of VP1 to VP4.  VP4 has an extended 
conformation compared to the other three proteins.  It is similar in position and 
conformation to amino-terminal sequences of VP1 and VP3 and functions as a 
detached amino-terminal extension of VP2 (Racaniello, 2007). 
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2A protein 
The enterovirus 2A protein functions primarily as a proteinase.  Once the 2A protein 
gene has been translated, it can adopt a three-dimensional structure component for 
proteolytic activity (Harris et al., 1990, Toyoda et al., 1986).  It then co-
translationally cleaves itself at its amino acid terminus to release the P1 structural 
protein region from the P2 and P3 nonstructural protein regions (Harris et al., 1990, 
Toyoda et al., 1986).  2A
pro also plays a role in viral RNA replication and host cell 
protein synthesis shutoff by cleaving elF4GI to inhibit host cell translation (Gradi et 
al., 1998, Liebig et al., 2002).  2A
pro utilizes a cysteine in its active site as the 
nucleophilic attack group.  Amino acid alignment and three-dimensional protein 
structure data indicated that 2A
pro adopts a serine protease fold similar to the 
protease chymotrypsin (Bazan & Fletterick, 1988).  It has been reported that 2A 
protein induced apoptosis and cell death in some members of human enteroviruses 
including PV and HEV71 (Goldstaub et al., 2000, Kuo et al., 2002).  This is because 
2A protein induces DNA fragmentation and chromatin condensation in PV, and 
induces DNA fragmentation and PAR cleavage in HEV71. 
 
2BC protein/2B protein 
Protein 2BC is the precursor to 2B and 2C proteins.  2B protein is a small, 
membrane-associated protein.  It has been reported that expression of 2BC and 2B 
changes membrane permeablilization, inhibits cellular secretory pathways and 
disrupts the Golgi complex (Cho et al., 1994, Doedens & Kirkegaard, 1995, 
Sandoval & Carrasco, 1997).  Synthesis of 2BC protein also induces the formation of 
membranous vesicles in infected cells (Cho et al., 1994).   
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because mutagenesis of the PV 2B causes defects in RNA synthesis (Johnson & 
Sarnow, 1991).  However, the exact role of 2B in RNA synthesis is not clearly 
known.  2B protein also induces the alteration of cell membrane permeability which 
is important for releasing of virus from cells (van Kuppeveld et al., 1997).  In 
addition, 2B contributes to the formation of membranous vesicles which are the site 
of viral replication in infected cells (van Kuppeveld et al., 1997).  However, the 
mechanisms of vesicle formation and regulation are not yet known. 
 
2C protein 
Protein 2C is highly conserved and multifunctional.  It has been shown to be 
involved in viral RNA replication (Barton & Flanegan, 1997, Pfister & Wimmer, 
1999).  Similar to 2BC protein, expression of 2C induces proliferation and 
rearrangement of membranous vesicles in infected cells (Cho et al., 1994).  2C also 
binds to membranes and RNA and has nucleoside triphosphatase (NTPase) activity 
that is inhibited by guanidine (Pfister & Wimmer, 1999, Rodriguez & Carrasco, 
1993, Rodriguez & Carrasco, 1995).  Mutagenesis of the conserved amino acid 
within the NTPase domain of 2C results in the loss of viral infectivity (Rodriguez & 
Carrasco, 1993).  Thus, it has been postulated that 2C may have two functions in 
RNA synthesis: as an NTPase and directing replication complexes to cell membranes 
(Aldabe & Carrasco, 1995, Cho et al., 1994, Rodriguez & Carrasco, 1995).   
 
3A/3AB protein 
3AB is a multifunctional protein.  It interacts with membranous vesicles, 3D
pol and 
3CD, and also forms a ribonucleoprotein complex on the 5′ cloverleaf with 3CD 
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autoproteolysis of 3CD and elongation activity of 3D
pol ((Molla et al., 1994).  It was 
also found that 3AB can serve as a substrate for VPg uridylylation by 3D
pol 
(Richards et al., 2006). 
 
Protein 3A is a mature protein from the 3AB precursor.  3A is associated with 
membranous vesicles during RNA replication (Towner et al., 1996).  It has been 
shown that 3A is important for homodimerization, inhibition of cellular trafficking 
and RNA replication (Wessels et al., 2006).  Protein 3A also inhibits tumor necrosis 
factor-induced apoptosis (Neznanov et al., 2001).    
 
3B protein 
Protein 3B is also known as VPg or viral protein, genome-linked.  It is covalently 
linked to the 5′ end of the genomic RNA (Flanegan et al., 1977).  Protein 3B plays 
an important role in RNA replication by acting as a protein primer for both negative- 
and positive-stranded RNA synthesis (Pettersson et al., 1978, Sean & Semler, 2008).  
VPg is uridylylated by 3D
pol at a tyrosine residue by using cre as a template (Paul et 
al., 1998, Takegami et al., 1983).  The uridylylated VPg then serves as a primer for 
RNA replication by the RNA-dependent RNA polymerase (Paul et al., 1998). 
 
3C/3CD 
Protein  3CD is a fusion between 3C proteinase  and 3D polymerase and is the 
precursor of both mature proteins.  Protein 3CD is multifunctional.  As a proteinase, 
3CD plays a role in proteolytic processing of the structural precursor P1 region of the 
polyprotein (Lawson & Semler, 1991).  Protein 3CD also has a role in RNA 
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with the cloverleaf of 5′ UTR either in the presence of 3AB or PCBP (Gamarnik & 
Andino, 1997, Parsley et al., 1997, Xiang et al., 1995).  It has been suggested that the 
3CD/PCBP complex mediates a circularization of the positive-stranded RNA 
genome (Herold & Andino, 2001).  The role of 3CD in RNA replication has been 
further supported by the finding that 3CD stimulates the PV synthesis in in vitro 
translation-RNA replication system (Herold & Andino, 2001).  Protein 3CD also 
influences the uridylylation of VPg by 3D
pol by an interaction with the cre, an RNA 
stem-loop element in the 2C coding region (Paul et al., 2000, Rieder et al., 2000).   
 
Protein 3C is the proteinase responsible for proteolytic processing of the P2 and P3 
precursor proteins (Lawson & Semler, 1991).  Similar to 3CD, 3C has RNA binding 
activity and is able to bind to the 5′ cloverleaf (Blair et al., 1998, Zell et al., 2002).  
The role of 3C in viral RNA replication is not clearly demonstrated.  Similar to 2A 
protein, proteinase of 3C cleaves cellular proteins important for host gene 
expression, including TATA-box binding protein and PABP (Clark et al., 1993, 
Kuyumcu-Martinez et al., 2002).  This cleavage enables the virus to shut down host 
gene expression.  In HEV71, 3C was found to induce apoptosis in human neural 
cells though a mechanism involving caspase activation (Li et al., 2002). 
 
3D 
Protein 3D
pol is the RNA-dependent RNA polymerase which is responsible for chain 
elongation during the synthesis of both positive-and negative- stranded RNAs 
(Flanegan & Baltimore, 1977, Van Dyke & Flanegan, 1980).  It has been shown that 
3D
pol activity is enhanced by the 3AB protein (Paul et al., 1994, Plotch & Palant, 
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pol and 3AB may facilitate 
localization of the polymerase to membranous vesicles, the sites for RNA replication 
(Sean & Semler, 2008).  Protein 3D
pol also catalyzes the VPg uridylylation reaction 
occurring through the precursor 3AB (Lyle et al., 2002, Xiang et al., 1995).  
1.1.7  Construction and use of infectious cDNA clones of 
enteroviruses 
An infectious clone is a full-length cDNA copy of the viral genome, carried on a 
plasmid vector, which serves as a template for the in vitro or in vivo transcription of 
infectious RNA.  In general, a promoter sequence recognized by Escherichia coli or 
phage DNA-dependent RNA polymerase (such as bacteriophages  SP6 or T7) is 
required for in vitro transcription of viral cDNA template, or a eukaryotic promoter 
sequence, such as cytomegalovirus (CMV) immediate early promoter, is required for 
in vivo transcription of viral cDNA after direct transfection into cells.   
 
The first infectious cDNA clone of an animal virus to be constructed was that of PV, 
an important member of the human enteroviruses (Racaniello & Baltimore, 1981).  
This cDNA clone contained no promoter sequence.  However, it was able to produce 
infectious virus after the cDNA transfection into CV-1 cells.  The mechanism by 
which this cDNA clone generates infectious virus is not known.  It has been 
postulated that the cDNA enters the nucleus, where it is transcribed by cellular 
DNA-dependent RNA polymerase from a cryptic, promoter-like sequence on the 
plasmid (Flint et al., 2004).  Similarly, cDNA of CBV3 virus containing only the 
bacteriophage T7 promoter sequence without an additional eukaryotic promoter 
sequence was also found to be infectious in vivo (Kandolf & Hofschneider, 1985).     
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have been constructed using different combinations of plasmid vector and/or 
bacterial host strains (Arita et al., 2005, Harvala et al., 2002, Kraus et al., 1995, 
Martino et al., 1999).  Most enterovirus infectious clones contain either 
bacteriophage or eukaryotic promoter sequences for initiation of RNA transcription 
(Arita et al., 2005, Harvala et al., 2002, Kraus et al., 1995, Martino et al., 1999).  
Viral cDNA instability in bacterial hosts is the major problem encountered in the 
construction of infectious cDNA clones for many positive-stranded RNA virus 
families, particularly flaviviruses and coronaviruses.  However, the instability 
problem has not been well documented in the construction of enterovirus infectious 
clones.  Although HEV71 has become an important pathogen causing large HFMD 
outbreaks with neurological complications since 1997, the first infectious clone of 
this virus was only reported in 2005 (Arita et al., 2005).  The initial construction of 
this HEV71 (BrCr) infectious clone in a high copy number plasmid was 
unsuccessful.  However, this group was later able to produce an infectious clone by 
using a medium-copy number plasmid and the bacterial host strain XL10-gold.   
Different combinations of plasmid vector and/or bacterial host strains were also 
found to be major determinants of success or failure in generating an infectious 
cDNA clone of HEV71 in this study (described in Chapter 3)   
 
With the advance of recombinant DNA technology that enables modification and 
introduction of mutations in genomic DNA, the establishment of infectious cDNA 
clones greatly enhances understanding of RNA virus biology.  Such clones facilitate 
genetic manipulation of viral RNA genomes.  Thus, infectious clones can serve as 
useful tools for the investigation of virulence determinants and can also potentially 
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coxsackievirus B3 (CBV3), the infectious clone has been utilized in various studies, 
including mutagenesis of a single amino acid in the puff region of the VP2 or 
mutagenesis in the 5′ UTR for the construction of attenuated myocarditic phenotypes 
(Dan & Chantler, 2005).      
 
1.2  Human enterovirus 71 (HEV71)   
1.2.1  HEV71 infection 
HEV71 was first isolated from the stool of an infant with encephalitis in California 
in 1969 (Schmidt et al., 1974).  Since then, HEV71 infections have been found to be 
associated with a wide range of diseases.  It is most often associated with outbreaks 
of hand, foot and mouth disease (HFMD), a self-limiting childhood disease 
characterised by a brief febrile illness and vesicular lesions on the hands, feet, mouth 
and buttocks.  In addition to HFMD, HEV71 often causes herpangina, a disease 
characterised by an abrupt onset of fever and sore throat, associated with small 
vesicular or ulcerative lesions on the posterior oropharynx.  Other members of HEV-
A, particularly coxsackievirus A16 (CAV16) and coxsackievirus A10 (CAV10) also 
cause HFMD and herpangina (Pallansch & Roos, 2007).  HFMD and herpangina 
caused by HEV71 is clinically indistinguishable from HFMD caused by other 
members of HEV-A (Pallansch & Roos, 2007).  
 
Unlike other causative agents of HFMD and herpangina, HEV71 has been 
recognised as a highly neurotropic virus causing a range of neurological diseases, 
including aseptic meningitis, brainstem and/or cerebellar encephalitis, and acute 
flaccid paralysis (AFP), which may lead to permanent paralysis or death (McMinn, 
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with a higher rate of complete recovery (Hayward et al., 1989, McMinn et al., 2001b, 
Samuda et al., 1987).  The most severe form of HEV71 neurological disease is 
brainstem encephalitis, which was found to involve several parts of the brain, 
including the medulla oblongata, reticular formation, pons and midbrain (Huang et 
al., 1999, Lum et al., 1998, Wang et al., 1999).  Brainstem encephalitis is 
occasionally associated with neurogenic pulmonary oedema, a clinical manifestation 
characterised by a rapid onset of cardiopulmonary failure (Huang et al., 1999, Lum 
et al., 1998, Wang et al., 1999).  The mortality rate of brainstem encephalitis 
associated with neurogenic pulmonary oedema is as high as 80% (Huang et al., 1999, 
Lum et al., 1998, Wang et al., 1999).  Children under 5 years of age are particularly 
susceptible to HEV71-associated neurological diseases.  Recently, a case of acute 
HEV71 encephalitis in an adult has been reported (Hamaguchi et al., 2008).  
 
Other diseases commonly associated with HEV71 infections include non-specific 
febrile illness in young children and acute respiratory diseases including pharyngitis, 
bronchiolitis and pneumonia (Merovitz et al., 2000, Rotbart et al., 1999, Tsai et al., 
2001).  A case of intrauterine HEV71 infection during pregnancy leading to foetal 
abnormalities (hepatomegaly, pleural effusion and hydrocephalus) and death has also 
been reported (Chow et al., 2000).      
1.2.2  Epidemiology of HEV71 
Since the first isolation in 1969, epidemics of HEV71 infection associated with 
HFMD and/or neurological diseases have occurred throughout the world including 
the USA, Brazil, Bulgaria, Hungary, Sweden, and countries in the Asia-Pacific 
  26region (Blomberg et al., 1974, Cardosa et al., 1999, Chumakov et al., 1979, Lin et 
al., 2006, Melnick, 1984, Nagy et al., 1982, Schmidt et al., 1974, Takimoto et al., 
1998, Tu et al., 2007).  The earliest large and severe epidemics of HEV71 infection 
occurred in Bulgaria in 1975 (Chumakov et al., 1979) and Hungary in 1978 (Nagy et 
al., 1982).  Both epidemics were associated with numerous cases of aseptic 
meningitis (545 cases in Bulgaria, 826 in Hungary), encephalitis or acute flaccid 
paralysis (149 cases in Bulgaria, 724 cases in Hungary, respectively).  Unlike other 
outbreaks, no cases of HFMD were reported in the Bulgarian epidemic, and only 
four cases of HEV71-associated HFMD were identified in Hungary (Melnick, 1984, 
Nagy et al., 1982).  Since then, there has been no report of large epidemics of 
HEV71 infection in European countries. 
In the Asia-Pacific region, the first report of HEV71 infection came from Australia, 
during an epidemic of aseptic meningitis in Melbourne in 1972, in which 39 out of 
49 HEV71-infected patients had aseptic meningitis (Kennett et al., 1974).  The 
second outbreak of HEV71 infection in Australia occurred in Victoria in 1986.  This 
outbreak also had a high incidence of neurological involvement, with 6 out of 114 
infected patients developing encephalitis and one patient developing poliomyelitis-
like paralysis (Gilbert et al., 1988).  In addition to Australia, small or large outbreaks 
of HEV71 associated HFMD or HFMD and acute neurological diseases occurred in 
several Asian countries including Japan in 1973 and 1978, Hong Kong in 1985, 
China in 1987 and Singapore in 1987 (McMinn, 2002).  These outbreaks were all 
generally mild and had low mortality.     
Since 1997, HEV71 activity has increased significantly in the Asia-Pacific region.  
Several large epidemics of HEV71 infection have occurred in many countries.  The 
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Chan et al., 2000).  This epidemic was associated with numerous cases of HFMD 
and herpangina, and was occasionally associated with severe neurological diseases 
such as aseptic meningitis, acute flaccid paralysis, cerebellar ataxia, and a previously 
undescribed clinical manifestation, fatal neurogenic pulmonary oedema associated 
with brainstem encephalitis (Cardosa et al., 1999, Chan et al., 2000).  During this 
epidemic, 889 infected children were hospitalized and 29 died from cardio-
respiratory failure.  Smaller and less severe epidemics with low mortality rates were 
later reported in Japan and peninsular Malaysia in the same year and in Singapore in 
1998 (Komatsu et al., 1999, Lum et al., 1998, Singh et al., 2000).  A large HEV71 
epidemic occurred in Taiwan in 1998, with about 130,000 cases of HFMD and 
herpangina.  Of these, 405 cases developed severe neurological diseases and 78 
(19%) cases were fatal, mainly due to the development of neurogenic pulmonary 
edema (Ho, 2000).  In 1999, a large outbreak of HEV71 infection occurred in Perth, 
Western Australia (McMinn et al., 2001b).  Approximately 6,000 cases of HFMD 
were reported, and 29 cases had severe neurological disease.  HEV71-associated 
neurological diseases in Perth included aseptic meningitis, acute cerebellar ataxia, 
and acute flaccid paralysis.   
HEV71 epidemic activity is still high in the Asia-Pacific region, with outbreaks and 
sporadic cases continuing to occur.  Outbreaks of HFMD with a proportion of 
neurological diseases occurred in Singapore, Korea, Japan and peninsular Malaysia 
in 2000, Taiwan in 2000 and 2001, Sarawak in 2000, 2003 and 2006, Vietnam in 
2005, India, Thailand, Malaysia, Hong Kong and Brunei in 2006 (Cardosa et al., 
2003, Fujimoto et al., 2002, Jee et al., 2003, Lin et al., 2006, Lum et al., 2002, Podin 
et al., 2006, Singh et al., 2002, Tu et al., 2007) (http://www.promedmail.com, 
  28http://www.cdc.gov).  The most recent and largest recorded outbreak occurred in 
China in 2008, with more than 200,000 cases reported (http://www.promedmail.com, 
http://www.cdc.gov). 
Interestingly, similar epidemic patterns were observed following long-term 
epidemiological studies in Japan and Sarawak.  Surveillance data from both 
countries indicated that HEV71 follows an epidemic mode of transmission, with 
outbreaks occurring every 3 years (Hosoya et al., 2006, Podin et al., 2006).  It has 
been suggested that quiescent periods between outbreaks could result from the 
development of population immunity caused by widespread infection in the 
community during an epidemic (Hosoya et al., 2006, Podin et al., 2006). 
Few studies have been performed to investigate the mode of transmission and risk 
factors associated with HEV71 infections.  The primary mode of HEV71 
transmission is via the faecal-oral route and, less commonly, via the respiratory 
route.  A study of risk factors for HEV71 infection during the large epidemics of 
HFMD/herpangina in Taiwan in 1998 showed that significant risk factors for HEV71 
infection are a large number of children in the family, attendance at a kindergarten or 
child care centre, contact with HFMD or herpangina cases, age between 6 months 
and 5 years of age, and living in a rural area (Chang et al., 2002).  The results 
indicated that efficient spread of HEV71 occurred in families, kindergartens and 
childcare centres, suggesting that virus transmission is aided by overcrowding and 
poor sanitation.  The faecal-oral route of transmission can occur by direct contact 
between people or by indirect contact via food, water or objects contaminated with 
faecal material.  Further studies need to be undertaken in order to clarify if the 
respiratory route is a true mode of transmission of HEV71 infection.  
  291.2.3  Molecular epidemiology of HEV71  
The molecular epidemiology and evolution of HEV71 was originally described by 
Brown et al. (1999).  In this study, the genetic diversity and rate of evolution of 
HEV71 isolates were determined by comparing the complete nucleotide sequences 
of the VP1 gene of 113 strains isolated from the USA, and five other countries over a 
thirty-year period.  Three distinct HEV71 genetic lineages (genotypes), designated 
A, B and C, were identified as shown in Figure 1.5.  Genotype A consists of a single 
virus, the prototype strain BrCr, which was the first HEV71 strain isolated in 
California in 1969.  Genotype B is divided into five subgenotypes, B1 to B5 and 
genotype C is divided into five subgenotypes, C1 to C5 (Brown et al., 1999, Cardosa 
et al., 2003, McMinn et al., 2001a, Shimizu et al., 2004, Tu et al., 2007).  The 
nucleotide sequence similarity between the genotypes is 78-83%.  Within the B 
genotype, the strains share at least 87.9% nucleotide sequence identity, and the 
strains within the C genotype share at least 84.5% identity.  Virus isolates within the 
same subgenotype share more than 90% nucleotide sequence similarity.  The 
nucleotide divergence between genotypes A and the other two genotypes, B and C, is 
20-21%, and the divergence between genotypes B and C is 16-25%. 
 
Several regions of the HEV71 genome have been used for phylogenetic analysis, 
including the 5′ UTR, VP1, VP4 and the VP4-VP2 junction.  The VP1 region is the 
most informative region for molecular epidemiology and evolutionary studies of 
enteroviruses (McMinn, 2002).  This is because the VP1 protein is the most exposed 
capsid protein and contains the major viral neutralisation epitopes; it is therefore 
antigenically and genetically distinct, with a strong correlation to virus serotype 
(Oberste et al., 1999).  In addition, no homologous recombination occurs within the  
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Figure 1.5  An overview of the genetic relationships of human enterovirus 71 
(HEV71) strains.  Dendrogram showing the genetic relationships among 49 HEV71 
strains based on the alignment of complete VP1 gene sequences.  The dendrogram 
shows genogroups A, B and C as identified by Brown et al. (1999).  Taken from Tu 
et al., 2007. 
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VP1 gene (Oberste et al., 1999).  The VP4 gene has been shown to provide similar 
phylogenetic information to the VP1 gene, and has also been commonly used in 
molecular epidemiology studies of HEV71 (Cardosa et al., 2003, Chu et al., 2001, 
Shimizu et al., 1999).  However, the VP1-based phylogenetic analysis provides 
greater statistical confidence than VP4-based analysis (Cardosa et al., 2003).      
 
Studies of molecular epidemiology have improved the understanding of the 
evolution of HEV71 and the association of genetic diversity of virus strains to 
pathogenic properties and epidemiologic circulation.  Similar to other enteroviruses, 
such as PV and HEV70, HEV71 is a genetically diverse virus with an estimated 
evolution rate of 1.35x10
-2 substitutions per nucleotide per year (Brown et al., 1999).  
The prototype, BrCr strain, isolated in 1969, is the only strain of genotype A 
identified.  Genotype B was the major strain circulating throughout the world in the 
1970s and 1980s, whilst genotype C strains were first isolated from the USA in 1987 
(Brown et al., 1999).  Strains of genotype B and C have continued to evolve and 
circulate throughout the world.  Co-circulation of different genotypes and the 
temporal change of dominant genotypes of HEV71 outbreaks have been well 
documented.  For example, four distinct subgenotypes (B3, B4, C1 and C2) co-
circulated in Malaysia during 1997-2000 (Herrero et al., 2003).  The co-circulation 
of genotypes B and C was also found in Taiwan in the 1998 HFMD outbreak, with 
C2 the predominant subgenotype (Lin et al., 2006).  The genotype shift occurred 
during 1999-2003 and genotype B4 was the predominant genotype which was then 
replaced by genotype C from 2004-2005 (Huang et al., 2008, Lin et al., 2006, Wang 
et al., 2002). 
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Recombination has been reported to contribute to genetic diversity and evolution of 
enteroviruses.  Phylogenetic and Simplot analysis of complete genome sequences of 
HEV-A prototype viruses and also the four newest HEV-A viruses identified has 
suggested that recombination may play a role in the evolution of viruses in the 
species (Oberste et al., 1999). The occurrence of intertypic recombinants between 
HEV71 and several HEV-A virus, including CAV16 has been demonstrated (Chan 
& AbuBaka, 2006).  In addition, intratypic recombination between genotype B and 
genotype C has also been identified among naturally circulating HEV71 isolates in 
Taiwan (Huang et al., 2008) and two recombination sites located at the 3′ terminus 
of protein 2A and 3D has been found.  The nonstructural gene region was found to 
be the recombination hot spot for both intertypic and intratypic recombination in 
HEV71 and also other HEV-A viruses.  Thus, recombinant events may play an 
important role in the emergence of HEV71 subgenotypes with different potential in 
disease associations. 
1.2.4  Pathogenesis of HEV71  
The wide variety of clinical manifestations resulting from HEV71 infection, ranging 
from mild HFMD to fatal encephalitis, has demonstrated the complexity of HEV71 
pathogenesis.  Although the pathogenesis of HEV71 associated with neurological 
diseases has been studied intensively, much remains to be clarified.  Initial viral 
replication probably occurs in the intestine, since virus can be detected in stool for 
several weeks after infection (Chung et al., 2001).  The ability of HEV71 to 
infiltrate, infect and replicate in cells of the CNS has been clearly demonstrated, as 
viral antigen was detected in the cytoplasm of neurons (Wong et al., 2008).  The 
  33major targets of HEV71 in the CNS are the spinal cord and brainstem (Wong et al., 
2008).  The distribution of viral lesions in the CNS is wider than PV infection, 
involving both the pyramidal and extrapyramidal tracts of the CNS (Wong et al., 
2008). 
 
The mechanisms of viral entry to the CNS after primary replication are currently 
unknown.  Several studies have shown that viraemia is necessary for the spread of 
virus, for example, monkeys inoculated intravenously with HEV71 developed 
neurological syndromes clinically and pathologically similar to human cases of 
encephalitis (Nagata et al., 2004).  Neuroinvasion is most likely preceded by virus 
replication in extraneural tissue. Wong et al. (2008) examined the distribution of 
inflammatory response in CNS of human HEV71 encephalitis cases.  Based on 
distinct inflammatory responses found in the CNS (spinal cord gray matter, 
brainstem, hypothalamus, and subthalamic and dentate nuclei), the authors 
speculated that virus spreads into the CNS via the peripheral nervous system, most 
likely the motor pathway.  However, spread of virus into the CNS via the 
haematogenous route and subsequent crossing of the blood-brain barrier cannot be 
ruled out.  
 
Both viral factors such as virulence and tropism, and host factors such as the 
distribution of host cell receptors and the immune system may contribute to the 
pathogenesis of HEV71 encephalitis and be responsible for the differences in clinical 
manifestations of HEV71 infection.  It has been postulated that the marked variation 
in the clinical signs of HEV71 infection are related to dermatotropism or 
neurotropism of viral strains (McMinn, 2002).  The role of host factors on HEV71 
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neurogenic pulmonary oedema (PE) had an abnormal cytokine activation that 
produces a severe systemic inflammatory response (Wang et al., 2003).  Patients 
with PE were found to have significant higher levels of plasma interleukin-6 (IL-6), 
IL-10, IL-13, IL-1β and interferon (IFN)-γ, and lower circulating CD4
+ T cells, 
CD8
+ T cells, and natural killer (NK) than the other HEV71 cases (Wang et al., 
2003).  It was also found that children with meningoencephalitis had an altered 
cellular immune response associated with a high frequency of the G/G genotype of 
the cytotoxic T lymphocyte antigen-4 polymorphism (Yang et al., 2001).  More 
studies need to be carried out to clarify the role of viral and host factors in the 
pathogenesis of HEV71 infection. 
1.2.5  Molecular determinants of virulence 
Like PV, HEV71 is a neurotropic enteric virus.  The determinants of HEV71 
neurovirulence remain to be elucidated.  Molecular genetic analysis of PV virulence 
has shown that minor sequence variations in the 5′ UTR are sufficient to account for 
large differences in neurovirulence (Evans et al., 1985, Kawamura et al., 1989, 
Macadam et al., 1991).  An attempt to identify HEV71 neurovirulence determinants 
by comparing nucleotide sequences of the 5′ UTR and VP1 gene of HEV71 strains 
isolated from mild HFMD and severe neurological cases has been unsuccessful 
(AbuBakar et al., 1999, Brown et al., 1999, Shih et al., 2000, Shimizu et al., 1999).  
During the Perth HEV71 epidemic in 1999, the genotype C2 viruses that have a 
single amino acid substitute in VP1 (A170V) were exclusively isolated from cases of 
severe neurological disease (McMinn, 2002).  The amino acid substitute in VP1 
(A170V) is predicted to affect virus-receptor interactions (McMinn, 2002).   
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shown.  It has been hypothesized that HEV71 neurovirulence may be determined by 
more than one genomic region, and host factors may play an important role in 
limiting the severity of most HEV71 infections (McMinn, 2002).   
 
In the related PV, single-nucleotide changes within the PV IRES greatly alter viral 
neurovirulence.  A point mutation from C to U at nucleotide position 472 in the 
IRES of PV Sabin type 3 exhibited an attenuated neurovirulence phenotype in both 
monkey and mouse models (Evans et al., 1985, La Monica & Racaniello, 1989).  PV 
Sabin type 1 and 2 strains also contain mutations in the IRES at position 480 (A to 
G) and 481 (G to A), respectively.  These mutations within IRES stem-loop domain 
V have been shown to cause impaired growth kinetics in cultured cells of neuronal 
origin (Haller et al., 1996).  The C472U mutation of Sabin type 3 was also found to 
cause a translation defect in neuronal cells (Svitkin et al., 1990).  It has been 
postulated that the attenuated phenotype associated with the C472U mutation is 
caused by decreased translation efficiency specific to the brain and spinal cord (La 
Monica & Racaniello, 1989, Ohka & Nomoto, 2001).  In a mouse model, the C472U 
mutation was found to cause a translation defect in both neuronal and non-neuronal 
tissues (Kauder & Racaniello, 2004).  Mutations within IRES stem-loop domain V 
were also found to destabilise the secondary structure of the IRES (Macadam et al., 
1992, Skinner et al., 1989).  The role of the IRES in the determination of PV 
neurovirulence has been strengthened by the finding that a polio/rhinovirus IRES 
recombinant (PV backbone with human rhinovirus type 2 IRES) has impaired 
growth kinetics specific to neuronal cells (Gromeier et al., 1996).  The 
polio/rhinovirus IRES recombinant also exhibited highly attenuated phenotype in 
  36both CD155 transgenic mice and non-human primates (Gromeier et al., 1996, 
Gromeier et al., 1999).        
      
Mutations within a non-structural protein, RNA-dependent RNA polymerase 3D
pol, 
of the Sabin PV type 1 vaccine strain were implicated in the temperature-sensitive 
(ts) and low-virulence phenotype of the virus (Christodoulou et al., 1990).  Unlike 
PV, the role of HEV71 IRES, and non-structural proteins in neurovirulence remains 
poorly defined.  Arita et al. (2005) generated HEV71 (BrCr) mutants by introduction 
of mutations corresponded to ts determinants of PV Sabin type 1 into the BrCr 
infectious clone.  It has been demonstrated that a HEV71 (BrCr) variant containing 
mutations in 5′ UTR (A485G), 3D
pol (Tyr-73 and Cys-363) and 3′ UTR (A7409G) 
has attenuated neurovirulent phenotype.  Monkeys infected intravenously with this 
HEV71 mutant showed mild neurological manifestations and histological changes in 
the CNS compared to monkeys inoculated with the parental BrCr strain (Arita et al., 
2005).  This group suggested that HEV71 and PV may share common genetic 
determinants of neurovirulence.   
1.2.6  Animal models of HEV71 
The development and use of animal models is essential for understanding viral 
pathogenesis and in the development of therapeutics and vaccines.  A number of 
animal models have been developed to investigate HEV71 infection, including non-
human primates and rodents.  Non-human primate models are considered the best 
animal models to study the pathogenesis of HEV71.  However, the high cost and 
restricted availability of monkeys limit their use for pathogenesis studies.   
Transgenic mice possessing human receptors to HEV71 would serve as a cheaper 
and more useful animal model.  Unfortunately, the receptors of HEV71 are currently 
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of recent studies have developed a mouse model for studies of HEV71 pathogenesis 
and for vaccine and antiviral efficacy testing (Liu et al., 2005, Tan et al., 2007, Wu et 
al., 2007).  Although a mouse-adapted strain is required for infection of mice, a 
mouse model is currently the most convenient small animal model that would allow 
the primary assessment of potential vaccines or antiviral agents against HEV71. 
1.2.6.1  Non-human primate model 
Old world monkeys including rhesus, green and cynomolgus monkeys were found to 
be susceptible to HEV71 infection, with cynomolgus monkeys being the most 
commonly used.  Infected cynomolgus monkeys develop neurological manifestations 
and histopathological features similar to human disease after subcutaneous (s.c.), 
intraspinal (i.s.), intravenous (i.v.) or oral routes of inoculation (Hashimoto & 
Hagiwara, 1982a, Hashimoto & Hagiwara, 1982b, Hashimoto et al., 1978, Nagata et 
al., 2004, Nagata et al., 2002).  Subcutaneous inoculation of HEV71 caused complete 
paralysis or weakness of hind limbs (Hashimoto et al., 1978).  Virus-induced lesions 
found in the CNS of infected monkeys include perivascular cuffings, degeneration 
and disappearance of the neurons, and meningial lymphocytic infiltration in the grey 
and/or white matter of the spinal cord, medulla oblongata, cerebral cortex and 
brainstem (Hashimoto et al., 1978).  Most monkeys infected orally with HEV71 do 
not develop clinical signs of disease, with only one infected monkey showing 
weakness of the lower extremities (Hashimoto & Hagiwara, 1982a).  However, 
similar lesions in the CNS observed in subcutaneously infected monkeys were also 
found in orally infected monkeys.   
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strains isolated from individual patients with fatal encephalitis, meningitis, and 
HFMD.  Following i.s. inoculation with each of the five strains, all monkeys 
developed neurological manifestations within 1-6 days post-infection regardless of 
the infecting strain.  All the strains of HEV71 appear to be neurotropic and there is 
no correlation between the neurovirulence and genotype of HEV71.  Infected 
monkeys showed both pyramidal tract signs, such as flaccid paralysis, and 
extrapyramidal tract signs, such as ataxia and tremor.  Histological analysis in the 
CNS revealed that virus-related lesions occurred in the spinal cord, brainstem, 
cerebrum and cerebellar cortex and dentate nuclei.  The cerebellar nuclei (dentate 
nuclei) were most severely damaged, with neuron degeneration and necrosis and 
inflammatory changes being observed.  Virus titres in the CNS were high at the 
acute phase of infection, while the titres dropped to undetectable levels at 3 days 
after the onset of neurological manifestations.  The authors suggested that the 
clinical course of HEV71 infection in monkeys inoculated via the i.s. route is 
triphasic involving an incubation period, an acute phase associated with the presence 
of virus in the CNS, and a subsequent inflammatory response associated with the 
disappearance of virus. 
 
The neuropathological features of HEV71 were also compared to PV type 1. After 
i.v. inoculation, HEV71-infected monkeys exhibited extrapyramidal signs including 
tremor, ataxia and brain oedema, whereas PV-infected monkeys only showed 
pyramidal signs of flaccid paralysis (Nagata et al., 2004).  The distribution of viral 
lesions in the CNS of HEV71-infected monkeys was spread in both the pyramidal 
and extrapyramidal tracts of the CNS (Nagata et al., 2004).  By contrast, the lesions 
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motor neurons, thalamus and motor cortex (Nagata et al., 2004).   
 
Pulmonary oedema is a frequent clinical manifestation associated with fatal cases in 
recent large HFMD outbreaks.  The pathogenesis of pulmonary oedema involves 
virus-induced damage to the brainstem (Chang et al., 1998, Lum et al., 1998).   
However, no HEV71-infected monkeys with lesions identified in the brainstem 
developed pulmonary oedema (Hashimoto et al., 1978, Nagata et al., 2004).   
1.2.6.2  Small animal model  
Newborn and adult cotton rats, Syrian hamsters and newborn mice have been shown 
to be susceptible to Bulgarian strains of HEV71 (Chumakov et al., 1979).  To date, 
the cotton rat and hamster models have not yet been fully developed and 
characterised for studies of pathogenesis of HEV71.  Mouse models have been 
extensively used and characterised in recent studies (Chen et al., 2004, Chua et al., 
2008, Ong et al., 2008, Wang et al., 2004).  The mouse is not the natural host of 
HEV71.  Experimental infections of HEV71 in various strains of adult mice, 
including random-bred ICR, BALB/c, C3H, nude (BALB/c), C57B/6J, SCID, CD28 
knock-out (BALB/c) and TNF-alpha receptor knock-out (C57BL/6J), caused 
asymptomatic infections (Wu et al., 2002).  In newborn ICR mice, unadapted strains 
of HEV71 produced illnesses leading to hindlimb paralysis and death within two 
weeks after i.p. inoculation at high viral titres (Yu et al., 2000).  However, mouse-
adapted strains of HEV71 were required to consistently produce disease in newborn 
mice at low viral titres (Chen et al., 2007, Chen et al., 2004, Chua et al., 2008).   
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The original strain of this virus was isolated in 1998 from a patient with fatal 
encephalitis during the large HFMD outbreak in Taiwan (Yan et al., 2001).  It was 
shown that 1- day-old ICR mice infected with MP-4643 via the i.p. or oral routes 
developed hindlimb paralysis and death.  The mouse oral HEV71 infection model 
has been further characterised using MP-4643 (Wang et al., 2004).  Experimental 
infection of 7-day-old ICR mice resulted in hindlimb paralysis and death at 5 to 9 
days after oral inoculation.  The virus first replicated in the intestine, and then in 
other organs including heart, muscle, skin, liver, spleen, lung, kidney, brain and 
spinal cord.  Neuronal loss and apoptosis were observed in the spinal cord and brain 
stem.  The limb muscles displayed massive necrosis and contained the highest viral 
titre, indicating that it is a primary site for viral replication in mice.  It was also 
found that anti-HEV71 antibody could protect HEV71-infected mice from 
developing disease, suggesting that viremia was necessary for the spread of virus to 
the CNS.  The authors suggested that virus could get entry into the CNS through the 
blood-brain barrier.  However, the pattern of spread of virus from the lower to upper 
segments of the spinal cord also suggested a neural transmission pathway.  Potential 
virulence determinants of the mouse-adapted strain, MP-4643, were located in the 5′ 
UTR (4 nucleotide changes), the capsid protein VP2 (3 nucleotide, and 1 amino acid 
changes) and in the protein 2C (8 nucleotide and 4 amino acid changes). 
 
Chen et al. (2007) later demonstrated that retrograde axonal transport was likely to 
be a major transmission route of HEV71 into the CNS of infected mice.  Following 
i.m. inoculation in the hindlimb, the virus was first detected in the lower segments of 
the spinal cord, followed by the upper segments and brain.  By contrast, a reverse 
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observed in mice inoculated in the forelimb.  In addition, treatment of HEV71 
infected mice with colchicine, a fast axonal transport inhibitor, was found to reduce 
HEV71 neuroinvasion in a dose-dependent manner.         
 
Chua et al. (2008) also developed a mouse model for studies of HEV71 pathogenesis 
using a mouse-adapted variant of HEV71 (MP-26M).  MP-26M was selected by 
serial passage of a HEV71 clinical isolate (HEV71-26M) in Chinese hamster ovary 
(CHO) cells and in newborn BALB/c mice.  Infection of newborn BALB/c mice 
with MP-26M resulted in severe disease of high mortality in age-, dose- and route-of 
inoculation-dependent manner.  By contrast, mice infected with HEV71-26M and 
CHO-adapted strain (CHO-26M) did not develop clinical signs of infection at any 
virus dose.  Similar to the previous studies (Chen et al., 2007, Chen et al., 2004, 
Wang et al., 2004), MP-26M infection induced severe necrotizing myositis and 
skeletal muscle was found to be the primary site of replication in mice, containing 
the highest viral titre. The molecular basis of mouse adaptation of HEV71 in this 
model has been identified and described in detail in Chapter 5.   
 
A more recent study by Ong et al. (2008) has characterised the neuropathology of a 
mouse model of HEV71 encephalomyelitis in more detail.  The histopathological 
changes reported in the CNS were neuropil vacuolation and neuronal damage or loss 
with no inflammatory response (Ong et al., 2008).  Spinal cord and brainstem, 
particularly the anterior horn cells, brainstem reticular formation and motor 
trigeminal nucleus, were the most severely affected parts of the CNS.  There were no 
obvious neuronal abnormalities in the cerebral cortex, thalamus, hypothalamus, 
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i.m. inoculation, viral RNA and antigens were found in ipsilateral lumbar anterior 
horn cells and adjacent axons at 24-36 h post-infection and in upper cord motor 
neurons, brainstem, and contralateral motor cortex neurons at 48-72 h post-infection.  
Similar to the study by Chen et al. (2007), this study strongly suggested that a neural 
pathway is the primary transmission route of HEV71 into the CNS, with virus 
gaining entry into the CNS via peripheral motor nerves that innervate skeletal 
muscles.  Similar to the previous studies (Chen et al., 2004, Wang et al., 2004), 
skeletal muscles were found to be the major sites of viral replication in mice.        
 
1.3  Aim of this study  
HEV71 has become an important human pathogen, causing epidemics of HFMD 
associated with severe neurological complications.  However, little is known about 
the biology and pathogenesis of this virus.  Research investigating positive-sense 
RNA viruses has been considerably advanced by the development of reverse genetic 
systems.  With the introduction of defined genetic changes into full-length 
infectious-clone constructs, the role of viral specific genetic elements in viral 
replication and virulence can be determined.  This information will provide a genetic 
basis for the development of a vaccine, and thus could shed light on ways to control 
this important pathogen. 
 
The specific objectives of this study are: 
1.  To establish a reverse genetics system for HEV71  
2.  To identify the genome regions responsible for the growth phenotypes of 
HEV71  
  433.  To determine the molecular basis of mouse adaptation by HEV71 
4.  To establish a mouse HEV71 oral infection model for future studies on 
pathogenesis and vaccine development. 
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MATERIALS AND METHODS 
 
2.1  Cells, Viruses and Antibodies 
2.1.1  Cell Lines 
African green monkey kidney (Vero) cells (ATCC CCL-81), human 
rhabdomyosarcoma (RD) cells (ATCC CCL-136), SV40 transformed African green 
monkey kidney (COS-7) cells (ATCC CRL-1651), mouse neuroblastoma (NB41A3) 
cells (ATCC CCL-147), and Chinese hamster ovary (CHO) cells (ATCC CCL-61) 
were used in this study.  All cell lines were grown at 37ºC in an atmosphere 
containing 5% CO2/95% air.  Growth medium for Vero, RD, COS-7 and CHO cells 
consisted of Dulbecco’s modified Eagle’s media (DMEM; MultiCel
TM) 
supplemented with 5% bovine growth serum (BGS; MultiSer
TM) and 2mM L-
glutamine.  Growth medium for NB41A3 cells contained Ham’s F12 media 
(MultiCel
TM) supplement with 2mM L-glutamine, 15% horse serum (MultiSer
TM) 
and 2.5% BGS.  
2.1.2  Viruses 
HEV71 strain 6F/AUS/6/99 (HEV71-6F, GenBank Accession Number: DQ381846) 
and strain 26M/AUS/4/99 (HEV71-26M, GenBank Accession number EU364841) 
were isolated from patients during the 1999 Western Australian HFMD outbreak.  
Both strains were plaque purified on Vero cells.  Isolated plaques were passaged on 
RD cells to increase the titre for use in subsequent assays.  CHO-adapted (CHO-
26M, GenBank Accession number EU376004) and mouse-adapted (MP-26M, 
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from Dr. Beng Hooi Chua, Division of Virology, Telethon Institute for Child Health 
Research, Perth, Australia.  
2.1.3  Antibodies 
Rabbit anti-HEV71 polyclonal antibody was kindly provided by Professor Mary Jane 
Cardosa, Institute of Health & Community Medicine, University Malaysia Sarawak, 
Sarawak, Malaysia.  A mouse anti-HEV71 monoclonal antibody reactive against the 
VP1 capsid protein of HEV71 was obtained from Chemicon, USA.  Both anti-
HEV71 polyclonal antibody and a mouse anti-HEV71 monoclonal antibody 
(Chemicon) were used for immunofluorescence assays. 
 
2.2  Molecular biology 
2.2.1  Plasmids 
Plasmid vectors used for the construction of sub-genomic and/or full-length clones 
of HEV71 in this study were pGEM3Z (Promega), pBR322 (New England Biolabs), 
pMC18 (a derivative of pWSK29 kindly provided by Dr. Andrew Davidson, Monash 
University, Melbourne, Australia).  Plasmid constructs pCMV-T7Pol expressing the 
T7 RNA polymerase, and pcDNA-lacZ expressing β-galactosidase (β-gal) enzyme, 
were provided by Dr. Rob Hurrelbrink, Division of Virology, Telethon Institute for 
Child Health Research, Perth, Australia.  Plasmids pCMV-T7Pol and pcDNA-lacZ 
were used for co-transfection to rescue clone-derived virus, and for determination of 
transfection efficiency, respectively.  Three bi-cistronic constructs, pCRHL, pCR6F 
and pCR26M were kindly provided by Dr. Chee Choy Kok, Discipline of Infectious 
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cDNA clones generated in this study are listed in Table 2.4-2.6. 
2.2.2  Bacterial strains  
Escherichia coli strains DH5α (Invitrogen), DH10B (Invitrogen), XL1-blue 
(Stratagene) and XL10-gold (Stratagene) were used for transformations in this study. 
2.2.3  Restriction endonuclease (RE) digestion 
DNA was digested with appropriate restriction enzymes (Promega or New England 
Biolabs) according to the manufacturer’s instructions.  Generally, RE digestions 
were performed with an excess of enzyme at 37ºC for 1-4 h or overnight when the 
complete digestion of vector and insert DNA were required for cloning purposes. 
2.2.4  Agarose gel electrophoresis 
DNA samples for electrophoresis were mixed with dye loading buffer and loaded 
into wells of preformed agarose gel (Probiogen).  DNA samples were separated by 
electrophoresis through 0.6-2% agarose gels depending on estimated product size.  
Gels were run at approximately 6 V/cm in 1xTAE buffer (1xTAE = 40mM Tris 
acetate, 1mM EDTA).  A 1 kb ladder (GeneWorks) or 100 kb ladder (GeneWorks) 
was used as a molecular weight marker.  DNA was visualised by exposure to UV 
light on a transilluminator (Bio-Rad) after staining in 10µg/mL of ethidium bromide 
solution (Bio-Rad). 
2.2.5  Purification of DNA from agarose gels 
For cloning or sequencing purposes, DNA samples were mixed with dye loading 
buffer and SYBR (Molecular Probes) before electrophoresis.  DNA was visualised 
by exposure to visible light on a Dark Reader Transilluminator (Clare Chemical 
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DNA from agarose gels was performed using a Qiaex II Gel Extraction Kit (Qiagen) 
according to the manufacturer’s instructions. 
2.2.6  Preparation of plasmid DNA 
Small, medium or large scale preparations of plasmid DNA were performed using 
the Plasmid Mini Kit (Qiagen), Plasmid Midi Kit (Qiagen) or Plasmid Maxi Kit 
(Qiagen) respectively, according to the manufacturer’s instructions. 
2.2.7  DNA ligation 
The plasmid vectors and insert DNA were digested with appropriate enzymes 
(Promega or New England Biolabs) according to the manufacturer’s instructions.  
Ligation reactions were performed overnight at either 4ºC or 15ºC.  Generally, insert 
to vector molar ratios of 1:1 or 3:1 were used.  Standard ligation reactions contained 
either 50 or 100 ng of vector DNA, an appropriate amount of insert DNA, 30mM 
Tris-HCL pH7.8, 10mM MgCl2, 10mM dithiothreitol (DTT), 1mM ATP and 1U of 
T4 DNA ligase (Promega). 
2.2.8  Transformation of DNA into Escherichia coli (E. coli) 
Electro-competent cells were prepared by the method of Siguret et al. (1994) and 
were stored in 15% glycerol at -80ºC until use.  A 40 µL volume of cells was thawed 
on ice and approximately 1-5 µL of the DNA ligation mix was added to the cells.  
The mixture was then added to a 0.1 cm electroporation cuvette (Astral scientific) 
previously cooled on ice, and cells were electroporated using a BioRad 
GenePulsor
TM apparatus (Bio-Rad) set at 1.25 kV, 200Ω resistance and 25 μF 
capacitance.  One milliliter of prewarmed 2YT medium [1.6% tryptone (w/v), 0.5% 
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extract (w/v), 8.5mM NaCl, 20mM glucose, 2.5mM KCl, 10mM MgCl2] was 
immediately added to each cuvette and the mixture was transferred to a 1.5 
eppendorf tube prior to incubation at 37ºC for 1 h with continuous shaking.  The 
transformation mixture was subsequently plated onto 2YT agar (2YT medium plus 
1.5%agar) containing appropriate antibiotics (ampicillin at 100 μg/mL or kanamycin 
at 50 μg/mL). 
2.2.9  Isolation of viral RNA 
Virus was propagated in cell culture until required.  Cells were subjected to freeze-
thaw for three times, and cell debris was separated by centrifugation at 3,000 rpm for 
15 min, leaving virus in the supernatant.  Viral RNA was then extracted using 
QIAamp® Viral RNA mini kit (Qiagen) according to the manufacturer’s 
instructions, and eluted in 60 μL of AVE buffer. 
2.2.10  Reverse transcription (RT) of viral RNA 
(a)  RT reaction using SuperScriptTM II or SuperScriptTM  III 
reverse transcriptase (Invitrogen) 
First strand cDNAs of viruses for subsequent cloning and sequencing were 
synthesised using SuperScript
TM II or SuperScript
TM  III reverse transcriptase 
(Invitrogen).  Reverse transcription reactions were carried out in 0.2 mL tubes in a 
reaction volume of 20 μL.  A sample of 8 μL of viral RNA prepared as described in 
section 2.2.9 and 3 μL of an appropriate primer (30 pmol) were mixed and heated for 
5 min at 65˚C before chilling on ice for 5 min.  Five hundred micromoles of dNTPs, 
1X concentration of enzyme buffer as supplied by the manufacturer, 10 mM DTT, 
40 U of RNasin (Promega) and 200 U of SuperScript
TM II or SuperScript
TM  III 
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before inactivation of the enzyme by incubation at 70ºC for 15 min.  One microliter 
of RNaseH (Promega) was added, and the mixture was incubated at 37ºC for 20 min.  
RT products were stored at -20ºC until required. 
 
(b)  RT reaction using M-MLV reverse transciptase (Promega) 
First strand cDNAs of strain HEV71-6F and HEV71-26M for subsequent 
amplification and sequencing of VP1 gene were synthesised using M-MLV reverse 
transciptase (Promega).  Seven microliters of extracted RNA (see section 2.2.9) were 
mixed with 100 pmol of primer NPIA, heated at 70˚C for 5 min followed by chilling 
on ice for 5 min.  A mixture of 500 μM dNTPs, 1X concentration of enzyme buffer 
as supplied by the manufacturer, 80 U of RNasin (Promega) and 2 μL of M-MLV 
reverse transcriptase were then added to a final volume of 50 μL.  The mixture was 
incubated at 42ºC for 1 h before incubation at 70ºC for 15 min.  RT products were 
stored at -20ºC until used.  
2.2.11  Polymerase Chain reaction (PCR) 
(a)  PCR reaction for cloning 
Viral DNA fragments used for cloning were amplified by PCR using platinum Taq 
DNA polymerase High Fidelity (Invitrogen).  The PCR was carried out in 0.2 mL 
tubes in a reaction volume of 25 μL.  PCR reactions contained 10 pmol each of 
appropriate forward and reverse primer, 200 μM each of dATP, dTTP, dCTP and 
dGTP, 2 or 3 mM MgSO4, 1 or 2.5 U of platinum Taq DNA polymerase High 
Fidelity, template first strand cDNA and 1x concentration of enzyme buffer as 
supplied by the manufacturer.   The amplifications were performed in an automated 
thermocycler, with an initial denaturation at 94˚C for 2 min, followed by 40 cycles of 
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min. 
 
(b)  PCR reaction for sequencing 
Viral DNA fragments used for sequencing were amplified using PCR supermix 
(Invitrogen).  The PCR was carried out in 0.2 mL tubes in a reaction volume of 25 
μL.  PCR reactions contained 10 pmol each of appropriate forward and reverse 
primers, 22 μL of PCR supermix, and 1 μL of template first strand cDNA.   
Reactions were incubated for 2 min at 94˚C, then 40 cycles of 94˚C for 30 s, 55˚C 
for 30 s and 72˚C for 1 min, and finally incubated at 70˚C for 10 min.  Primers used 
for sequencing in this study are listed in Table 2.1 and 2.2. 
 
(c)  PCR reaction for sequencing of VP1 gene 
The PCR for amplification of VP1 gene was carried in 0.2 mL tube in a final volume 
of 50 μL.  PCR reaction contained 10 pmol each of primers 159 and NPIA (Table 
2.3), 200 μM dNTPs, 2 mM MgSO4, 1 unit of Taq DNA polymerase (Invitrogen), 1 
x concentration of enzyme buffer and 7 μL of viral cDNA.  The PCR mixture was 
then incubated at 94˚C for 2 min, followed by 35 cycles of 94˚C for 1 min, 50˚C for 
45 s and 72˚C for 2.5 min, then a final incubation at 72˚C for 10 min. 
2.2.12  DNA sequencing 
The nucleotide sequences of the PCR products or cloned DNA fragments were 
determined by automated DNA sequencing using Big dye-terminator sequencing 
technology.  Sequencing was performed by Australian Genome Research Facility 
Ltd, University of Queensland, Brisbane, Queensland.  Analysis of DNA 
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Table 2.1  Primers used for sequencing of full-length cDNA clones or clone 
derived virus of strain HEV71-6F and chimeric recombinant viruses 
 
Primer Name∗# 
Nucleotide 
position
† 
Sequence (5′ - 3′) 
EV71-1F  1 – 24  TTA AAA CAG CCT GTG GGT TGC ACC 
EV71-488R  464 – 488  GTG CTC CGC AGT TAG GAT TAG CCG C 
EV71-509F  510 – 536  GTG TGT CGT AAC GGG CAA CTC TGC AGC 
EV71-747R  748 – 772  AGC GTT GTG TGG ACA CCT GTG AGC C 
EV71-1258F  1,259 – 1,282  GGT CAG GGT TCT GCA TTC ACG TGC 
EV71-1636R  1,613 – 1,639  GCG TCG CAC CTT GGT CAT AAT CTA ACG 
EV71-1823F  1,824 – 1,849  CGG TGA AGT TAG AAA CTT GCT AGA GC 
EV71-2225F  2,226 – 2,249  GAT CAG CAA CAC TCA CTA CAG AGC 
EV71-2248R  2,225 – 2,250  GGA TCA GCA ACA CTC ACT ACA GAG CG 
EV71-2490F  2,462 – 2,490  TTG AGA GTT CTA TAG GGG ACA GTG TGA GC 
EV71-2717R  2,693 – 2,718  TAT CTC TCC AAC TAA TCC TGC TCT GC 
EV71-3208F  3,209 – 3,238  ATG TCA GGG CGT GGA TAC CTC GCC CAA TGC 
EV71-3607R  3,608 – 3,632  GCA AGC ATG AGA TGT GAC TGG TAT C 
EV71-3783F  3,759 – 3,783  GGA TGA TGA GGC TAT GGA GCA GGG C 
EV71-4260F  4,261 – 4,285  AAT CTC GAA CAG TCA GCA GCT TCG C 
EV71-4408R  4,409 – 4,433  CGG TGT TTG CTC TTG AAC TGC ATG T 
EV71-4867F  4,868 – 4,892  GGA GAG CAG CTA GGC TGT GCT CTG A 
EV71-5579R  5,556 – 5,580  ATC TAC TAG CTC CAC AGC ATC TAC G 
EV71-5878F  5,879 – 5,903  GCA ACG GTA GGC AAG GTT TCT GCG C 
EV71-6020R  6,021 – 6,041  GCC TTC GAA CAC ATC GTG AAA GAC A 
EV71-6235F   6,210 – 6,236  GAC CAC CAA GAT GAG CAT GGA GGA TGC 
EV71-6656F  6,657 – 6,682  TCT CAG CCC AGT GTG GTT CAG GGC GC 
EV71-7260R  7,237 – 7,261  TTG GAA CTG ATC TGA TTG TAC TCA C 
Oligo-d(T)24   TTT TGT ACA AGC (T)24 
 
#  Primers were designed by Dr. Robert Hurrelbrink, except Oligo-d(T)24 primer. 
∗
  Forward primers are suffixed with “F” and reverse primers are suffixed with “R”. 
 
†  Nucleotide position is based on HEV71-6F. 
 
 
 
  52 
 
Table 2.2  Primers used for sequencing of full-length cDNA clones or clone 
derived virus strain HEV71-26M and chimeric recombinant viruses  
 
Primer 
Name∗# 
Nucleotide 
position
† 
Sequence (5′-3′) 
EV71-1F  1 – 24  TTA AAA CAG CCT GTG GGT TGC ACC 
26M-533F  536 – 557  CAG CGG AAC CGA CTA CTT TGG G 
26M-1386F  1,389 – 1,412  CCC TCC TTA CAT ACA AAC GCA ACC 
26M-1576R  1,558 – 1,579  GGT TCA GGG CAG AGT CGA AAG G 
26M-1954F  1,957 – 1,990  GAA TTG TGT GCC GTG TTT AGG GCC 
26M-2132R  2,112 – 2,135  CCA CCA GGA GGT GTA TAG GCT ATG 
26M-2408F  2,411 – 2,436  CTA GTC ACA TAT TAC AGA CAG CCT CC 
26M-2622R  2,599 – 2,625  CTC ATC ACT AGT ATT TGA CGA TGC CCC 
26M-2806F  2,809 – 2,831  GTG GAG TTG TTC ACC TAC ATG CG 
26M-3111R  3,090 – 3,114  CGC TCC ATA TTC AAG GTC TTT CTC C 
26M-3451F   3,454 – 3,475  CTA GTG TCG TCT ACC ACT GCC C 
26M-3519R   3,496, – 3522,  GTA CAC TCC TGT TTG ACA GTC ACA ACG 
26M-3989F  3,992 – 4,013  TAG CTC TGA TAG GGT GCC ACG G 
26M-4098R  4,077 – 4,101  CTT TTT AAG CCA GGA CGC ACT TTG C 
26M-4591F  4,594 – 4,618  GTC ACG GTC ATG GAT GAC TTA TGT C 
26M-4710R  4,689 – 4,713  AAC TCC TTT CTC TTC TAG GGA AGC C 
26M-5264F 5,267  –  5,290 CAG  TTG  TGG  CAG TCG TTT CAC TGG 
26M-5389R  5,373 – 5,392  CCT GTA CTG TTG CCG TGC GG 
26M-5992F  5,995 – 6,016  GGG CCA ACT CGC ACT AAG CTC G 
26M-6109R  6,090 – 6,112  AAG CCT GCT CAA AAT CCA CCT CG 
26M-6662F  6,665 – 6,688  GCC CTG TCT GGT TCA GAG CAT TGG 
26M-6787R  6,768 – 6,790  GCA CAC AGT AAG TTT TGT TGC GG 
26M-6787R  6,768 – 6,790  GCA CAC AGT AAG TTT TGT TGC GG 
 
# Primers were designed by Dr Beng Hooi Chua 
∗ Forward primers are suffixed with “F” and reverse primers are suffixed with “R”.  
†  Nucleotide position is based on HEV71-26M. 
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TM version 2.3 
(Technelysium Pty Ltd., Australia). 
2.2.13  Construction of full-length cDNA clones of HEV71 
The strategy for construction of all full-length cDNA clones of HEV71 in this study 
was similar.  Generally, first-strand cDNA fragments covering the full-length 
genome of HEV71 virus were synthesized from genomic viral RNA with 
SuperScript
TM II or SuperScript
TM III reverse transcriptase (Invitrogen), as described 
in section 2.2.10, plus an appropriate primer.  cDNA fragments were then used for 
PCR amplifications to amplify the 5′ terminus and the 3′ terminus fragments of viral 
genome.  The amplified products were then cloned into plasmid vectors to construct 
sub-genomic 5′ and 3′ half clones.  With the use of unique restriction sites, the 5′ 
terminus and the 3′ terminus fragments from two sub-genomic clones were 
assembled into a genome length cDNA clone.  Construction procedures of each full-
length cDNA clone are described in detail below.  A list of HEV71 full-length clones 
constructed during this study is provided in Table 2.4.  Primers used for construction 
of all full-length cDNA clones of HEV71 are listed and described in Table 2.5. 
2.2.13.1  Nucleotide numbering system 
The nucleotide numbering in sub-genomic or full-length clones in this study is 
presented in the form of X
Y.  X represents restriction enzyme sites and superscript Y 
represents the nucleotide position in the viral genome.  For example, EcoRI
1400 
corresponds to the EcoRI restriction enzyme digestion site at nucleotide position 
1400 of the viral genome. 
  542.2.13.2  Construction of a full-length cDNA clone of HEV71 strain 
6F in a medium copy number plasmid, pBR322  
The full genome sequence of HEV71-6F was obtained from Dr Rob Hurrelbrink 
(GenBank Accession Number: DQ381846) and is shown in the Appendix A.   
Primers used for construction of the full-length cDNA clones of HEV71-6F were 
designed from the published sequence.  The numbering of nucleotides in sub-
genomic and full-length clones corresponds to the published sequence in the 
GenBank database.  The first-strand cDNA of HEV71-6F was synthesized from viral 
RNA using primer 6FMluI.  Figure 2.1 shows the schematic diagram of the 
construction of the sub-genomic and full-length cDNA clones of HEV71-6F in 
pBR322. 
 
(a)  Construction of the 5′ half clone, pBR/5′-6F 
A cDNA fragment of the 5′ terminus of viral genome spanning nucleotides 1- 4556 
was synthesized by PCR using platinum Taq DNA polymerase High Fidelity 
(Invitrogen) and primers 6F01Fh and 6F04R.  A unique SalI restriction site, a T7 
RNA polymerase promoter and GGG residues were incorporated into the forward 
primer, 6F01Fh, upstream of the 5′ terminus of the viral genome, and a unique AatII 
restriction site was incorporated into reverse primer, 6F04R, downstream of 
nucleotide 4556 of the viral genome to facilitate the cloning.  The PCR was carried 
out as described in section 2.2.11.  The resultant PCR product was subsequently 
digested with SalI and AatII to excise a SalI-AatII fragment and the fragment was 
cloned into the SalI and AatII sites of predigested plasmid pBR322.  The resultant 
clone, pBR/5′-6F, is 8,214 nucleotides in length. 
  55Table 2.3  Primer pairs used for amplification and sequencing of full VP1 genes 
of HEV71  
 
Primer Name# Nucleotide  position  Sequence (5′-3′)* 
159 2385-2403  ACYATGAAAYTGTGCAAGG 
NP1A 3355-3336  GCICCICAYTGITGICCRAA 
 
# Primers were designed by Brown et al., 1999. 
•  Y = C or T, R = A or G, I = inosine 
 
 
 
 
 
Table 2.4  Full-length cDNA clones of HEV71 strain HEV71-6F and HEV71-
26M 
Plasmid 
clone 
Derived virus 
Description 
 
pBR/HEV71-
6F 
 
 
Not obtained 
 
Contains a T7 RNA polymerase promoter, GGG residues, 
viral cDNA of the HEV71-6F genome and 25 poly A; 
cloned into plasmid vector pBR322 
 
pHEV71-6F 
 
 
CDV-6F 
 
Contains a T7 RNA polymerase promoter, GG residues, 
viral cDNA of the HEV71-6F genome and 25 poly A; 
cloned into plasmid vector pMC18 
 
pHEV71-26M 
 
 
CDV-26M 
 
Contains a T7 RNA polymerase promoter, GG residues, 
viral cDNA of the HEV71-26M genome and 25 poly A; 
cloned into plasmid vector pMC18 
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Table 2.5  Primers used for construction of full-length cDNA clones of HEV71-
6F and HEV71-26M 
 
Primer Name  Nucleotide Sequence (5′-3′)  Special features 
6F01Fh 
 
 
AAG CTT GCA TGC GTC GAC TAA TAC GAC TCA 
CTA TA GGT TAA AAC AGC CTG TGG GTT G 
 
 
Contains a SalI site 
(GTCGAC), a T7RNA 
polymerase promoter, GG 
residues immediately upstream 
of the 5′ terminus of viral 
sequence 
6F-5′FT7g 
 
 
GGC TGT GTC GAC TAA TAC GAC TCA CTA TAG 
TTA AAA CAG CCT GTG GGT TGC 
 
 
 
Contains a SalI site, a T7RNA 
polymerase promoter, G 
residue immediately upstream 
of the 5′ terminus viral 
sequence 
 
6F-5′T7GG 
 
 
GGC TGT GTC GAC TAA TAC GAC TCA CTA TAG 
GTT AAA ACA GCC TGT GGG TTG C 
 
 
 
Contains a SalI site, a T7RNA 
polymerase promoter, GG 
residues immediately upstream 
of the 5′ terminus viral 
sequence 
 
6F02R 
 
 
 
GGA TCC GAC GTC ACG CGT TTT TTT TTT TTT 
TTT TTT TTT TTT GCT ATT CTG GTT 
 
 
 
Contains AatII (GACGTC) and 
MluI (ACGCGT) sites, 25 
polyA at the 3′ terminus of viral 
sequence 
 
6F03F 
 
 
AAG CTT GTC GAC TCC GGA CCC AGA CCA CTT 
TGA CGG 
 
Contains a SalI site adjacent to 
viral sequence          
 
6F04R 
 
 
AAG CTT GAC GTC TCC GGA GGT AAG GAA TAC 
ACA CTG 
 
Contains AatII site adjacent to 
viral sequence 
6FMID 
 
TCT AGA GAA TTC TCC GGA GGT AAG GAA TAC 
ACA CTG 
 
Contains EcoRI (GAATTC) 
site adjacent to viral sequence 
6F-MluI 
 
CCG CGG GAA TTC ACG CGT TTT TTT TTT TTT 
TTT TTT TTT TTT GCT ATT CTG GTT 
 
Contains EcoRI and MluI sites, 
25 polyA at the 3′ terminus of 
viral sequence  
 
26M-2806F  GTG GAG TTG TTC ACC TAC ATG CG  No special features 
 
26M-3111R  CGC TCC ATA TTC AAG GTC TTT CTC C  No special features 
CA16-3′MluI 
 
GAT CCC CGG GGC GGC CGC ACG CGT TTT TTT 
TTT TTT TTT TTT TTT TTT TGC TAT TCT GG 
 
 
Contains NotI (GCGGCCGC) 
and MluI sites, 26 polyA at the 
3′ terminus of viral sequence 
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Figure 2.1  The schematic diagram of the construction of the sub-genomic and full-length cDNA clones of HEV71-6F in pBR322.
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(b)  Construction of the 3′ half clone, pBR/3′-6F 
A 3′ terminus fragment spanning nucleotides 4551-7409 of the viral genome and 25 
poly A tail was amplified by PCR using primers 6F03F and 6F02R.  A unique SalI 
site was incorporated into the forward primer, 6F03F, upstream of nucleotide 4551, 
and  MluI and AatII sites were incorporated into the reverse primer, 6F02R, 
downstream of the poly A tail.  The PCR was performed using the conditions 
described in section 2.2.11.  The PCR product was then digested with SalI and AatII.  
The excised SalI-AatII fragment was subsequently cloned into SalI and AatII sites of 
plasmid pBR322.  The resultant clone, pBR/3′-6F, is 6,528 nucleotides in length. 
 
(c)  Construction of the full-length cDNA clone, pBR/HEV71-6F  
The full-length clone pBR/HEV71-6F was constructed by excising a BspEI
4551-AatII 
fragment from clone pBR/3′-6F and then the fragment was cloned into the BspEI
4551-
AatII sites of clone pBR/5′-6F.  The resultant clone was 11,097 nucleotides in length 
and contained a T7 RNA polymerase promoter and additional G residues (2G or 3G) 
upstream of the viral cDNA and 25 poly A tail. 
2.2.13.3  Construction of a full-length cDNA clone of HEV71 strain 
6F in a low copy number plasmid, pMC18 
The steps involved in the construction of sub-genomic and full-length cDNA clones 
of HEV71-6F in pMC18 are shown in Figure 2.2. 
(a)  Construction of the 5′ half clone, pMC/5′-6F 
A 5′ terminus fragment of the viral genome spanning nucleotides 1-4551 was 
generated by PCR as described in section 2.2.11.  Forward primers, 6F-5′ T7GG or 
6F-5′ T7G, and reverse primer, 6F-MID, were used in the PCR reaction.  SalI 60 
Figure 2.2  The schematic diagram of the construction of the sub-genomic and full-length cDNA clones of HEV71-6F in pMC18. 
  
 
 restriction site, T7 RNA polymerase promoter and G residues (1G or 2G) were 
incorporated into the forward primer upstream of the viral genome, and EcoRI site 
was added into the reverse primer downstream of nucleotide 4551.  The PCR product 
was digested with SalI and EcoRI, and the fragment cloned into plasmid pMC18 at 
the SalI and EcoRI sites.  The resultant clone, pMC/5′-6F, is 9,952 nucleotides in 
length. 
 
(b)  Construction of the 3′ half clone, pMC/3′-6F 
A 3′ terminal covering nucleotides 4551-7409 of the viral genome and 25 poly A tail 
was amplified using primers 6F03F and 6FMluI, with SalI and EcoRI sites were 
incorporated into forward and reverse primers, respectively.  PCR conditions were as 
described in 2.2.11.  The PCR product was digested with SalI and EcoRI, and the 
excised fragment was then cloned into SalI- and EcoRI-predigested pMC18.  The 
resultant clone, pMC/3′-6F, is 8,272 nucleotides in length. 
 
(c)  Construction of the full-length clone, pHEV71-6F  
The genome-length clone pHEV71-6F was constructed by excising a BspEI
4551-
EcoRI fragment from clone pMC/3′-6F and then cloned into the BspEI
4551-EcoRI 
sites of clone pMC/5′-6F.  The resultant clone was 12,835 nucleotides in length and 
contained a T7 RNA polymerase promoter and additional GG or G residues 
upstream of the viral cDNA. 
2.2.13.4  Construction of a full-length cDNA clone of HEV71 strain 
26M in low copy number plasmid, pMC18  
The full genome sequence of HEV71-26M was kindly provided by Beng Hooi Chua, 
Division of Virology, Telethon Institute for Child Health Research, Perth, Australia 
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(GenBank Accession number EU364841).  The numbering of nucleotides in sub-
genomic and full-length clones corresponds to the viral genome sequence as shown 
in the Appendix A.  Figure 2.3 is a schematic diagram of the construction of the sub-
genomic and full-length cDNA clones of HEV71-26M in pMC18. 
 
(a)  Construction of the 5′ half clone, pMC/5′-26M 
A cDNA copy of the 5′ terminus spanning nucleotides 1-3114 was generated by 
PCR.  PCR reactions were similar to the conditions described in 2.2.11, except that 
the primers 6F-5′ T7GG, and 26M-3111R were used in amplification.  Restriction 
enzymes SalI and EcoRI were then used to digest the PCR product, and then a SalI-
EcoRI
2842 fragment was cloned into SalI- and EcoRI-predigested
  pMC18.  The 
resultant clone, pMC/5′-26M, is 8,237 nucleotides in length. 
 
(b)  Construction of the 3′ half clone, pMC/3′-26M 
A cDNA fragment covering nucleotides 2809-7409 of the viral genome and 25 poly 
A tail was amplified by PCR using primers 26M-2806F and CA16-3′MluI.  A unique 
NotI restriction enzyme site was incorporated into the reverse primer downstream of 
the polyA tail for cloning.  The fragment PCR was cut by EcoRI and NotI restriction 
enzymes, and a EcoRI
2842-NotI fragment was cloned into pMC18 at the EcoRI and 
NotI sites.  The resultant clone, pMC/3′-26M, is 9,964 nucleotides in length.   
 
(c)  Construction of the full-length clone, pHEV71-26M  
The full-length cDNA clone, pHEV71-26M was constructed by excising a SalI-
EcoRI
2842 fragment from clone pMC/5′-26M and then cloned into the SalI-EcoRI
2842 
sites of clone pMC/3′-26M.  The resultant clone is 12,803 nucleotides in length and 63 
Figure 2.3  The schematic diagram of the construction of the sub-genomic and full-length cDNA clones of HEV71-26M in pMC18.
 
 
 contains a T7 RNA polymerase promoter and additional GG residues upstream of the 
viral cDNA.   
2.2.14  Construction of chimeric recombinant viruses 
between HEV71-6F and HEV71-26M 
To identify the molecular determinants affecting phenotypic differences between 
strains HEV71-6F and HEV71-26M, a collection of chimeric recombinant viruses, 
exchanging the corresponding 5′ UTR, structural protein genes (P1 region), and non-
structural protein genes (P2 and P3 regions) between these two strains, were 
constructed.  In order to design the constructs, the full genome sequences of both 
strains were compared and found to have 80% nucleotide sequence identity.  All 
chimeric recombinant viruses were constructed using fusion PCR and/or site-
directed mutagenesis, and plasmids pHEV71-6F and pHEV71-26M were used as the 
templates.  The list of chimeric recombinant constructs is shown in Table 2.6.  The 
construction procedures of each clone are described in detail below.  Primers used 
for construction of all chimeric recombinant clones are listed and described in Table 
2.7. 
2.2.14.1  Naming system 
The name of the recombinant constructs is presented in the form pA/B/C, where A is 
a backbone virus, B is the exchanged genomic region, and C is the name of virus 
providing the exchanged genomic region.  For example, plasmid p6F/5′UTR/26M 
contains 5′ UTR from HEV-26M, while the rest of the viral cDNA genome is from 
HEV71-6F. 
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Table 2.6  Chimeric recombinant clones between HEV71-6F and HEV71-26M 
 
Plasmid clone  Derived virus  Description* 
 
p6F/5′UTR/26M 
 
CDV-
6F/5′UTR/26M Contains  5′UTR of 26M, P1 of 6F, P2 and P3 of 6F  
 
p26M/5′UTR/6F 
 
CDV-
26M/5′UTR/6F 
Contains 5′UTR of 6F, P1 of 26M, P2 and P3 of 
26M  
 
p6F/P1/26M 
 
CDV-6F/P1/26M  Contains 5′UTR of 6F, P1 of 26M, P2 and P3 of 6F 
 
p26M/P1/6F 
 
CDV-26M/P1/6F 
Contains 5′UTR of 26M, P1 of 6F, P2 and P3 of 
26M 
 
p6F/NS/26M 
 
CDV-6F/NS/26M  Contains 5′UTR of 6F, P1 of 6F, P2 and P3 of 26M 
 
p26M/NS/6F 
 
CDV-26M/NS/6F 
Contains 5′UTR of 26M, P1 of 26M, P2 and P3 of 
6F 
 
*All plasmid clones contain a T7 RNA polymerase promoter, GG residues, 25 poly A; 
cloned into plasmid vector pMC18 
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between HEV71-6F and HEV71-26M 
 
Primer Name  Nucleotide Sequence (5´-3´)∗  Special features 
6FIRES26MF 
 
ACA GTC AAA CAT GGG CTC ACA GGT GTC 
CAC 
 
No special features 
6FIRES26MR 
 
TAC CCG ATC GCT GTA ACC AC 
  No special features 
 
6F-5′T7GG 
 
 
GGC TGT GTC GAC TAA TAC GAC TCA CTA 
TAG GTT AAA ACA GCC TGT GGG TTG C 
 
 
Contains a SalI site, a 
T7RNA polymerase 
promoter, GG residues 
immediately upstream of 
the 5′ terminus viral 
sequence 
26MIRES6FF 
 
CACAACCAAAT ATGGGCTCACAAGTGTCTAC 
  No special features 
 
26M-1576R 
 
 
GGT TCA GGG CAG AGT CGA AAG G  No special features 
6FBlnIF 
 
CGC ACA GCT ATC ACC ACC CTA GGG AAA 
TTT G 
 
Contains a single point 
mutation A to introduce 
BlnI site (CCTAGG) 
6FBlnIR 
 
AGG GTG GTG ATA GCT GTG CGA CTG GCA 
CCA 
  No special features 
26MBlnIF 
 
GTA CTG CCA TTA CTA CCC TAG GAA AGT 
TCG 
 
 
Contains a single point 
mutation A to introduce 
BlnI site  (CCTAGG) 
26MBlnIR 
 
AGG GTA GTA ATG GCA GTA CGG CTA GTG 
CCG 
  No special features 
6FP126MR 
 
GTA GAC ACT TGT GAG CCC ATA TTT GGT 
TGT G 
  No special features 
 
6FP126MR2 
 
CCA AAT TTC CCT AGG GTA GTA ATG GCA  Contains BlnI site   
 
26MP16FR 
 
GTG GAC ACC TGT GAG CCC ATG TTT 
GAC TGT A  No special features 
 
26MP16FR2 
 
TGT CCA AAT TTC CCT AGG GTG GTG ATA 
GCT G  Contains BlnI site   
     
 
∗26M sequences are underlined. Restriction sites are in bold font. 
 
  662.2.14.2  Nucleotide numbering system 
The numbering of nucleotides in sub-genomic and full-length clones corresponds to 
the viral genome sequences as shown in the Appendix A.  Nucleotide numbering is 
presented in the form X
YZ, where X is the restriction enzyme site, and superscript Y 
is the name of the virus, and superscript Z is the nucleotide position. 
2.2.14.3 Construction of the chimeric virus cDNA clone, 
p6F/5′UTR/26M 
Chimeric virus cDNA clone p6F/5′UTR/26M was constructed using fusion PCR and 
molecular cloning.  A fragment containing part of the 5′ UTR of 26M (10 nt) and 
part of the 6F P1 region (246 nt) was amplified by PCR, as described in section 
2.2.11, using pHEV71-6F as template DNA.  Forward primer, 6FIRES26MF, 
contained 10 bp of the 3′ end of 26M 5′ UTR adjacent to 20 bp of the 5′ end of 6F P1 
region, and the reverse primer, 6FIRES26MR, contained 6F P1 region that has a 
BbvCI
6F961 restriction site for cloning.  The resultant PCR product was purified and 
used as a reverse primer for a second round PCR, in which primer 6F-5′ T7GG was 
used as a forward primer to amplify the whole 26M 5′ UTR from pHEV71-26M 
template.  Fusion PCR product was digested with SalI and BbvCI
6F961, and a SalI-
BbvCI
6F961  fragment was cloned into SalI- and BbvCI
6F961-predigested plasmid 
pHEV71-6F in a three-fragment ligation reaction.  
2.2.14.4 Construction of the chimeric virus cDNA clone 
p26M/5′UTR/6F 
Chimeric virus cDNA clone p26M/5′UTR/6F was constructed using a similar 
strategy to p6F/5′UTR/26M.  The first round PCR was performed using primers 
  6726MIRES6FF and 26M-1576R.  PCR conditions were as described in 2.2.11, with 
pHEV71-26M used as template DNA.  Forward primer, 26MIRES6FF, contained 11 
bp of the 3′ end of 6F 5′ UTR and 20 bp of the 5′ end of 26M P1 region.  The reverse 
primer, 26M-1569R was part of 26M P1 region.  The second round PCR to amplify a 
full 5′ UTR of 6F from pHEV71-6F template was performed using forward primer, 
6F-5′ T7GG, and gel-purified first round PCR product as a reverse primer.  The 
fusion PCR product was digested with SalI and BsiwI
26M1442, and a SalI-BsiwI
26M1442 
fragment was cloned into SalI- and BsiwI
26M1442-predigested plasmid pHEV71-26M. 
2.2.14.5  Construction of pHEV71-6FBlnI and pHEV71-26MBlnI 
To facilitate the construction of other chimeric recombinant viruses, a BlnI 
restriction site was introduced into the parental clones, pHEV71-6F and pHEV71-
26M at the P1/P2 junction by site-directed mutagenesis.  Briefly, a PstI
6F530- 
BamHI
6F5864 fragment of pHEV71-6F was excised and then sub-cloned into 
pGEM3Z.  The resultant clone, pGEM3Z-6F was 8,059 nucleotides in length.  An 
EcoRI
26M2842 - EcoRV
26M4819 fragment of pHEV71-26M, spanning the 26M P1 and 
P2 regions, was sub-cloned into pBR322.  The resultant clone, pBR-26M, was 6,151 
nucleotides in length.  Both sub-genomic clones, pGEM3Z-6F and pBR-26M, were 
then methylated using HpaI methylase enzyme.  The methylation reaction contained 
plasmid DNA (100 ng), 1XSAM, 1X methylation buffer as supplied by the 
manufacturer and 4 units HpaI methylase.  The reaction was incubated at 37˚C for 4 
h before incubation at 65˚C for 15 min to inactivate the enzyme.  Methylated 
plasmids were then used for subsequent PCR mutagenesis reactions. 
 
Mutagenesis was achieved by designing a forward primer for PCR containing a 
single C to A transition mutation at nucleotide position 3,330 for HEV71-6F and T 
  68to A mutation at nucleotide position 3,333 for HEV71-26M.  This mutation did not 
change the encoded amino acid sequence of either strain.  PCR conditions are 
described below. 
 
DNA template (100 ng of methylated pGEM3Z-6F or pBR-26M), 10 μM each of 
primers (primers 6FBlnIF and 6FBlnIR or primer 26MBlnIF and 26MBlnIR), 200 
μM of dNTP’s, 2.5 U of platinum Taq DNA polymerase High Fidelity, and 1x 
concentration of enzyme buffer (as supplied by the manufacturer) were combined in 
a final volume of 50 μL.  The amplifications were performed in an automated 
thermocycler, with an initial denaturation at 94˚C for 2 min, followed by 20 cycles of 
94˚C for 30 s, 55˚C for 30 s and 68˚C for 5 s, then a final incubation at 68˚C for 10 
min.  One hundred nanograms of PCR products were then transformed into E. coli 
strain XL1-blue.  Plasmids pGEM3Z-6F and pBR-26M with an introduced BlnI site 
were screened by restriction enzyme digestion and sequencing and positive clones 
selected.  Plasmid pGEM3Z-6F+BlnI site was digested with StuI and BspEI to excise 
a  StuI
6F1689-BspEI
6F4551 fragment.  This fragment was then cloned back into 
pHEV71-6F to generate pEV71-6FBlnI.  Plasmid pBR-26M+BlnI was digested with 
KpnI and EcoRV.  The excised KpnI
26M3062-EcoRV
26M4819 fragment was cloned back 
into pHEV71-26M to create pHEV71-26MBlnI. 
2.2.14.6  Construction of the chimeric virus cDNA clone 
p6F/P1/26M 
Construction of the chimeric virus cDNA clone p6F/P1/26M was performed using 
fusion PCR.  The 796 nt fragment containing 6F 5′ UTR adjacent to the 5′ terminus 
(20 nt) of 26M P1 was amplified by PCR using primer 6F-5′ T7GG and a reverse 
  69primer 6FP126MR.  This gel purified fragment was then used in the second round 
PCR as a forward primer and 6FP126MR2 (containing a BlnI site) was used as a 
reverse primer.  Both PCR reactions were performed in the conditions described in 
2.2.11.  The fusion PCR product was 3,362 nt in length and contained 6F 5′UTR and 
26M P1.  The PCR product was digested with SalI and BlnI
26M3333, and a gel purified 
SalI-BlnI fragment cloned into pHEV71-6FBlnI to generate p6F/P1/26M. 
2.2.14.7  Construction of the chimeric virus cDNA clone 
p26M/P1/6F 
Chimeric virus cDNA clone p26M/P1/6F was constructed using a similar procedure 
to the construction of p6F/P1/26M.  Primers 6F-5′ T7GG and 26MP16FR were used 
in the first round PCR.  The 799 nt PCR product containing 26M 5′ UTR adjacent to 
the 5′ terminus (20 nt) of 6F P1 was used for a second round PCR with a reverse 
primer, 26MP16FR2.  The fusion PCR product was 3,365 nt in length and contained 
26M 5′ UTR and 6F P1.  The product was digested with SalI and BlnI, and a gel 
purified SalI-BlnI
6F3330 fragment was then cloned into pHEV71-26MBlnI to generate 
p26M/P1/6F.  
2.2.14.8  Construction of the chimeric virus cDNA clone 
p6F/NS/26M 
Chimeric virus cDNA clone p6F/NS/26M was constructed by digestion of plasmid 
pHEV71-26MBlnI with BlnI and MluI.  The excised BlnI
26M3333-MluI fragment was 
then cloned into BlnI6F
3330-and  MluI-predigested plasmid pHEV71-6FBlnI to 
produce p6F/NS/26M. 
  702.2.14.9  Construction of the chimeric virus cDNA clone 
p26M/NS/6F 
Chimeric virus cDNA clone p26M/NS/26M was constructed by digestion of plasmid 
pHEV71-6FBlnI with BlnI and MluI.  The excised BlnI
6F3330-MluI fragment was then 
cloned into BlnI
26M3333-and  MluI-predigested pHEV71-26MBlnI to produce 
p26M/NS/6F. 
2.2.15  Construction of the chimeric recombinant viruses 
between the parental strain HEV71-26M and its mouse-
adapted strain (MP-26M) 
To identify genetic determinants of mouse adaptation and virulence, chimeric 
recombinant viruses between the parental strain 26M and its mouse-adapted strain, 
MP-26M were constructed.  pHEV71-26M was used as a backbone plasmid, and 
one, two or three mutations of MP-26M were introduced into the clone at the 
corresponding sites to produce mutant viruses.  The list of recombinant clones is 
shown in Table 2.8.  The clone construction methods included RT-PCR of mouse-
adapted virus, restriction enzyme digestion and cloning, as described in detail below.  
Primers used for construction of all chimeric recombinant viruses between HEV71-
26M and MP-26M are listed and described in Table 2.9. 
2.2.15.1  Naming system 
The name of the recombinant constructs is presented in the form pA-Bm (one 
mutation) or pA-B-Cm (two mutations) where A is a backbone virus HEV71-26M, 
and B and C are the genomic regions containing amino acid substitutions of MP-
26M.  For example, plasmid p26M-VP2m contains an amino acid substitution of 
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Table 2.8  Chimeric recombinant clones between HEV71-26M and MP-26M 
 
Plasmid clone  Derived virus  Description*# 
p26M-VP2m 
 
CDV-26-VP2m 
 
Contains viral cDNA of the 26M genome with a 
mutation in the VP2 protein 
p26M-VP1m 
 
CDV-26M-VP1m 
 
Contains viral cDNA of the 26M genome with a 
mutation in the VP1 protein  
p26M-2Cm 
 
CDV-26M-2Cm 
 
Contains viral cDNA of the 26M genome with a 
mutation in the 2C protein  
p26M-VP1-2Cm 
 
CDV-26M-VP1-2Cm 
 
Contains viral cDNA of the 26M genome with 
mutations in the VP1 and 2C proteins 
p26M-VP2-2Cm 
 
CDV-26M-VP2-2Cm 
 
Contains viral cDNA of the 26M genome with 
mutations in the VP2 and 2C proteins 
p26M-VP2-VP1m 
 
CDV-26M-VP2-
VP1m 
 
Contains viral cDNA of the 26M genome with 
mutations in the VP2 and VP1 proteins 
pMP-26M 
 
CDV-MP-26M 
 
Contains viral cDNA of the 26M genome with 
mutations in the VP2, VP1 and 2C proteins 
 
*All plasmid clones contain a T7 RNA polymerase promoter, GG residues, 25 poly A; 
cloned into plasmid vector pMC18 
# VP2 mutation is at nucleotide A1400→T or amino acid K218→I. 
   VP1 mutation is at nucleotide G2876→A or amino acid G710→E. 
   2C mutation is at nucleotide A4727→G or amino acid K1327→R. 
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Table 2.9  Primers used for construction of chimeric recombinant viruses 
between HEV71-26M and MP-26M 
 
Primer Name  Nucleotide Sequence (5´-3´)  Special features 
 
26M-553F 
 
CAG CGG AAC CGA CTA CTT TGG G 
 
No special features 
26M-2806F  GTG GAG TTG TTC ACC TAC ATG CG  No special features 
26M-3111R  CGC TCC ATA TTC AAG GTC TTT CTC C  No special features 
CA16-3′MluI 
 
 
GAT CCC CGG GGC GGC CGC ACG CGT TTT 
TTT TTT TTT TTT TTT TTT TTT TGC TAT TCT 
GG 
 
 
Contains NotI and MluI sites, 
26 polyA at the 3′ terminus 
of the viral sequence 
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mutations) was named pMP-26M. 
2.2.15.2  Nucleotide numbering system 
The numbering of nucleotides in sub-genomic and full-length clones corresponds to 
the viral genome sequences, as shown in the Appendix A.  Nucleotide numbering is 
present in the form X
Y, where X is the restriction enzyme site, and superscript Y is 
the nucleotide position that is identical between these two strains. 
2.2.15.3  Construction of the chimeric virus cDNA clone p26M-
VP2m 
The first strand cDNA of the mouse-adapted strain, MP-26M, was generated using 
SuperScript
TM  III reverse transcriptase (Invitrogen) as described in 2.2.10 with 
primer CA16-MluI.  A fragment of nucleotide 533-3111 was then amplified by PCR 
using primers 26M-533F and 26M-3111R.  The PCR fragment was digested with 
HindIII
  and  EcoRI, and a HindIII
968-EcoRI
2842 digested fragment was then sub-
cloned into HindIII- and EcoRI- predigested pBR322.  The resultant plasmids, 
pBRMP-VP2, were screened by restriction enzyme digestion and sequencing.  A 
positive clone, pBRMP-VP2, was digested with HindIII and BsiwI, and then the 
excised  HindIII
968-BsiwI
1442 fragment cloned into the corresponding fragment of 
pHEV71-26M to produceHEV71-26M with the VP2 mutation (nt A1400→T or aa 
K218→I). 
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VP1m 
Clone p26M-VP1m was constructed by PCR amplification of a 4,654 fragment of 
MP-26M using primers 26M-2806F and CA16-3′MluI.  An EcoRI
2842 - EcoRV
4819 
digested PCR fragment was sub-cloned into pBR322.  The resultant clones, pBRMP 
were screened by restriction enzyme digestion and sequencing.  Clone pBRMP was 
digested with EcoRI and KpnI, and the excised EcoRI
2842- KpnI
3062 fragment cloned 
into the corresponding fragment of pHEV71-26M to produce HEV71-26M with the 
VP1 mutation (nt G2876→A, aa G710→E). 
2.2.15.5  Construction of the chimeric virus cDNA clone p26M-
2Cm 
Clone p26M-2Cm was constructed from plasmids pBRMP and pEV71-26M.  Both 
plasmids were digested with KpnI and EcoRV.  An excised KpnI
3062- EcoRV
4819 
fragment from pBRMP was cloned into KpnI
3062-  and  EcoRV
4819-  predigested 
plasmid pHEV71-26M to produce HEV71-26M with the 2C mutation (nt 
A4727→G, aa K1327→R). 
2.2.15.6  Construction of the chimeric virus cDNA clone p26M-
VP1-2Cm 
To construct clone p26M-VP1-2Cm, plasmids pBRMP and pHEV71-26M were 
digested with EcoRI and EcoRV.  An excised EcoRI
2842-EcoRV
4819 fragment from 
pBRMP was cloned into EcoRI
2842- and EcoRV
4819-predigested plasmid pHEV71-
26M to generate mutant HEV71-26M with the VP1 and 2C mutations. 
  752.2.15.7  Construction of the chimeric virus cDNA clone p26M-
VP2-2Cm 
Clone p26M-VP2-2Cm was constructed from plasmids pBRMP and p26M-VP2m.  
Both plasmids were digested with KpnI  and EcoRV.  An excised KpnI
3062- 
EcoRV
4819  fragment from pBRMP was cloned into KpnI
3062-  and  EcoRV
4819- 
predigested plasmid p26M-VP2m. 
2.2.15.8  Construction of the chimeric virus cDNA clone p26M-
VP2-VP1m 
Clone p26M-VP2-VP1m was constructed from plasmids pBRMP and p26M-VP2m.  
Plasmid pBRMP was digested EcoRI and KpnI, and the excised EcoRI
2842- KpnI
3062 
fragment was cloned into the corresponding fragment of p26M-VP2m to produce 
mutant HEV71-26M with the VP2 and VP1 mutations. 
2.2.15.9  Construction of the chimeric virus cDNA clone pMP-26M 
A full-length clone of MP-26M was constructed from plasmids pBRMP-VP2 and 
p26M-VP1-2Cm.  Both plasmids were digested with HindIII and BsiwI.  An excised 
HindIII
968-BsiwI
1442  fragment from pBRMP-VP2 was cloned into HindIII
968- and 
BsiwI
1442 –predigested plasmid p26M-VP1-2Cm. 
2.2.16  In vitro transcription (IVT) of viral RNA from a cDNA 
template 
Plasmids containing full-length HEV71 cDNA were linearlised with MluI for at least 
4 h, followed by incubation at 50ºC with proteinase K (200 µg/mL) and SDS (0.5%).  
Approximately 1 µg of linearlised plasmid was purified by phenol/chloroform 
extraction and ethanol precipitation and resuspended in 8 µL of nuclease-free water.  
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reaction mixture according to manufacturer’s instruction.  The reaction mixture was 
incubated at 37ºC for 4 h, followed by the addition of 1 µL DNaseI to remove the 
DNA template.  RNA products were precipitated by adding 2.5 M Lithium chloride 
at -20ºC for 1 h, and then pelleted by centrifugation for 15 m at 13,200 rpm, washed 
with 70% ethanol, and resuspended in nuclease-free water.  The concentration of 
RNA was quantified using spectrophotometry or by running RNA samples on a 
denaturing formaldehyde-agarose gel. 
2.2.17  Transfection  
(a)  Transfection of RNA and DNA to rescue clone-derived virus 
Transfections of in vitro transcribed RNA or plasmid full-length cDNA clones were 
performed on COS-7 cells using Lipofectamine
TM 2000 (Invitrogen) according to 
manufacturer’s protocols.  Briefly, COS-7 cells were seeded into 12-well tissue 
culture trays (Cellstar) at a density of 3x10
5 cells/well.  Cells were grown in DMEM 
supplemented with 2 mM L-glutamine and 5% BGS.  After incubation for 18-24 h, 
cells were washed once with PBS and replaced with serum-free medium, Optimem 
(Invitrogen), prior to transfection.  For transfection of RNA, the lipid-nucleic acid 
complex containing 1 or 3 μg of transcribed RNA and 3 μL of Lipofectamine
TM 
2000 was added to the cells.  For DNA transfection, 1.6 μg of each full-length cDNA 
clone construct, 1.6 μg pCMV-T7Pol and 4 μL of Lipofectamine
TM 2000 was added 
to the cells.  Transfected cells were incubated for 4 h, after which the transfection 
medium was removed and replaced with DMEM supplemented with 2 mM L-
glutamine and 2% FCS, and the cells incubated for a further 72 h.  Transfected cells 
were then subjected to three cycles of freeze-thawing and the virus supernatant 
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viruses (CDV) were then passaged to increase the titre for subsequent assays or were 
stored at -80 ºC until required.  
 
(b) Transfection of DNA to determine transfection efficiency 
Plasmid pcDNA-lacZ expressing β-gal was used to transfect cell lines used in this 
study to determine transfection efficiency.  RD, Vero or COS-7 cells were seeded in 
a 24-well tissue culture tray (Cellstar).  The seeding density was such that the cells 
were approximately 90% confluent at the time of transfection.  Cells were 
transfected with pcDNA-lacZ (0.8-1.6 μg) and Lipofectamine
TM 2000 (1-3 μL), 
following the protocol as described above.  Transfected cells were incubated for 24 
h, and in situ staining was then performed to detect β-gal expression.  Briefly, 
transfected cells were washed with D-PBS (2.7 mM KCl, 1.1mM KH2PO4, 0.41 M 
NaCl, 8.1 mM Na2HPO4.7H2O), and then fixed for 5 min at RT with fixative (D-
PBS, 2% formaldehyde, 0.05% glutaraldehyde).  Cells were then washed twice with 
D-PBS, followed by staining with substrate/stain solution (D-PBS, 5 mM potassium 
ferricyanide, 5mM potassium ferrocyanide, 2 mM MgCl2, 1mg/mL X-gal).  After 
incubation for at least 2 h, the cells were observed and evaluated for the proportion 
of β-gal-positive (blue) cells. 
2.2.18  Stability testing of full-length infectious cDNA clones 
of HEV71-6F and HEV71-26M 
The instability of the viral cDNA during passage in bacteria is a common problem 
encountered in the construction of full-length infectious cDNA clones.  Therefore, 
the genetic structure and functional integrity of full-length infectious cDNA clones 
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containing 100 μg/mL ampicillin at two different incubation temperatures, 37˚C or 
30˚C, for five passages.  Briefly, plasmids pHEV71-6F or pHEV71-26M were 
transformed into E. coli XL10-gold.  Two clones of each construct were 
subsequently selected and grown in 6 mL of 2YT at 37˚C or 30˚C for 16 h, then 
plated onto 2YT agar.  The inoculated plates were incubated at 37˚C or 30˚C for 
about 18-24 h.  Two isolated colonies were picked from each plate, and grown in 6 
ml of 2YT at 37˚C or 30˚C for 16 h, then plated onto 2YT agar.  Colonies were 
picked after 18-24 h of incubation.  The passages were repeated ten times, and 
plasmid mini-preparations were performed from 2YT culture media at passages 1 
and 5.  The genetic structure of the clones was examined by restriction endonuclease 
digestion with BglI or PvuII for pHEV71-6F and pHEV71-26M, respectively.  
 
The functional integrity of these clones was assessed by infectivity testing.  Briefly, 
COS-7 cells were seeded in a 24-well tissue culture tray (Cellstar) at a density of 
1.6x10
5 cells/well.  After incubation for 24 h, 0.8 μg of plasmids pHEV71-6F or 
pHEV71-26M and 0.8 μg of pCMV-T7 were co-transfected into COS-7 cells using 3 
μL of Lipofectamine
TM 2000 (Invitrogen), following the protocol described in 
section 2.2.17.  Viral RNA was transcribed in the transfected cells by T7 RNA 
polymerase.  Transfected cells were freeze-thawed three times, and clarified by 
centrifugation.  Virus supernatants were then determined for viral titre by TCID50.  
2.2.19  In vivo translation efficiency and luciferase assays 
The IRES translation efficiencies of strains HEV71-6F and HEV71-26M were 
compared using bi-cistronic constructs and luciferase assays.  Each bi-cistronic 
  79construct contained two luciferase genes; renilla luciferase (LucR) and firefly 
luciferase (LucF).  LucR is controlled by the cytomegalovirus immediate-early 
promoter (IE) and LucF was controlled by a hairpin structure, HEV71-6F IRES or 
HEV71-26M IRES for pCRHL, pCR6F and pCR26M, respectively.  RD or COS-7 
cells were seeded onto 24-well plates and incubated for 24 h to reach about 90% 
confluency at the time of transfection.  One microgram of each bi-cistronic construct 
and 3 μL of Lipofectamine
TM 2000 were transfected into the cells using the protocol 
described in 2.2.17.  Cells were assayed for luciferase activity at 24 h post-
transfection using dual luciferase reagents (Promega), following the manufacturer’s 
protocol, and were quantitated using a Luminometer (Ascent). 
2.2.20  Stability testing of mouse-adapted virus in vitro and 
in vivo 
Mutations in the VP2, VP1, and 2C genes of the mouse-adapted strain MP-26M 
were examined for genetic stability by serial passage of MP-26M in RD, Vero or 
CHO cells for five passages.  Virus stocks from each passage were collected and 
viral RNA extracted.  A part of the VP2, VP1, and 2C genes covering the mutation 
sites were amplified by RT-PCR, and the amplified products sequenced. 
 
The stability of the VP2, VP1 and 2C mutations in MP-26M was also tested by five 
serial passages in mice.  Briefly, a group of seven day-old mice were inoculated with 
MP-26M by the intramuscular (i.m.) route.  Mice were observed twice daily for 
clinical signs of infection.  At 4 and 5 days post-infection, brain and muscle tissues 
were aseptically collected from infected mice after perfusion with PBS.  The tissue 
samples were immediately frozen in liquid nitrogen and stored at -80˚C until used.  
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solution (HBSS, pH8), freeze-thawed three times and centrifuged.  Five microliters 
of clarified virus supernatant from muscle tissue was then used to inoculate a further 
group of seven day-old mice; the passage was repeated five times. 
2.3  Virus Assays 
2.3.1  Plaque assays 
Vero cell monolayers in 12-well tissue culture trays (Cellstar) at a density of 2.2x10
5 
cells/well or RD cells at 3x10
5 cells/well, were used for plaque assays.  Ten-fold 
serial dilutions of virus were inoculated at 100 µL per well.  After incubation for 30 
min at 37ºC, virus was removed and the cells washed with PBS.  Cells were then 
overlaid with 1 mL of 0.5% agarose (ICN) in DMEM supplement with 2 mM L-
glutamine and 2.5% FCS.  After incubation for four days, 0.5% agarose in 
2.5%FCS/DMEM was overlaid onto the first layer of agarose gel and further 
incubated for three days.  The cells were then fixed and stained with crystal violet 
solution (1% crystal violet (w/v), 10% formaldehyde in PBS) to visualise plaques.  
2.3.2  Median tissue culture infectious dose (TCID50) 
TCID50 assays were used to determine virus titres.  Monolayers of Vero cells in 96-
well tissue culture trays at a density of 1x10
4 cells/well (Cellstar) were inoculated 
with 100 µL of ten-fold serial dilutions of virus solution per well and then incubated 
at 37ºC with 5% CO2 for 5 days before observing for CPE.  TCID50 titres were 
determined by the method of Reed and Muench (1938).   
  812.3.3  Single-step growth analysis 
Monolayers of Vero, RD, CHO or NB41A3 cells were cultured in 12- or 48-well 
tissue culture trays (Cellstar).  Virus was inoculated onto the cells at a multiplicity of 
infection (MOI) of 5 or 10TCID50 per well and then incubated for 1 h at 37ºC.  
Inoculated cells were then washed three times with PBS and overlaid with 200 µL 
DMEM supplemented with 2 mM L-glutamine and 2% FCS per well.  The cells and 
supernatants were collected every 4 h over 24 h, with the first time point (time=0) 
being collected immediately after cell inoculation.  Samples at each time point were 
freeze-thawed three times and clarified by centrifugation at 8,000xg for 10 min prior 
to determination of virus titre by TCID50 assay. 
2.3.4  Immunofluorescence assays (IFA) 
Vero or RD cells on glass coverslips in 96-well tissue culture trays (Cellstar) were 
seeded at confluent density and incubated overnight at 37ºC, prior to inoculation 
with virus.  Cells that showed CPE were fixed in 50:50 acetone/methanol for 10 min, 
then air dried.  Cells were then overlaid with mouse anti-HEV71 monoclonal 
antibody (Chemicon) or rabbit anti-HEV71 polyclonal antibody and incubated for 30 
min at 37ºC in a moist chamber.  Cells were subsequently washed in PBS for 30 min 
and air dried before being overlaid with FITC conjugate goat anti-mouse IgG or 
FITC conjugate goat anti-rabbit IgG (Sigma).  Both secondary antibodies contained 
0.2% Evans blue as a counter stain.  Cells were incubated for a further 30 min at 
37ºC in a moist chamber, then washed in PBS for 15 min and air dried.  Mounting 
fluid was added prior to visualisation under a UV light microscope (Leica BX-210) 
for fluorescence. 
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Temperature sensitivity testing of cloned-derived viruses was performed by plaque 
assay on Vero cells, as described in section 2.3.1.  Infected cells were incubated at 
33ºC, 37ºC, or 39ºC.  Plaque numbers and morphologies were compared in cells 
incubated at the different temperatures. 
2.3.6  Polyethylene glycol concentration of virus 
Virus from tissue culture supernatants was concentrated using polyethylene glycol 
6000 (PEG) to increase viral titre for oral inoculation of mice.  RD cell monolayers 
in 175 cm
2 tissue culture flasks were infected with HEV71-6F, HEV71-26M or MP-
26M at MOI of 0.1-5.  After 16 to 24 hours incubation, cells were freeze-thawed 
three times and clarified by centrifugation at 3,000 xg for 15 min.  NaCl was then 
slowly added to the virus supernatant to a final concentration of 2.2% with constant 
stirring at 4°C, followed by adding PEG to a final concentration of 7% with constant 
stirring at 4°C overnight.  Virus was collected by centrifugation for 20 min at 10,000 
xg, and the precipitated pellets were drained and resuspended in PBS with 2%BSA.  
The suspension was then centrifuged twice at 10,000 xg for 1 min, and virus 
supernatant stored at -80°C.  The infectivity and the titre of virus supernatant were 
determined using plaque and TCID50 assays. 
2.4  Mouse experiments 
All animal procedures were approved by the Animal Experimentation Ethics 
Committee of the Telethon Institute for Child Health Research, Perth, Australia.   
Animal care and observation were performed in accordance to the guidelines of the 
committee.  Animal were provided with food and water ad libitum.  Specific 
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Resources Centre, Murdoch University, Perth, Australia. 
2.4.1  Oral inoculation 
(a) Determination of gastrointestinal transit time 
In order to define a suitable fasting time before oral infection of suckling mice, 
gastrointestinal transit time was determined in newborn mice.  One-day-old BALB/c 
mice were separated from their mothers for 6 h.  They were then fed with 20-30 µL 
milk (30 mL/kg body weight) containing phenol red using a 24 gauge plastic feeding 
tube.  Mice were sacrificed at 1, 2, or 4 h after feeding and the stomach contents 
collected.  Gastric emptying at specific times were determined following the method 
described by Scarpignato et al. (1980), with slight modifications.  Briefly, the 
stomach was immersed in 100 mL of 0.1 N NaOH and homogenised.  The 
suspension was allowed to settle for 60 min at RT.  Five millilitres of supernatant 
was then added to 0.5 mL 20% w/v trichloroacetic acid (TCA).  The mixture was 
centrifuged at 3,000 xg for 20 min at 4°C, and the supernatant was added to 4 mL of 
0.5 N NaOH.  The absorbance of samples was read at a wavelength of 560 nm.  The 
gastric emptying was calculated from the presence of residual phenol red using the 
following formula; 
  
Percent gastric emptying = 1- absorbance of sample x 100 
                             ----------------------------- 
                              absorbance of standard 
 
Phenol red recovered from stomach immediately after the administration of meal 
was normalised to 100%. 
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Mice were infected orally after fasting for 2 h, using 24 gauge plastic feeding tubes.  
Virus was PEG precipitated to increase the titre, as described in section 2.3.7.  Blue 
food dye (1%v/v) tracer was added to each virus dilution prior to inoculation to 
allow the virus inoculum be visualised in the stomach through the translucent 
abdominal wall. 
2.4.2  Virulence assays in mice 
The mouse virulence phenotype of wild-type HEV71 strains 6F and 26M, the 
mouse-adapted strain MP-26M and other mutant viruses were determined by 
intraperitoneal (i.p.), intracranial (i.c.), intramuscular (i.m.) or oral inoculation of 
one-or seven- day old BALB/c mice.  The inoculation volume was 50 μL for i.p., 10 
μL for i.c., 5 μL for i.m. and 50 μL for oral inoculation.  In all experiments, infected 
animals were observed twice daily for clinical signs of illness for up to 14 days post-
inoculation and animals that succumbed to infection were euthanised by overdose of 
pentobarbitone sodium. 
 
In order to minimise distress in experimental animals, the 50% humane end-points 
(HD50) were utilized instead of 50% lethal doses (LD50).  Humane endpoints have 
been found to be almost identical to lethal endpoints in several animal models of 
viral virulence (Wright & Phillpotts, 1998).  Determination of the HD50 was 
performed by infecting groups of 8 to10 one-or seven-day-old mice with ten-fold 
serial dilutions of virus via i.p., i.m. or oral routes.  HD50s were calculated by the 
method of Reed and Muench (1938). 
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were infected with virus at an appropriate dose by the i.p. or i.m. routes.  Deaths of 
infected mice were recorded over a period of 14 days.   
2.4.3  Viral RNA extraction from mouse brain and muscle 
Brain and muscle tissues were collected after perfusion with PBS and immediately 
frozen in liquid nitrogen.  Tissues were then stored at -80˚C until used.  Tissue 
samples were thawed on ice, homogenised in 10% (w/v) HBSS (pH 8), followed by 
freeze-thawing three times.  Virus supernatant was clarified by centrifugation at 
3,000 xg for 15 min, and then at 10,000 xg for 1 min.  Virus in clarified supernatants 
was used for RNA extraction using the QIAamp® Viral RNA mini kit (Qiagen) 
according to the manufacturer’s instructions. 
 
2.5  Statistical analysis 
Statistic significance was statistically calculated using unpaired Student’s t-test 
(Elwood, 1988).  P values of less than 0.05 were considered significant 
 
2.6  Bioinformatics 
2.6.1  RNA secondary structure prediction 
 
All secondary structures were predicted using MFOLD (version 3.2) software 
program (Mathews et al., 1999, Zuker, 2003).  The parameters used are as followed; 
folding temperature at 37°C, linear RNA sequence, percent suboptimality number of 
5, upper bound on the number of computed foldings of 50, default window 
parameter, maximum interior/bulge loop size of 30, maximum asymmetry of an 
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structure draw mode of untangle with loop fix and no base numbering. 
2.6.2  Protein homology modeling 
The complete amino acid sequences of the capsid proteins VP2 and VP1 from 
HEV71-26M, CHO-26M and MP-26M were individually submitted to an online 
automated protein homology modeling program, ESyPred3D (Lambert et al., 2002); 
available on line at http://www.fundp.ac.be/sciences/biologie/urbm/bioinfo/esypred/.  
The predicted three-dimensional structure of each of the proteins were then viewed 
in RasMol 2.7 (http://rasmol.org/). 
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CONSTRUCTION OF GENOME LENGTH INFECTIOUS 
cDNA CLONES OF HEV71 GENOTYPE B3 AND C2 
STRAINS AND PHENOTYPIC CHARACTERISATION OF 
CLONED-DERIVED VIRUSES 
 
3.1  Introduction 
The development of reverse genetic systems has greatly enhanced the understanding 
of RNA virus biology.  Here, infectious cDNA clones, a double-stranded copy of the 
viral genome carried on a plasmid vector, are constructed and become templates for 
producing synthetic viruses (Racaniello, 2007).  Clone-derived viruses are generated 
by transfecting either plasmid cDNA clones or RNA transcripts derived by in vitro 
transcription into susceptible cells (Racaniello, 2007).  The first infectious cDNA 
clone of an animal RNA virus was that of poliovirus (Racaniello & Baltimore, 
1981).  Such clones facilitate genetic manipulation of RNA viral genomes and thus 
the role of specific viral genetic elements in viral replication, transcription, 
translation or virulence can be investigated.   
 
The construction of infectious cDNA clones of RNA viruses can be technically 
difficult and require extensive optimisation.  In general, the first step is reverse 
transcription of the viral RNA into a single-stranded cDNA.  A double-stranded copy 
of the viral genome is generated by PCR amplification using a single-stranded cDNA 
as a template, and the double-stranded cDNA copy cloned into a plasmid vector 
followed by transformation into a bacterial host to multiply.  The full-length cDNA 
clone is in vitro transcribed into RNA, and the RNA transcript is transfected into 
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transfected into cells directly.    
 
The recent increase in the distribution of HEV71 represents an emerging disease 
problem in the Asia-Pacific region.  In order to develop effective vaccines and 
control strategies, it is essential to understand the biology of this virus.  A reverse 
genetic system will help in investigating the molecular mechanisms of HEV71 
replication, transcription and translation, and assist in identifying the genetic 
determinants of virulence and pathogenesis.  In this study, we established a reverse 
genetic system for representative strains of HEV71 genotype B and C, the two 
genotypes associated with recent outbreaks.  The construction and characterisation of 
infectious cDNA clones of HEV71 is reported in this chapter. 
 
3.2  Results 
3.2.1  Design and construction of full-length cDNA clones of 
HEV71  
HEV71 strain 6F/AUS/6/99 (HEV71-6F) and strain 26M/AUS/4/99 (HEV71-26M), 
belonging to genotype C2 and B3, respectively, were used as parental strains for 
developing a reverse genetic system for HEV71.  Both strains were isolated from 
clinical cases during the 1999 Western Australian HFMD outbreak.  Both strains 
have been fully sequenced in our laboratory.  In order to produce infectious RNA 
from full-length cDNA clones in vitro or in vivo, the RNA polymerase promoter of 
bacteriophage T7, and an additional one, two or three G residues were positioned 
immediately upstream of the 5′ terminus of viral cDNA in order to facilitate 
transcription and to improve transcription efficiency, respectively.  A poly (A) tail of 
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downstream of the viral cDNA in order to generate synthetic virus with an authentic 
3′ terminus.   
 
Selection of appropriate plasmid vectors and bacterial host strains has been found to 
be critical for construction of infectious cDNA clones of several RNA viruses 
(Hurrelbrink et al., 1999, Lai et al., 1991, Rice et al., 1989).  The full-length cDNA 
clone of HEV71-6F was previously constructed using a high copy number plasmid 
vector, pDONR201, and amplified in E. coli strain DH5α (Beng Hooi Chua, 
unpublished data), but the clone was found to be non-infectious.  In this study, the 
full-length cDNA clone of HEV71-6F was initially constructed using a medium copy 
number plasmid, pBR322, and E. coli strain DH5α.  Plasmid pBR322 contains a 
pMB1 origin of replication (ori) and has an intermediate copy number of 40 per cell.  
pBR322 and DH5α were chosen because they have been used successfully for 
construction of infectious cDNA clones of several other enteroviruses and 
flaviviruses (Cello et al., 2002, Kapoor et al., 1995, Khromykh & Westaway, 1994, 
Mandl et al., 1997, Martino et al., 1999).  
 
Initially, the construction strategy involved amplification of the complete viral 
genome by RT-PCR and the amplified product was cloned into a plasmid vector to 
generate a full-length cDNA clone.  However, several attempts to amplify the whole 
genome of HEV71-6F from the first strand cDNA template by PCR were 
unsuccessful.  Thus, the 5′ and 3′ terminal fragments of 5,000 and 2,907 nucleotides 
in length were amplified and the resulting PCR products cloned into pBR322 to 
produce two sub-genomic clones, pBR/5′-6F and pBR/3′-6F.  The full-length 
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two overlapping fragments using appropriate unique restriction sites.  As noted 
above, these clones contained an additional one, two or three G residues at the 5′ 
terminus.  Cloning and assembly of sub-genomic and full-length clones was assisted 
by use of the computer program SECentral.  The cloning procedures are described in 
detail in section 2.2.13 and the schematic diagram of the construction of the sub-
genomic and full-length cDNA clones are shown in Figure 2.1-2.3. 
 
Sub-genomic and full-length clones of HEV71-6F were propagated in E. coli strain 
DH5α at 37˚C, and the clones were screened by restriction enzyme digestion with 
appropriate enzymes.  Of 20 full-length pBR/HEV71-6F clones screened, none were 
found to be infectious.  In order to identify the problem, one of the clones was fully 
sequenced and compared to the HEV71-6F sequence.  Sequencing results revealed 
that there were 17 nucleotide differences between HEV71-6F and pBR/HEV71-6F 
sequences (Table 3.1).  These mutations resulted in 8 deduced amino acid changes, 
located in both structural and non-structural proteins, and 2 stop codons, located in 
the viral capsid protein VP3 and in the non-structural protein 2A. 
 
The mutations found in pBR/HEV71-6F are likely to be introduced by the bacterial 
host.   It has been suggested that the instability of full-length viral cDNA clones in 
bacterial cells could be improved by changing the E. coli strain and/or the plasmid 
vector (Boyer & Haenni, 1994).  We attempted to solve this problem by changing the 
E. coli strain from DH5α to DH10B and by propagating the cells at 37˚C or at a 
reduced temperature of 30˚C.  The bacterial host strain, DH10B, has the ability to
  91Table 3.1  Differences between the sequences of HEV71-6F and full-length clone 
pBR/HEV71-6F 
 
Position in viral 
genome 
 
Nucleotide 
position 
 
 
Nucleotide 
substitution 
 
Amino acid 
substitution 
      
5′ UTR  477  A→G  - 
VP2 1694  T→C L→P 
VP3 2197  C→T  Stop codon 
(CAA→TAA) 
 
VP3 2202  G→A   
VP1 2462  T→C I→T 
VP1 2772  A→G I→M 
2A 3476  G→A G→D 
2A 3679  C→T  Stop codon 
(CAA→TGA) 
 
2A 3680  A→G  Stop codon 
(CAA→TGA) 
 
2B 3849  A→G  none 
2B 3947  T→A V→D 
3C 5631  A→G  none 
3C 5808  T→C  none 
3D 6131  A→G N→S 
3D 6508  T→C F→L 
3D 6904  A→G N→D 
3D 7056  T→C  none 
      
 
 
  92propagate large cloned DNA such as BAC constructs and allows stable replication of 
high-copy number plasmids (Raleigh et al., 1988).  Previous studies (Shi et al., 2002, 
Sriburi et al., 2001) have shown that full-length cDNA clones with medium or high 
copy number plasmids are more stable when propagated at reduced temperature. 
 
However, no infectious clone-derived virus was obtained from clone pBR/HEV71-
6F (24 clones) propagated in DH10B at either 30˚C or 37˚C.  In order to solve the 
problem, another plasmid vector, pMC18, with a seven-fold lower copy number to 
pBR322 and an additional E. coli strain, XL10-gold, were also tested.  The pMC18 
vector has been used successfully for construction an infectious cDNA clone of the 
flavivirus Murray Valley Encephalitis Virus (MVE) (Hurrelbrink et al., 1999) and is 
a modified version of the pWSK29, containing a pSC10 ori and a low copy number 
of six per cell.  Similar to E. coli strain DH10B, XL10-gold allows propagation of 
large DNA molecules and is recombinant deficient (recA), helping to ensure insert 
stability (http://www.stratagene.com). 
 
Sub-genomic (pMC/5′-6F and pMC/3′-6F) and full-length cDNA clones of HEV71-
6F (pHEV71-6F) were successfully constructed in pMC18 using different restriction 
sites for cloning according to the unique restriction sites in the viral genome and the 
pMC18 vector.  These pHEV71-6F clones contain an additional one or two extra G 
residues at the 5′ terminus.  All sub-genomic and full-length clones were grown in E. 
coli strain DH10B or XL10-gold at 30˚C.  No infectious clone-derived virus of 
HEV71-6F (CDV-6F) was recovered from pHEV71-6F (24 clones) propagated in 
DH10B.  However, CDV-6F was obtained from two of 18 pHEV71-6F clones 
  93propagated in XL10-gold.  These infectious pHEV71-6F clones have an additional 
two G residues at the 5′ terminus.   
 
By the use of a similar clone construction strategy, an infectious cDNA clone of 
HEV71 strain 26M (pHEV71-26M) was also successfully constructed.  Plasmid 
vector pMC18 and the bacterial host XL10-gold were used.  Clone-derived virus 
26M (CDV-26M) was recovered from 10 of 16 pHEV71-26M clones screened.  The 
use of different plasmid vectors, bacterial host strains, incubation temperatures, and 
number of additional 5′ terminal G residues in construction of full-length cDNA 
clones of HEV71 and infectivity of clone-derived virus is summarised in Table 3.2. 
3.2.2  Recovery of infectious clone-derived viruses 
For in vitro RNA synthesis, full-length cDNA plasmids were linearised with MluI 
and the linearised plasmids were transcribed using MEGAscript T7 kit (Ambion), as 
described in section 2.2.16.  RNA transcripts had an authentic 3′ end of the HEV71 
genomic RNA and two additional 5′ nonviral G residues, which is the transcription 
start site of T7 RNA polymerase.  Analysis of RNA transcripts on formaldehyde-
denatured agarose gels showed a single band with a mobility identical to that of 
genomic RNA extracted from HEV71 (Figure 3.1).   
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Table 3.2  Summary of the use of different plasmid vectors, bacterial host 
strains, incubation temperatures, and number of G residues in construction of 
full-length HEV71 cDNA clones and infectivity of clone-derived virus.   
 
 
Virus 
(strain) 
 
Plasmid 
vector 
 
 
Bacterial 
host strain 
 
Incubation 
Temperature
 
Number of G  
residues 
 
Recovery of 
clone-derived 
virus 
         
HEV71-6F pBR322  DH5α  37˚C  1, 2 or 3G  No 
 pBR322  DH5α  30˚C  1, 2 or 3G  No 
 pBR322  DH10B  37˚C  1, 2 or 3G  No 
 pBR322  DH10B  30˚C  1, 2 or 3G  No 
         
 pMC18  DH10B  30˚C  1G or 2G  No 
 pMC18  XL10-Gold  30˚C 1G  No 
 pMC18  XL10-Gold  30˚C 2G  Yes   
         
HEV71-26M pMC18  XL10-Gold  30˚C 2G  Yes 
 
 
  95Transfection of RNA or DNA into mammalian cells has been achieved by calcium 
phosphate, DEAE-dextran, electroporation and cationic lipid reagents (liposomes) 
(Sambrook & Russell, 2000).  Most of the recent studies used electroporation or 
liposomes to transfect clone-derived RNA or cDNA clones into susceptible cells 
(Boot et al., 2001, Bredenbeek et al., 2003, Hurrelbrink et al., 1999, Shi et al., 2002).  
Initial attempts to transfect Vero cells with RNA transcripts by electroporation 
resulted in approximately 50-60% cell death.  Transfection of RNA and DNA using 
liposomes (Lipofactamine
TM 2000, invitrogen) was found to be simpler, easier to 
optimise, required fewer cells, and caused less cell death than electroporation.  Thus, 
this method was chosen and fully optimised for use in our experiments.   
 
The transfection efficiency of Lipofactamine
TM 2000 in different HEV71-susceptible 
cell lines was determined using plasmid pcDNA-lacZ expressing β-gal.  RD, Vero or 
COS-7 cells were seeded in 24-well tissue culture trays and were approximately 90% 
confluent at the time of transfection.  These cells were transfected with the same 
amount of Lipofactamine
TM 2000-pcDNA-lacZ complex: 3 μL of Lipofactamine
TM 
2000 and 0.8 μg of pcDNA-lacZ.  Transfection and in situ staining protocols are 
described in section 2.2.17 (b).  COS-7 cells had the highest transfection efficiency, 
with the highest number of β-gal-positive cells, as shown in Figure 3.2.  Therefore 
COS-7 cells were chosen for subsequent transfection experiments in order to rescue 
clone-derived viruses.   
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Figure 3.1  Formaldehyde-denatured agarose gel showing identical mobility 
between extracted genomic RNA of HEV71 (Lane 2) and RNA transcripts from a 
full-length cDNA clone of HEV71 (Lane 3).  Molecular size standards (0.5-10 kb 
RNA ladder, Invitrogen) are shown in base pairs on the left for comparison (Lane 1)    
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Figure 3.2  Comparison of transfection efficiency in different cell lines.  COS-7  
(A), Vero (B) or RD cells  (C) were transfected with pcDNA-lacZ (0.8 μg) and 
Lipofectamine
TM2000 (3 μL).  Transfected cells were incubated for 24 h and the 
cells were stained with X-gal to detect β-gal expression.  
  98The optimal conditions for transfection of COS-7 cells with Lipofactamine
TM 2000 
were determined using pcDNA-lacZ.  COS-7 cells were seeded in 12-well tissue 
culture trays at a density of 3.2x10
5 cells/well.  Cells were subsequently transfected 
with different combinations of mixtures of the pcDNA-lacZ (0.8, 1.6, 3.2, 6.4 μg) 
and Lipofactamine
TM 2000 (2, 4, 6, 12 μL).  Optimal conditions were obtained when 
COS-7 cells were transfected with 3.2 μg of pcDNA-lacZ and 4 μL of 
Lipofactamine
TM 2000, with approximately 15% cell death and 80% transfection 
efficiency.  
 
Initially, both RNA transcripts and plasmid full-length cDNA clones were used to 
transfect COS-7 cells in order to rescue clone-derived virus populations.  For DNA 
transfection, the full-length cDNA clone was co-transfected with plasmid pCMV-
T7Pol.  pCMV-T7Pol, which expresses T7 RNA polymerase, provides the T7 RNA 
polymerase for transcription of full-length viral cDNA in the cells.  Transfection of 
DNA was undertaken by mixing 1.6 μg of full-length viral cDNA and 1.6 μg of 
pCMV-T7Pol with 4 μL of Lipofactamine
TM 2000, and the mixture added to the 
cells.  For RNA transfection, 3 μg of RNA transcript was mixed with 3 μL of 
Lipofactamine
TM 2000, and the mixture added to the cells.  Transfection protocols 
are described in detail in section 2.2.17.  Clone-derived viruses were obtained from 
both RNA and DNA transfection.  CPE was observed from secondary infected Vero 
and RD cells within 24-48 h.  However, the specific infectivity of these two methods 
was not compared.  As the DNA transfection method is simpler, with no in vitro 
transcription step required, this method was chosen for the rescue of clone-derived 
viruses in all subsequent studies. 
  993.2.3  Confirming the presence of clone-derived viruses 6F 
and 26M 
The presence of clone-derived viruses was confirmed by immunofluorescence 
assays.  Clone-derived viruses 6F and 26M harvested from transfected COS-7 cells 
were passed into Vero and RD cell monolayers on glass cover slips.  Infected cells 
were fixed in 50:50 acetone/methanol and labelled with mouse anti-HEV71 
monoclonal antibody, as described in section 2.3.4.  Cells infected with wild-type 
viruses HEV71-6F and HEV71-26M, and mock-infected cells were used as positive 
and negative controls, respectively.  Cells infected with CDV-6F or CDV-26M 
showed immunofluorescence similar to the wild-type virus infected cells, indicating 
that HEV71 clone-derived viruses had been rescued from the cDNA clones (Figure 
3.3 and 3.4).  Furthermore, the presence of CDV-6F and CDV-26M was confirmed 
by extracting viral RNA from the culture supernatant of RD passage 1, and 
performing RT-PCR to amplify the full VP1 gene, as described in section 2.2.10 (b) 
and 2.2.11 (b).  The VP1 PCR products were sequenced and compared to the 
sequences of wild-type HEV71-6F and HEV71-26M.  Nucleotide sequences of 
clone-derived viruses were found to be identical to that of their respective wild-type 
viruses. 
3.2.4  Stability of clones in E.coli 
Instability of the full-length clones pBR/HEV71-6F during passage in E. coli, 
prompted an investigation into the stability of pHEV71-6F and pHEV71-26M.   
E.coli strain XL10-gold was transformed with pHEV71-6F or pHEV71-26M.  Two 
colonies from each transformation were propagated for five cycles consisting of 
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Figure 3.3  Immunofluorescence assay of Vero cells infected with HEV71-6F  (A) 
or CDV-6F  (B) Cells were infected with virus and incubated for 24 h prior to 
staining with mouse anti-HEV71 monoclonal antibody and FITC conjugated goat 
anti-mouse IgG.  (C) Mock infected cells were included as negative controls.  Both 
infected and non-infected cells were counterstained with Evans blue showing a dull 
red fluorescence. 
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Figure 3.4  Immunofluorescence assay of Vero cells infected with HEV71-26M  (A) 
or CDV-26M  (B). Cells were infected with virus and incubated for 24 h prior to 
staining with mouse anti-HEV71 monoclonal antibody and FITC conjugated goat 
anti-mouse IgG.  (C) Mock-infected cells were included as negative controls.  Both 
infected and non-infected cells were counterstained with Evans blue showing a dull 
red fluorescence. 
  102alternating growth in liquid and solid media at two different incubation temperatures, 
30˚C or 37˚C, as described in section 2.2.18.  The functional integrity of the full-
length clones was examined by restriction endonuclease digestion with appropriate 
enzymes and by infectivity testing.  Digestion of pHEV71-6F (12,835 nucleotides) 
with BglI was predicted to generate fragments of 4265, 3642, 2906, 1267, 290, 234 
and 231 nucleotides.  Plasmid pHEV71-26M (12,803 nucleotides) digested with 
PvuI was predicted to generate fragments of 4986, 2928, 2731 and 2158 nucleotides.  
Restriction enzyme digestions of plasmid DNA purified after 1 and 5 passages at 
30˚C or 37˚C incubation generated the expected patterns, as shown in Figure 3.5.  
The specific infectivity of purified plasmids from passage 1 and 5 at both 
temperatures of incubation was assessed by co-transfection of 0.8 μg of purified 
plasmids and 0.8 μg of pCMV-T7 into COS-7 cells.  Viral RNA was transcribed in 
the transfected cells by T7 RNA polymerase.  The specificity of these plasmids did 
not differ significantly (Table 3.3).  These data indicate that the full-length clones 
were genetically stable during passage in bacterial cells. 
3.2.5  Genotypic characterisation of infectious clones and 
clone-derived viruses 
The sequence of HEV71-6F cDNA within the plasmid full-length clone, pHEV71-6F 
was determined using Big-dye-terminator sequencing technology.  Primers used for 
sequencing pHEV71-6F are shown in Table 2.1.  The HEV71-6F cDNA sequence 
was compared to the published sequence of HEV71-6F (DQ381846).  One 
nucleotide difference was identified in the 3D gene (T
7056→C).  However, this 
nucleotide substitution does not lead to an amino acid change.  Clone-derived virus 
CDV-6F at RD stock passage 3 was also sequenced.  Similar to sequencing results of 
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Figure 3.5  Stability of full-length cDNA clones, pHEV71-6F and pHEV71-26M 
during five passages in E. coli at 30˚C or 37˚C.  Plasmids pHEV71-6F and pEV71-
26M were digested BglI and PvuI, respectively.  (A) The expected banding pattern 
was observed in pHEV71-6F at passage 1 at 30˚C and 37˚C (Lanes 2 and 3), and at 
passage 5 at 30˚C and 37˚C (Lanes 4 and 5).  (B) The expected banding pattern was 
observed in pHEV71-26M at passage 1 at 30˚C and 37˚C (Lanes 2 and 3), and at 
passage 5 at 30˚C and 37˚C (Lanes 4 and 5).  
  104Table 3.3 Specific infectivity of the RNA derived from pHEV71-6F and 
pHEV71-26M after 1 and 5 passages in E. coli 
 
Viral titre (log10 TCID50/mL) 
 
 
 
 
Incubation 
temperature 
(˚C) 
 
CDV-6F  
passage 1 
 
 
CDV-6F  
passage 5 
 
CDV-26M 
passage 1 
 
CDV-26M 
passage 5 
 
30 
 
 
2.72 (± 0.19) 
 
2.61 (± 0.2) 
 
7.83 (± 0.47) 
 
7.76 (± 0.12) 
 
37 
 
 
2.61 (± 0.19) 
 
2.65 (± 0.17) 
 
7.54 (± 0.07) 
 
7.57 (±0.29) 
 
 
  105HEV71-6F cDNA, the nucleotide substitute, T
7056→C, was identified in CDV-6F.  
This nucleotide change can be used as a genetic marker to differentiate between 
clone-derived virus and the wild-type HEV71-6F virus.  Viral cDNA of HEV71-
26M was also sequenced and compared to the sequence of the parental HEV71-26M 
(EU364841); no nucleotide differences were identified. 
3.2.6  Phenotypic characterisation of clone-derived virus  
Clone-derived viruses CDV-6F and CDV-26M were compared phenotypically to 
their parental viruses by plaque morphology and by determining growth kinetics in 
susceptible cell lines. 
 
The plaque size and morphology of CDV-6F and CDV-26M were compared to their 
parental viruses on Vero and RD cells.  Both HEV71-6F and HEV71-26M produced 
clearer plaques in Vero-infected cells than in RD cells.  CDV-6F and HEV71-6F 
displayed an identical small plaque phenotype (Figure 3.6).  CDV-26M and HEV71-
26M also had an indistinguishable large plaque phenotype (Figure 3.6). 
 
The growth kinetics of clone-derived viruses and their parental viruses were 
compared using RD cells.  RD cell monolayers in 24-well tissue culture trays were 
infected with CDV-26M or HEV71-26M at an MOI of 10.  Since both CDV-6F and 
HEV71-6F produced low viral titres, the growth kinetics of CDV-6F and HEV71-6F 
were examined by infecting monolayers of RD cells in 24-well tissue culture trays at 
an MOI of 1.  Viruses were harvested at 4 h intervals for 24 h and the yields 
quantified by TCID50 assay.  As shown in Figure 3.7, the replication kinetics of 
CDV-6F and HEV71-6F were nearly identical.  The growth kinetics of CDV-26M 
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Figure 3.6  Plaque morphology of parental and clone-derived HEV71-6F and 
HEV71-26M in Vero cells.  Vero cells in 12-well tissue culture trays were infected 
with the indicated viruses.  Plaques were visualised 7 days post-infection by staining 
with crystal violet.  (A) HEV71-6F  (B) CDV-6F  (C) HEV71-26M  (D) CDV-26M 
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Figure 3.7  Growth kinetics of the parental and clone-derived HEV71-6F and 
HEV71-26M on RD cells.  RD cell monolayers were infected with viruses at an MOI 
of 1xTCID50/cell (HEV71-6F) or MOI of 10xTCID50/cell (HEV71-26M).  Samples 
of cell culture supernatant were collected at the times indicated and viral titres were 
determined by TCID50 assay.  All assays were performed in duplicate.  (A) HEV71-
6F and CDV-6F  (B) HEV71-26M and CDV-26M           
  108and HEV71-26M were also very similar (Figure 3.7).  These data suggest that the 
parental and clone-derived viruses of both HEV71 strains are indistinguishable in 
their replication and spread in susceptible cells.   
 
3.3 Discussion 
Infectious cDNA clones provide a valuable tool for studying the molecular biology 
of RNA viruses.  This approach is based on the infectious nature of the viral RNA 
genome in permissive host cells.  In this study, full-length cDNA clones of two 
recent clinical isolates of HEV71 were successfully generated.  RNA transcripts 
from plasmid DNA were infectious upon transfection into susceptible COS-7 cells.  
The clone-derived viruses exhibited biological properties indistinguishable from 
their parental viruses, including identical plaque morphology and growth kinetics.   
 
A common problem encountered in the construction of infectious cDNA clones is 
the instability of the viral cDNA insert during passage in bacteria.  This problem has 
been reported for several positive-stranded RNA viruses, including coronavirus and 
flavivirus (Masters, 1999, Mishin et al., 2001, Rice et al., 1989, Sumiyoshi et al., 
1992).  It has been hypothesized that genetic instability results from the expression 
of viral cDNA fragments encoding products that are potentially toxic to the bacterial 
host (Boyer & Haenni, 1994).  Multiplication of clones containing toxic fragments in 
bacteria leads to the selection of mutations, deletions or gene rearrangements in the 
viral sequence (Boyer & Haenni, 1994).   
 
Several strategies have been used to overcome this problem:  (1) The cloning and 
propagating of full-length cDNA clones in bacteria was avoided.  Full-length 
  109infectious cDNA clones of several viruses were successfully obtained using sub-
genomic clones and in vitro ligation approach in which the full-length in  vitro-
ligated fragments were directly used as a template for in vitro transcription (Kapoor 
et al., 1995, Rice et al., 1989, Sumiyoshi et al., 1992).  In addition, high fidelity RT-
PCR has been employed to generate full-length cDNA containing an upstream 
promoter for direct in vitro transcription.  This approach was used to generate 
infectious RNA transcripts in tick-borne encephalitis virus (TBEV) (Gritsun & 
Gould, 1995).  (2) Use of nonbacterial cloning systems, for example, the 
construction of full-length infectious cDNA clones of dengue virus type 1 and 2 in 
yeast cells (Polo et al., 1997).  (3) Infectious cDNA clones designed to contain 
eukaryotic promoters for direct transfection of cell culture.  The insertion of an 
intron into a toxic region in the viral genome prohibits the expression of toxic 
products, thus allowing stable amplification of the plasmid in bacteria (Yamshchikov 
et al., 2001).  Infectious RNA was generated in the cell nucleus and the intron was 
removed by splicing during RNA translocation from the nucleus to the cytoplasm 
(Yamshchikov et al., 2001).  Using this approach, infectious cDNA clones of 
Japanese encephalitis virus (JEV) and transmissible gastroenteritis coronavirus 
(TGEV) were successfully obtained (Gonzalez et al., 2002, Yamshchikov et al., 
2001).  (4) Full-length cDNA clones in high copy number plasmids were propagated 
in bacteria at low temperature and under a low level of antibiotic selection.  This 
approach was reported in the construction of infectious dengue virus type 2 (Sriburi 
et al., 2001).  (5) Full-length infectious cDNA clones were constructed by the use of 
medium- or low-copy number plasmid vectors and appropriate bacterial host strains.  
This approach has been reported for several positive-stranded RNA viruses 
(Hurrelbrink et al., 1999, Lai et al., 1991).  (6) Bacterial artificial chromosomes 
  110(BACs) have been employed.  Genetic instability of JEV cDNA was overcome by 
cloning into a BAC plasmid (Yun et al., 2003).      
 
There has been no report on the instability of enterovirus full-length cDNA clones.  
In a previous study by Arita et al. (2005), an infectious cDNA clone of the prototype 
HEV71 strain BrCr was initially constructed in a high copy number plasmid pCR-
XL-TOPO which was found to be infectious.  The authors did not comment on any 
genetic instability problems.  However, this infectious cDNA clone was later cloned 
into a medium copy number plasmid P/Hd40 (Arita et al., 2005).  In our study, 
attempts to generate an infectious cDNA clone of HEV71 strain 6F using the 
medium copy plasmid pBR322 were unsuccessful.  The full-length cDNA clone, 
pBR/HEV71-6F propagated in DH5α at 37˚C was found to be non-infectious.   
Sequencing one of the pBR/HEV71-6F clones revealed that there were two stop 
codons, one located in the viral capsid protein VP3 and another in the non-structural 
protein 2A.  It is likely that the bacterial host introduces these mutations into the 
viral genome in order to decrease the expression of HEV71 proteins that are toxic to 
bacterial host cell.  Although less likely, the introduction of these mutations during 
PCR amplification cannot be ruled out.  
 
Approaches to overcoming genetic instability of the full-length HEV71-6F in 
pBR322 by propagating bacterial host at a lower temperature of 30˚C and changing 
the bacterial host strain to DH10B was also not successful.  Interestingly, pBR322 
has been used successfully in the construction of infectious cDNA clones of some 
enteroviruses and flaviviruses such as PV and dengue virus type 2 and 4 (Cello et al., 
2002, Kapoor et al., 1995, Lai et al., 1991).  By contrast, infectious clones of JEV 
  111(Sumiyoshi et al., 1992), TBE (Mandl et al., 1997), yellow fever virus (Rice et al., 
1989) and MVE (Hurrelbrink et al., 1999) virus could not be constructed with this 
plasmid.  These results indicate that the intermediate copy number of plasmid 
pBR322 may have exceeded the tolerance of bacterial cells to the toxic products 
derived from full length cDNA clones of these viruses. 
 
In order to solve the problem of genetic instability, the low copy number plasmid 
pMC18 (approximately 6 copies per cell; Wang and Kushner, 1991) was tested.   
This plasmid has been used successfully for construction of an MVE infectious clone 
(Hurrelbrink et al., 1999).  Sub-genomic and full-length cDNA clones of HEV71-6F 
were constructed in pMC18 and the clones propagated in two bacterial strains; 
DH10B and XL10-gold.  Two full-length clones amplified in XL10-gold were found 
to be infectious whilst none of the clones propagated in DH10B were infectious.  
Using pMC18 and XL10-gold, an infectious cDNA clone of HEV71 strain 26M was 
also successfully constructed.  These results clearly demonstrate that a fortuitous 
combination of plasmid vector and bacterial host was critical for generating 
infectious cDNA clones of HEV71.  It remains unclear why XL10-gold was more 
suitable for propagating cDNA clones of HEV71 than DH5α and DH10B.  The 
influence of bacterial host strain on infectivity of full-length cDNA clones has also 
been reported for several viruses, including dengue virus type 4 (Lai et al., 1991).   
The inclusion of non-viral nucleotide sequences at the 5′ end of viral cDNA has been 
reported to have an adverse effect on the infectivity of some infectious clones, 
particularly in plant RNA viruses (Boyer & Haenni, 1994).  In animal viruses, the 
influence of the number of non-viral nucleotides at the 5′ end on infectivity was 
assessed in Sindbis virus clones (Rice et al., 1987).  Clones containing 8 to 198 non-
  112viral nucleotides were not infectious while only clones containing one additional G 
residue were infectious.  These results indicated that large numbers of non-viral 
nucleotides at the 5′ end are deleterious to infectivity.  In addition to length, the 
sequence of 5′ end non-viral nucleotides has also been found to have an effect on 
infectivity (Duechler et al., 1989).  It has been hypothesized that the extra non-viral 
nucleotides at the 5′ end interfere with initiation of positive strand RNA synthesis 
from the 3′ end of the negative strand (Boyer & Haenni, 1994).   
 
The effect of 5′ extension on clone-derived viral RNA infectivity has been reported 
for PV infectious clones (Kaplan et al., 1985).  Similar to a Sindbis virus clone, the 
specific infectivity of a PV clone containing 60 non-viral nucleotides including 18 G 
residues was much lower than that of viral RNA, while the infectivity of clone-
derived RNA with two additional G residues was similar to that of parental virus 
(van der Werf et al., 1986).  Most enterovirus infectious cDNA clones contain an 
additional 1, 2 or 3 G residues at the 5′ end of the viral cDNA and these non-viral 
nucleotides have not been shown to alter infectivity (Arita et al., 2005, Kraus et al., 
1995, Martino et al., 1999).  It has been shown that one extra G residue at the end of 
the T7 promoter sequence is important for in vitro transcription efficiency (Janda et 
al., 1987).  In this study, only HEV71-6F clones containing two G residues at the 5′ 
terminus were found to be infectious.  The earlier report of HEV71 infectious clone 
of strain BrCr also contains two G residues.  It is possible that the inclusion of two G 
residues in HEV71 clones provide the optimal conditions for efficient transcription 
and RNA synthesis.   
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effect on infectivity than at the 5′ end, the inclusion of 1 to 7 non-viral nucleotides at 
the 3′ end appears to be well tolerated (Boyer & Haenni, 1994).  Similar to most 
animal viruses, the presence of four non-viral nucleotides in enterovirus cDNA 
clones as a result of linearisation at a unique restriction site has no apparent effect on 
infectivity (Kraus et al., 1995, Sarnow, 1989).  By comparing the sequences of in 
vitro transcribed RNA with viral RNA of clone-derived virus, several studies found 
that non-viral nucleotide at the 5′ and 3′ end are removed, presumably during 
transfection and replication of the RNA templates in infected cells. (Khromykh & 
Westaway, 1994, Klump et al., 1990).  It has been hypothesized that host cell 
nucleases may eliminate non-viral nucleotides or, alternatively, viral RdRps may be 
able to initiate replication of extended transcripts by recognizing their cognate 
binding site internally, leading to elimination of non-viral nucleotides in the daughter 
strand (Boyer & Haenni, 1994).    
 
The poly (A) tail at the 3′ end may play an important role in the infectivity of 
enterovirus cDNA clones.  It has been reported that PV RNAs with poly (A) tails 
less than 8 nucleotides in length were much less efficient in negative-strand RNA 
synthesis than those with 80 nucleotides (Herold & Andino, 2001).  Silvestri et al. 
(2005) showed that PV RNAs with poly (A)11 and poly(A)12 had negative-strand 
RNA synthesis at 1-3% of the level observed with poly (A)80 RNA, and increasing 
the length of the poly (A) tail from 12 to 20 residues resulted in an increase in 
negative strand synthesis by 30-fold or more.  PV RNA with poly (A)20 had a similar 
level of negative-strand RNA synthesis to poly(A)80.  These results indicate that the 
length of poly (A) tail plays an important role in viral RNA replication and 
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HEV71 clones reported in this study and by Arita et al. (2005) were designed to 
contain a 25-mer poly (A) tail.  Further studies are necessary to determine the 
minimum size of the poly (A) tail required for infectivity of HEV71 RNAs and to 
elucidate the role of the poly (A) tail in HEV71 RNA infection.  
 
Either the cDNA clone or RNA transcripts have been used for transfection to recover 
clone-derived virus populations in most infectious clone systems (Boot et al., 1999, 
Hurrelbrink et al., 1999, Yun et al., 2003).  Transfection of plasmid cDNA has been 
reported to have several advantages (Boot et al., 2001).  In vitro transcription, which 
is an expensive and laborious process, is not required and infectivity is less affected 
by RNA degradation.  In addition, Boot et al. (2001) compared RNA and cDNA 
transfection methods for rescue of infectious bursal disease virus (IBDV) and found 
that cDNA transfection gave rise to a much higher level of protein expression than 
RNA transfection, and was more efficient in recovering a crippled variant of IBDV.  
By contrast, porcine enteric calicivirus (PEC) could not be recovered by transfecting 
the plasmid cDNA clone, but only by transfecting of RNA transcripts (Chang et al., 
2005).  In this study, clone-derived HEV71 was obtained by transfection of either 
plasmid cDNA or RNA transcripts into susceptible cells.  However, the recovery 
efficiencies between these two transfection methods were not compared.  Since 
transfection of cDNA is simpler and less expensive, this method is preferable for 
recovering of clone-derived HEV71 populations.   
 
Genotypic and phenotypic characterisation of clone-derived virus by comparison 
with parental virus is required to confirm the authenticity of the clone-derived virus.  
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population by complete nucleotide sequencing revealed one nucleotide difference 
compared to parental virus (GenBank).  This mutation may have been introduced 
either during RT-PCR amplification or during cloning.  Alternatively, this mutation 
may reflect the quasispecies nature of the parental virus stock.  This silent mutation 
in the pHEV71-6F clone has no effect on infectivity and was still present in clone-
derived virus.  Complete sequencing of clone-derived CDV-26M showed no 
nucleotide difference compared to parental virus.  Clone-derived CDV-6F and CDV-
26M were compared to their parental virus in several aspects of viral replication, 
including plaque morphology and growth kinetics in cell culture.  These clone-
derived viruses showed in vitro growth properties indistinguishable from their 
parental viruses. 
 
In conclusion, we have successfully constructed full-length infectious cDNA clones 
of two recent clinical isolates of HEV71.  The availability of these infectious cDNA 
clones will make a significant contribution to the future study of viral replication and 
disease pathogenesis.  Due to the distinct growth characteristics of these two strains, 
further studies were undertaken to determine the genomic regions responsible for 
their growth phenotypes, by constructing chimeric constructs between these two 
infectious clones.  This work is described in Chapter 4. 
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MAPPING GENETIC DETERMINANTS OF THE CELL 
CULTURE GROWTH PHENOTYPE OF HUMAN 
ENTEROVIRUS 71 
4.1  Introduction 
Human enterovirus 71 (HEV71) is a genetically diverse virus with an estimated 
evolution rate of 1.35x10
-2 substitutions per nucleotide per year in the VP1 gene 
(Brown et al., 1999).  Three distinct HEV71 genotypes, designated A, B and C were 
identified by Brown et al. (1999).  The prototype strain BrCr is the sole member of 
genotype A.  Most HEV71 isolates belong to either genotype B or C, which are 
further divided into subgenotypes B1-B5 and C1-C5, respectively (Brown et al., 
1999, Cardosa et al., 2003, McMinn et al., 2001a, Shimizu et al., 2004, Tu et al., 
2007).  Co-circulation of these two distinct genotypes, B and C, in the same region 
has been well documented (Herrero et al., 2003, Lin et al., 2006, McMinn et al., 
2001a).  During an HEV71 outbreak in the USA in 1987, strains of both genotypes 
were isolated (Brown et al., 1999).  Viruses belonging to both genotypes were also 
identified during the large HFMD epidemic in Taiwan in 1998 and several outbreaks 
in Malaysia from 1997 to 2000 and in Perth in 1999 (Herrero et al., 2003, Lin et al., 
2006, McMinn et al., 2001a).     
 
During the 1999 HFMD epidemic in Western Australia, HEV71 belonging to 
genotypes B3 and C2 were isolated, indicating the co-circulation of both genotypes.  
Genotype C2 viruses were isolated mainly from cases of severe neurological disease, 
while viruses belonging to genotype B3 were isolated mainly from uncomplicated 
HFMD cases and aseptic meningitis (McMinn et al., 2001a).  Interestingly, we have 
  117found that two HEV71 strains isolated during the Western Australian epidemic, 
26M/AUS/99 (genotype B3) and 6F/AUS/99 (genotype C2) had distinct cell culture 
growth phenotypes.  The studies in this chapter aim to identify genome regions 
responsible for the growth phenotypes of the two strains.  Chimeric recombinant 
viruses carrying reciprocal exchanges of HEV71-6F and HEV71-26M 5′ UTR, 
structural protein genes (P1 region) and non-structural protein genes (P2 and P3 
regions) were generated and biological properties of the parental and chimeric 
viruses in tissue culture were compared.   
 
4.2  Results 
4.2.1  Phenotypic differences of HEV71-6F and HEV71-26M 
Both HEV71-6F and HEV71-26M are able to grow on human and monkey cell lines 
(RD and Vero cells).  However, during the propagation of both wild-type and clone-
derived viruses of these two strains, we were unable to generate high titre stocks of 
HEV71-6F; the maximal titre was approximately 10
6 TCID50/mL, whilst HEV71-
26M grew to high titres of ≥10
7 TCID50/mL.  This prompted us to investigate the 
phenotypic differences of these two strains, including the use of plaque morphology, 
growth kinetics, virulence in mice and adaptation to rodent cells.  Infectious clone-
derived viruses, CDV-6F and CDV-26M, were used throughout the studies.  Plaque 
size and morphology of HEV71-6F and HEV71-26M were examined on RD and 
Vero cells.  HEV71-6F displayed a pinpoint plaque phenotype while HEV71-26M 
exhibited a large plaque phenotype (Figure 3.6).  Both strains produced clearer 
plaques on Vero than on RD cells.  The growth properties of HEV71-6F and 
HEV71-26M were compared by infecting monolayers of RD cells in 24-well tissue 
  118culture trays at an MOI of 1 TCID50/cell.  HEV71-6F grew to approximately 100-
fold lower titres than HEV71-26M (data not shown).   
 
It has been reported that newborn mice are susceptible to HEV71 infection after 
intraperitoneal (i.p.) inoculation at a high viral titre (Yu et al., 2000).  To determine 
if HEV71-6F and HEV71-26M are able to infect newborn mice and if there is an 
observable difference in virulence phenotype between these two strains, groups of 
five one-day-old BALB/c mice were inoculated by intracranial (i.c.) or i.p infection. 
with the highest doses possible, at 10
4 and 5x10
4 TCID50, for i.c. and i.p. inoculation, 
respectively.  Similar to most HEV71 strains, both HEV71-6F and HEV71-26M 
caused no observable signs of infection in newborn mice (data not shown). 
 
In order to determine if HEV71-6F and HEV71-26M are able to adapt and grow in 
cells of rodent origin, confluent CHO cells were infected with each virus at MOI = 1.  
Both viruses were then blind passaged five times in CHO cells and the viral titre at 
each passage was determined by TCID50 assay.  HEV71-6F was not able to adapt to 
CHO cells; the viral titres decreased at approximately one log in each subsequent 
passage and no virus was detected at passages four and five (Figure 4.1).  By 
contrast, HEV71-26M adapted to grow well in CHO cells after passage two, with the 
titre increasing by approximately one log at each passage (Figure 4.1).   
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Figure 4.1 Adaptation of HEV71-6F and HEV71-26M to growth in CHO cells.  
CHO cells monolayers were infected with each virus at an MOI of 1.  Virus was then 
blind passaged five times and the viral titre at each passage determined by TCID50 
assay on Vero cells.  At each passage, virus was harvested after 72 h of incubation.   
(A) HEV71-6F  (B) HEV71-26M    
  1204.2.2  Comparison of nucleotide and deduced amino acid 
sequences of HEV71-6F and HEV71-26M 
Whole genome sequencing of strains HEV71-6F and HEV71-26M was performed by 
Robert Hurrelbrink and Beng Hooi Chua (Division of Virology, Telethon Institute 
for Child Health Research).  The complete nucleotide and deduced amino acid 
sequences of HEV71-6F and HEV71-26M were compared by pair-wise alignment 
using global parameters of the Clone Manager 5/Align Plus 4 software program.  
The nucleotide and amino acid sequence similarities between HEV71-6F and 
HEV71-26M are shown in Table 4.1.   
 
The HEV71-26M genome is three nucleotides longer than that of HEV71-6F, with 
the three nucleotide difference located in the 5′ UTR.  Overall, the nucleotide and 
amino acid identity between these two strains are 80% and 95%, respectively.  The 
non-coding regions, 5′- and 3′- UTRs of HEV71-6F and HEV71-26M had a similar 
degree of nucleotide sequence identity at 85% and 84%, respectively.  The capsid 
region, P1, has the highest nucleotide and amino acid sequence identity at 82% and 
96%, respectively, while the P3 region has the lowest sequence identity at 77% and 
93%, respectively.  For each individual protein cleavage product, VP4 is the most 
conserved protein (100% amino acid identity) and 3C and 3D proteins appear the 
least conserved (93% amino acid identity).      
  121Table 4.1  Nucleotide and deduced amino acid sequence identity of HEV71-6F 
and HEV71-26M  
 
Sequence identity (%)  Genetic region  Length (nt) 
Nucleotide Amino  acid 
 
Genome 7409/7412  80  95 
5′ UTR  744/747 85  - 
      
P1 2586  82  96 
VP4 207  81  100 
VP2 762  83  97 
VP3 726  80  96 
VP1 891  82  95 
      
P2 1734  78  96 
2A 450  81  96 
2B 297  76  94 
2C 987  78  96 
      
P3 2259  77  93 
3A 258  76  94 
3B 66  80  95 
3C 549  74  93 
3D 1386  78  93 
      
3′ UTR  86 84 - 
 
 
  1224.2.3  Secondary structure analysis of HEV71-6F and HEV71-
26M 
Complex RNA secondary structures have been identified both in the non-coding and 
coding regions of the enterovirus genome (Goodfellow et al., 2000, Le et al., 1996, 
Pilipenko et al., 1989, Pilipenko et al., 1992b).  The non-coding regions, 5′- and 3′- 
UTRs, contain RNA structural motifs that are important for viral replication and/or 
translation (Andino et al., 1993, Andino et al., 1990, Le et al., 1996, Pilipenko et al., 
1989, Pilipenko et al., 1992a).  An internal structural element, termed the cis-acting 
replication element or cre has been identified within the 2C coding region of several 
enteroviruses (Goodfellow et al., 2000, Paul et al., 2000, Van Ooij et al., 2006).  
Enteroviruses employ both stem-loops and bulges within these RNA secondary 
structures as a contact point for cellular and viral protein binding (Andino et al., 
1993, Andino et al., 1990, Paul et al., 2000, Pilipenko et al., 1996).  The protein-
RNA interactions on the secondary structures are required during RNA replication 
and translation processes.  
 
As RNA secondary structures are involved in important viral replication activity, 
such as RNA replication and translation, we predicted and compared secondary 
structures of 5′- and 3′- UTRs and cre between HEV71-6F and HEV71-26M in order 
to identify potential molecular determinants of growth phenotype.  All secondary 
structures were predicted using the MFOLD (version 3.2) software program 
(Mathews et al., 1999, Zuker, 2003).  Computer predictions of RNA secondary 
structures of HEV71-6F and HEV71-26M were performed based on the cognate 
structures of poliovirus type 1 (PV1) Mahoney strain and CBV3 Nancy strain.  The 
  123predicted secondary structures of these viruses have been validated by chemical and 
enzymatic probing for nucleotides involved in base pairing and mutagenesis analysis 
(Bailey & Tapprich, 2007, Pilipenko et al., 1992a).        
4.2.3.1  5′ UTR and 3′ UTR 
The 5′ UTR of enteroviruses contains two highly conserved elements, the 5′ 
cloverleaf (stem loop I) and the internal ribosomal entry site (IRES).  Stem-loop 
structures II to VI form the IRES (Pilipenko et al., 1989, Skinner et al., 1989).  The 
5′ UTR sequences of PV1, CBV3, HEV71-6F and HEV71-26M were aligned, and 
the nucleotide sequence and boundary of each domain of HEV71 5′ UTR identified 
(Figure 4.2).  The structure of each domain of HEV71 5′ UTR was then predicted 
using MFOLD software (Mathews et al., 1999, Zuker, 2003).  The predicted 
structures of each virus are shown in Figure 4.3.  The 5′ UTR secondary structures of 
HEV71-6F and HEV71-26M were found to be highly similar to one another.  
 
In addition to structural elements, three common sequence motifs that have been 
identified as key elements in the function of enterovirus IRES were also compared.  
The first motif is located in the region linking domains V and VI.  This motif is 
described as Yn-Xm-AUG, where Yn is a pyrimidine-rich sequence, Xm is a 15- to 
25- nt spacer, and AUG is the 3′ boundary of the IRES (Pilipenko et al., 1992b).  The 
second motif, GNRA tetra-loops, is located at the terminal loop of domain IV 
(Ehrenfeld & Teterina, 2002).  The third motif are two A/C rich loops located at 
domain IV and V (Lopez de Quinto & Martinez- Salas, 1997).  Similar to PV1 and 
CBV3, these three IRES motifs were identified in both HEV71-6F and HEV71-26M 
(Figure 4.3).         
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Domain I 
PV1           uuaaaacagcucugggguuguacccaccccagaggcccacguggcggcuaguacuccgguauugcgguacccuuguacgccuguuuuauacucccuuccc 100 
HEV71-6F      ..........cugu......c......-...c...g..uac...gc.....c....u..c.c..a......u....g..........gacu.........  99  
HEV71-26M     ..........cugu......c......u.acag............-.....c....u.a.uc.a...a.u.u....g...........c.ac...cc...  99 
CBV3-Nancy    ..........cugu......au.....-...c.......-u...gc.....c....u.....ca.......u....g..............c....c...  98 
 
                                                                       Domain II 
 
PV1           -------gu-----a------acuuagacgc---a---caaaaccaa-guucaa----uagaagg----ggguacaaaccaguaccaccacgaacaagca 167     
HEV71-6F      cgaa---..-----.------.......a..---u---gu...u...c.a....----...u...----u.ug...c......cau.u.uu..u...... 171     
HEV71-26M     aauuu--.c-----.------.......a..---.aua..c...acu-.a....----c..c...----caugg.gc.....ccaugu.uu..u...... 174     
CBV3-Nancy    caacu--..-----.------.......a.u---.---ac.c..acc-.a....----c..uca.----c.ugg..c.....cca.guuuu..u...... 170      
 
 
                                            Domain III 
PV1           cuucuguuuccccgg--u--gaugucguauagacugcuugcgugguugaaagcgacgga-uccguuauccgcuuauguacuucgagaagcccaguaccac 262 
HEV71-6F      ...............ac.--..guauca....g.....c...c..c....g.a..aaacg.u.....c...acc.ac.............uu........ 269     
HEV71-26M     ...............ac.--..guauca..........ca..c.......g.a..aa.cg...........gc..ac...........a..u....g... 272    
CBV3-Nancy    ........a......ac.--..guauca..........ca..c.......g.a..aa.cg.u.........gcc.ac........a..a..u....a... 268     
 
                                            Domain IV 
                                                   
PV1           cucggaaucuucgaugcguugcgcucagcacucaaccccagaguguagcuuaggcugaugagucuggacaucccucaccggugacggugguccaggcugc 362 
HEV71-6F      .au.a.cgagg.aga.u...u..u.......--......--.......a.c...........c.acug..a...c..ug..c...ca...cagu...... 365 
HEV71-26M     .auu...g..g..ga.u...u.....g.....ucc...----......a.c....c........acug..au..c...g..c...c....cagu...... 368 
CBV3-Nancy    .gu....gu.g.aga.u...u...........--.....--.......a.c...uc........accg...u..c...g..c...c....cggu...... 364 
 
 
 
PV1           guuggcggccuaccuauggcuaacgccaugggacgcu--agu-uguga-acaaggugugaagagccuauugagcuacauaagaauccuccggccccugaa 458     
HEV71-6F      ...........g..c....ag..au............cu.a.-.c..--...u.......................gc.ggu.g................ 462     
HEV71-26M     .c.........g.......ggc.ac....a.......--cuaa....g-...u....c......u...........gu..gu.g................ 465     
CBV3-Nancy    ...........g..c....gg..ac............--cua-auac.g...u....c......u...........gu.ggu.g................ 461     
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PV1           ugcggcuaaucccaaccucggagcagguggucacaaaccagugauuggccugucguaacgcgcaaguccguggcggaaccgacuacuuuggguguccgug 558     
HEV71-6F      ............u...ug.......ca..c.............gg...ug..........g....c..u.ca............................ 562     
HEV71-26M     ............u...ug.......ca..cc.u...c....a.gg.a.ug..........g....c..u.ca............................ 565    
CBV3-Nancy    ............u...ug.......cacacc.u...g....a.ggca.ug..........g....c..u.ca............................ 561    
 
                                                                                              Domain VI 
 
PV1          uuuccuuuuauu-u-uauuguggcugcuuauggugacaauc-acaga-uuguuaucauaaagcgaauuggauuggccauccggugaaagugagacucauua 655 
HEV71-6F     ............c.-...au.....................-.a...a......c....u...-u....................ugcaac...gca...g 660 
HEV71-26M    ............c.-..cau.....................-.....a......c....u...-u....................ugcaau...gcu.... 663 
CBV3-Nancy   ....a.......-cc...ac....................ug.g...-.c....c....u...-u.....................cuaau...gcu.... 659          
 
 
 
PV1          ucuaucuguuugcuggauccgcuccauu---------gaguguguuuacucuaaguac-----------aauuucaacag-uuauuucaaucagacaauug 735 
HEV71-6F     .u..c..a...au...u.uu.ua.....aucacugaa.uc....a.c.....c.aauu-----------c....ug..cc-.c.aca...c..-------- 741     
HEV71-26M    .ac.c..a....u...c.uu.ua...c.---------a.--ccu.aa.a....uaac.-----------.ccc.....u--....a.u..-.ucu....ac 739     
CBV3-Nancy   .a....cc....u...g.uuaua...c.---------u..cu..aaagagg.u.aa..-----------.u.----...a-..ca..-gu.a..uug.a.a 734     
Figure 4.2  Sequence alignments of the cloverleaf and IRES elements of HEV71-6F, HEV71-26M, CBV3 and PV1 based on known 
PV1M and CBV3 5´UTR secondary structure sequences (Andino et al., 1990, Bailey & Tapprich, 2007, Pilipenko et al., 1989, 
Skinner et al., 1989).  Corresponding domains are indicated.  Consensus sequence is represented as (•) and gap sequence is 
represented as (-). 
 
 
 
PV1          uau--cauaaug------- 745         
HEV71-6F     --------...-------- 744    
HEV71-26M    ag.--..a.c--------- 747    
CBV3-Nancy   c.g--..a.---------- 741   
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Figure 4.3  Comparison of the predicted 5′ UTR secondary structures of HEV71-6F 
and HEV26M.  The 5′ UTR structures of HEV71-6F and HEV71-26M were 
predicted based on the structures of PV1 (A) and CBV3 (B).  The structure of each 
domain was predicted using MFOLD (Version 3.2) software.  (C) HEV71-6F, (D) 
HEV71-26M.  Three common sequence motifs are shown in different colours, Yn-
Xm-AUG motif in blue, GNRA motif in red and A/C rich sequence motif in yellow. 
 (A)  PV1 Mahoney 
 
(B)  CBV3 
 
 
 
 
 
  128(C)  HEV71-6F 
 
(D)  HEV71-26M  
 
 
 
  129The 3′ UTR of enteroviruses encodes a stem-loop structure that is not universally 
conserved.  Two forms of the 3′ UTR secondary structure of enteroviruses have been 
identified (Pilipenko et al., 1992b).  Two stem-loops, X and Y, were predicted to 
form within the 3′ UTR of PV (Pilipenko et al., 1992b), while the 3′ UTR of CBV3 
was predicted to contain three stem-loops, X, Y and Z (Pilipenko et al., 1992b).  
Similar to the 3′ UTR of CBV3, the 3′ UTR secondary structures of HEV71-6F and 
HEV71-26M were predicted to contain three stem-loops, X, Y and Z, and are similar 
to one another (Figure 4.4).   
4.2.3.2  Cis-acting replication element (cre) 
Cre functions as a template for 3D
pol during the uridylylation of VPg in RNA 
synthesis.  Cre elements have been identified within the 2C protein gene of PV 
(Goodfellow et al., 2000, Paul et al., 2000) and CBV3 (Van Ooij et al., 2006).  The 
cre elements identified thus far share similar stem-loop structures (Goodfellow et al., 
2000, McKnight & Lemon, 1998, Paul et al., 2000, Van Ooij et al., 2006).  A 
common motif, R
1NNNA
1A
2R
2NNNNNNR
3, has been proposed for the loop 
segment.  The cre sequences of HEV71-6F and 26M were identified by nucleotide 
sequence comparison with the PV1 and CBV3 cre sequences (Figure 4.5), and the 
cre  structures predicted by MFOLD software.  The predicted cre structures of 
HEV71-6F and HEV71-26M were found to be different (Figure 4.5), in which cre 
structures of HEV71-6F and HEV71-26M were similar to that of PV1 and CBV3, 
respectively.  The predicted cre structure of HEV71-6F contained 9 nucleotides of 
terminal loop and 7 nucleotides internal loop.  For HEV71-26M, a difference at the 
nucleotide position 13 of the core cre consensus sequence from HEV71-6F resulted 
in the formation of a larger terminal loop of 16 nucleotides.        
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Figure 4.4  The predicted 3′ UTR secondary structures of HEV71-6F and HEV71-
26M based on the 3′ UTR sequences and structures of PV1 and CBV3 (Pilipenko et 
al., 1992b).  (A) nucleotide sequence alignments of 3′ UTR of PV1, CBV3, HEV71-
6F and HEV71-26M.  (B) The 3′ UTR secondary structures of each virus were 
predicted using MFOLD (Version 3.2) software.  Stem-loop structures X, Y and Z of 
the 3′ UTR are indicated. 132 
 
 
 
 
 
 
 
 
 
(A) 
   Domain Z    Domain Y     Domain X 
 
PV1         ---------------------------------uaacccuaccucagucgaauuggauugggucauacuguuguagggguaaauuuuucuuuaauucggagaaaaaaaaaa 
CBV3        auuagagacaauuugaaauaauuuagauuggcuuaacccuacugugcu--aaccgaaccagauaacgguacaguagggguaaauucuccgca-uucggugcggaaaaaaaaaa- 
HEV71-6F    ----------....---.c.g..c.---.aa..g.....c..--cag.--..u.uggu.gug.u.au.acug..g..........uguuau.ac.a.aaua.c.........a 
HEV71-26M   ----------.gg.u..g..u------a.ac..c.....c..--cag.--..u.u.g.cgug...aug..u.g.g..........uguuau.ac.a.aaua.c.........a 
 
 
 
 
 
 (B)
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PV1    uauuaacaacuacauacaguucaagagcaaacaccguauugaaccaguauguuugcuagua-- 4504  
CBV3   g..g.g...u...............uc....ug............u...........cc.g-- 4421 
6F     a..g..u..u.....g.............................u.....cc.aa.ca.u-- 4458 
26M    a..g...........g....................a........u......c.--..u..uu 4461 
 
 
 
 
 
 
(B) 
 
 
 
Figure 4.5  The predicted cre structures of HEV71-6F and HEV71-26M based on 
the cre sequences and structures of PV1 and CBV3 (Goodfellow et al., 2000, Paul et 
al., 2000, Van Ooij et al., 2006).  (A) nucleotide sequence alignments of cre of PV1, 
CBV3, HEV71-6F and HEV71-26M; the consensus sequence is highlighted in 
yellow.   (B) The cre  secondary structures of each virus were predicted using 
MFOLD (Version 3.2) software.    
  1344.2.4  Construction and recovery of chimeric recombinant 
viruses    
 To identify the genome regions responsible for the growth phenotype of HEV71-6F 
and HEV71-26M, six chimeric recombinant cDNA constructs (p6F/5′UTR/26M, 
p26M/5′UTR/6F, p6F/P1/26M, p26M/P1/6F, p6F/NS/26M and p26M/NS/6F) were 
generated by exchanging corresponding 5′ UTR, structural protein gene (P1 region) 
and non-structural protein gene (P2 and P3) regions between these two strains, 
resulting in three reciprocal pairs of chimeric genomes (Figure 4.6).  Chimeras are 
identified in the form of pA/B/C, where A is a backbone virus, B is the exchanged 
genomic region, C is the name of the virus providing the exchange genomic region.  
Chimeric recombinant clones were constructed using fusion PCR and site-directed 
mutagenesis; the full-length infectious cDNA clones of HEV71-6F and HEV71-26M 
were used as backbone templates.  Construction procedures are described in detail in 
section 2.2.14.      
 
Six chimeric cDNA clones were co-transfected with pCMV-T7Pol into COS-7 cells, 
as described in section 2.2.17, in order to rescue chimeric recombinant viruses.   
Viable virus populations were recovered from all six cDNAs.  Recovered viruses 
were passaged five times in RD cells to increase the titre for use in subsequent 
assays.  In order to verify that the recovered viruses contained the expected genetic 
composition, RNA extracted from each recovered virus population at RD passage 5 
was sequenced.  Analysis of the sequence data obtained from the junction sites of 
each virus revealed that all recovered viruses had the expected genotype (data not 
shown).      
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Figure 4.6  Schematic diagram of the intratypic chimera recombinant constructs 
between HEV71-6F and HEV71-26M.  Chimeras are identified by using the 
following nomenclature; pA/B/C where A is the backbone virus, B is the exchange 
genomic region, C is the the name of virus providing the exchanged genomic region.       
  1364.2.5  Characterisation of chimeric recombinant viruses in 
vitro 
In order to map genetic determinants of the cell culture growth  phenotype of 
HEV71-6F and HEV71-26M, plaque morphology and growth kinetics of the parental 
CDV-6F, CDV-26M and all chimeric recombinant viruses were compared. 
4.2.5.1  Plaque morphology  
Plaque morphologies of the parental and recombinant viruses were examined on 
Vero and RD cell monolayers.  Although the parental and recombinant viruses 
produced a clearer plaque morphology on Vero cells, similar patterns of plaque 
morphology were observed on both Vero and RD cells (Figure 4.7).  Average plaque 
size was determined on Vero cells from samples of 9 to 13 plaques.  Results are 
shown in Table 4.2.  Parental viruses and reciprocal chimeras with a replacement in 
the 5′ UTR displayed similar plaque morphology: HEV71-6F and 6F/5′UTR/26M 
had extremely small plaque phenotypes (less than 0.5 mm diameter), whereas 
HEV71-26M and 26M/5′UTR/6F had large plaque phenotypes (average sizes of 
more than 2 mm diameter).  Interestingly, compatibility between capsid (P1) and 
non-structural proteins (P2 and P3) of HEV71-6F and HEV71-26M were found to be 
nonreciprocal.  The HEV71-26M-based chimera with a derived 6F P1 region, 
26M/P1/6F, had a small plaque phenotype similar to that of HEV71-6F (less than 0.5 
mm).  However, the HEV71-6F-based chimera with the 26M P1 region, 6F/P1/26M, 
was also found to display a small plaque phenotype, with an average size of 0.9 
(±0.5) mm.  The HEV71-6F-based chimera with 26M P2- P3 regions, 6F/NS/26M, 
exhibited a large plaque size of 1.4 (±0.46) mm.  The plaque size of 6F/NS/26M 
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HEV71-6F 6F/P1/26M  6F/NS/26M  6F/5′UTR/26M
 
(B) 
 
 
HEV71-26M  26M/5′UTR/6F  26M/P1/6F  26M/NS/6F 
HEV71-6F  6F/5′UTR/26M   6F/P1/26M  6F/NS/26M 
26M/P1/6F  HEV71-26M  26M/NS/6F  26M/5′UTR/6F 
 
 
 
Figure 4.7  Plaque phenotype of parental HEV71-6F and HEV71-6F based chimera 
viruses on Vero (A) and RD (B)  cells.  Ten-fold serial dilutions of virus were 
inoculated at 100 μL per well in 12-well tissue culture trays.  Infected cells were 
incubated for seven days before staining with crystal violet solution.   
 
  138Table 4.2  Plaque phenotypes of parental and chimeric recombinant viruses on 
Vero cells 
 
 
Parental backbone virus 
 
 
Viruses 
 
Average diameter of 
plaques (mm)
# 
 
 
HEV71-6F 
 
HEV71-6F 
 
<0.5 
 
 
 
6F/5′UTR/26M 
 
<0.5 
 
 
 
6F/P1/26M 
 
0.9 (0.5) 
 
 
 
6F/NS/26M 
 
1.4 (0.46) 
    
    
HEV71-26M HEV71-26M  2.29  (0.78) 
  
26M/5′UTR/6F 
 
2.09 (0.76) 
  
26M/P1/6F 
 
<0.5 
  
26M/NS/6F 
 
1 (0.47) 
 
 
# Numbers in brackets = standard deviation. 
  
 
 
 
  139was, however, smaller than that of HEV71-26M.  In addition, HEV71-26M-based 
chimera with 6F P2-P3 regions, 26M/NS/6F, produced a larger plaque size than   
HEV71-6F.   The average plaque size of 26M/NS/6F is 1 (±0.47) mm.  
4.2.5.2  Growth kinetics 
The growth characteristics of parental and chimeric viruses were compared in Vero 
and RD cells.  Both Vero and RD cells were infected at a MOI of 5 TCID50/cell.  All 
assays were performed in triplicate and results are shown in Figure 4.8.   
 
Overall, similar growth characteristics were observed on Vero and RD cells.  In 
general, all viruses exhibited similar growth patterns, with titres rising from 4 h post-
infection and peaking between 10
6-10
7.7  TCID50/mL at about 12 to 16 h post-
infection.  Similar to plaque morphology results, reciprocal 5′ UTR chimeras, 
6F/5′UTR/26M and 26M/5′UTR/6F had similar growth to their parental backbone 
viruses.  HEV71-6F and 6F/5′UTR/26M produced a peak titre of 10
6 TCID50/mL in 
both Vero and RD cells, whilst HEV71-26M and 26M/5′UTR/6F replicated more 
efficiently, with peak titres of 10
7 and 10
7.7 TCID50/mL in Vero and RD cells, 
respectively.   
 
Reciprocal P1 and P2-P3 chimeras were found to display growth characteristics in 
between that of the parental backbone viruses.  In HEV71-6F-based chimera viruses, 
6F/NS/26M replicated most efficiently, with titres of 10
6.5 and 10
7.2 TCID50/mL at 12 
h post-infection in Vero and RD cells, respectively.  Chimeric virus, 6F/P1/26M, 
grew slower than that observed for 6F/NS/26M during initial stages of infection.   
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Figure 4.8  Single step growth kinetics of parental and chimeric viruses on Vero (A) 
and RD cells (B).  Cell monolayers were infected with at an MOI of 5xTCID/cell.  
Cell culture supernatants were collected at the times indicated and titrated by TCID50 
assay.  All assays were performed in triplicate.  At each time point, titres are the 
average of three samples; error bars represent the standard error of the mean. 
  141The growth rate of 6F/P1/26M at 12 h post-infection was comparable to HEV71-6F, 
with titres of 10
5.7 and 10
6.5  TCID50/mL in Vero and RD cells, respectively.   
However, this virus produced high peak titres of 10
6.7 TCID50/mL at 20 h post-
infection in Vero cells and 10
7.1 TCID50/mL at 16 h post-infection in RD cells.  In 
summary, the peak titres obtained for 6F/NS/26M were about threefold lower than 
HEV71-26M in both Vero and RD cells, and 6F/P1/26M produced two- and fourfold 
lower titres than HEV71-26M in Vero and RD cells, respectively.  Both 6F/NS/26M 
and 6F/P1/26M replicated to higher titres than the parental HEV71-6F. 
 
In HEV71-26M based chimera viruses, the titres obtained at 12 h post-infection for 
26M/NS/6F were 10
6.5 and 10
7 TCID50/mL in Vero and RD cells, respectively.   
These titres were three- and fivefold lower than the titre produced by HEV71-26M.  
Chimeric 26M/P1/6F replicated less efficiently than 26M/NS/6F, with titres at 10
6.2 
and 10
6.6 TCID50/mL in Vero and RD cells, respectively.  These titres correspond to 
six- and thirteen-fold lower than the titres observed for HEV71-26M.  Both 
26M/NS/6F and 26M/P1/6F replicated to higher titres than the parental HEV71-6F. 
 
Taken together, the results of plaque morphology and growth kinetics indicated the 
5′ UTR of both strains were compatible but not responsible for the observed 
phenotypes.  Both the P1 and P2-P3 genome regions were found to influence the 
HEV71 growth phenotype in cell culture.   
  1424.2.6  Translation efficiency of HEV71-6F and HEV71-26M 5′ 
UTR 
In order to verify the compatibility of the 5′ UTR between HEV71-6F and HEV71-
26M, the translation efficiencies of 5′ UTR of these two strains were compared using 
bi-cistronic constructs and luciferase assays.  Each bi-cistronic construct contained 
two luciferase genes; renilla luciferase (LucR) and firefly luciferase (LucF).  LucR is 
controlled by the cytomegalovirus immediate-early promoter (IE) and LucF was 
controlled by a hairpin, HEV71-6F 5′ UTR or HEV71-26M 5′ UTR for pCRHL, 
pCR6F and pCR26M, respectively. (Three bi-cistronic constructs were kindly 
provided by Dr. Chee Choy Kok, Discipline of Infectious Diseases and Immunology, 
The University of Sydney, Australia).  In vivo translation efficiencies of these three 
constructs were measured in both RD and COS-7 cells.  RD and COS-7 cells were 
seeded onto 24-well plates and incubated for 24 h on order to reach about 90% 
confluency at the time of transfection.  One microgram of each bi-cistronic construct 
and 3 μL of Lipofectamine
TM 2000 were transfected into the cells using the protocol 
described in 2.2.17.  Cells were assayed for luciferase activity at 24 h post-
transfection.  The resulting translation efficiencies are shown in Figure 4.9.  The 
translation efficiency of HEV71-6F 5′ UTR or HEV71-26M 5′ UTR was not 
significantly different in both RD and COS-7 cells (p>0.05). 
 
  143Figure 4.9  Comparative translation efficiency of 5′ UTR HEV71-6F and HEV71-
26M in COS-7 and RD cells.  Bi-cistronic constructs, pCRHL, pCR6F and pCR26M 
, were transfected into COS-7 and RD cells using Lipofectamine
TM 2000.  The 
luciferase expression was measured by luciferase assay.  Results presented represent 
the means of triplicate samples; error bars represent the standard error of the mean.    
  1444.3  Discussion 
HEV71 is a genetically diverse virus that is continuously evolving.  Most HEV71 
isolates belong to the two genotypes, B and C, which have a nucleotide similarity of 
75-84%.  We have previously observed that two HEV71 strains (HEV71-26M and 
HEV71-6F), isolated during the 1999 HFMD epidemic in Perth, Western Australia, 
displayed distinct replication kinetics during virus propagation.  These two isolates 
belong to different genetic lineages (B3 and C2) that co-circulated during the Perth 
epidemic.  To date, there has been no report on phenotypic differences between 
strains belonging to different genotypes.  In this study, we describe the distinct 
growth phenotypes of these two strains.  Genotypic and RNA secondary structure 
differences between these two strains were also investigated.  In addition, we created 
a series of chimeric viruses in order to identify the genome regions responsible for 
their respective growth phenotypes.  
 
Growth phenotypes of HEV71-6F and HEV71-26M were initially compared in terms 
of plaque morphology and growth kinetics in human (RD) and monkey kidney 
(Vero) cells.  Plaque size correlates well with viral growth kinetics.  HEV71-26M, 
which has a large-plaque phenotype, replicated to a significantly higher titre in both 
RD and Vero cells than HEV71-6F, which has a small-plaque phenotype.  In this 
study, however, the growth phenotypes at different temperatures of these two viruses 
have not yet been identified.  Further studies are needed in order to fully characterise 
growth properties of these two HEV71 strains, particularly their growth at different 
temperatures and in other human non-neuronal and neuronal cells.  Differences in 
temperature sensitivity and replication efficiency in human cell lines between two 
HEV71 strains (genotypes C) isolated from the 1998 HFMD outbreak in Taiwan 
  145have been reported (Kung et al., 2007).  The HEV71 strain TW98NTU2078 isolated 
from a patient with encephalitis, was found to be temperature-resistant and to 
replicate more efficiently in human astrocytoma (HTB-14) and human peripheral 
blood mononuclear (PBMCs) cells than the strain TW98NTU1186, isolated from a 
patient with herpangina (Kung et al., 2007).  Genetic determinants underlying 
different growth phenotypes of these two strains have not yet been identified. 
 
Interestingly, HEV71-26M was able to adapt to grow in CHO cells, while HEV71-
6F failed to adapt to CHO cells.  Further investigation is needed to understand the 
differences of CHO cell adaptation between the two strains.  It could be due to 
differences in an early event in virus replication, such as virus binding and entry, or 
in viral translation and RNA replication within the cells.  Virus binding assays and 
entry studies of these two viruses in CHO cells would help to clarify this issue.  
Additionally, HEV71-26M may have more efficient translation and replication 
mechanisms in the cellular environment of CHO cells than HEV71-6F.  In order to 
verify this hypothesis, further studies can be undertaken by transfection of viral 
RNAs of these two viruses into CHO cells and by determination of their specific-
infectivity.  In addition, HEV71 luciferase replicons, in which the P1 regions of 6F 
and 26M are replaced by the firefly luciferase gene, can be used in CHO cell 
transfection experiments.  Luciferase activity is then measured in order to determine 
replication efficiency of the viruses.    
 
We later describe how a single amino acid mutation, K
218→I, located in the EF loop 
of capsid protein VP2 is responsible for the CHO cell-adapted phenotype of HEV71-
26M (described in Chapter 5).  HEV71-6F also has the positive charged polar lysine 
  146(K) at this position.  A neutral non-polar isoleucine (I) mutation identified in CHO-
adapted HEV71-26M can be introduced into VP2 protein of HEV71-6F using the 
infectious cDNA clone in order to investigate if the K
218→I mutation confers CHO 
cell adaptation of HEV71-6F.           
 
The 5′ UTR cloverleaf structure and the stem-loop elements in 3′ region of 
enteroviruses, are highly conserved.  The cloverleaf is involved in RNA replication, 
by interacting with cellular proteins PCBP and 3CD, resulting in the formation of an 
RNA-protein (RNP) complex ((Parsley et al., 1997).  This complex functionally 
circularises the viral RNA template though its interaction with PABP on the 3′ poly 
(A) tract for the initiation of negative-strand RNA synthesis.  The IRES structure is 
essential for initiation of cap-independent translation of viral protein (Ehrenfeld & 
Teterina, 2002).  It has been suggested that the RNA secondary structures of the 3′ 
UTR are not essential for enterovirus RNA replication, but may allow for efficient 
RNA synthesis through arrangement of the enterovirus RNA on membranous 
vesicles (Todd et al., 1997).  Investigation of the predicted RNA structural folding of 
the 5′- and 3′- UTRs of HEV71-6F and HEV71-26M revealed strong similarity in 
the structures, suggesting that the 5′- and 3′- UTRs stem-loop structure may not 
influence the observed replication phenotype of HEV71-6F and 26M.  In addition, 
the translation efficiencies of these two strains were found to be similar.  Reciprocal 
5′ UTR chimeras displayed parental virus phenotypes, suggesting that the 5′ UTR of 
both strains are compatible and not responsible for the observed phenotypes.  The 
role of 3′ UTR on growth phenotype of the two viruses will need to be confirmed by 
construction of reciprocal 3′ UTR chimeras between HEV71-6F and HEV71-26M. 
 
  147The cre element was first discovered within the VP1 gene of human rhinovirus 14 
(Ref).  Similar cre structures have since been found within the 2C gene sequence of 
several enteroviruses, including PV and CBV3 (Goodfellow et al., 2000, Paul et al., 
2000, Van Ooij et al., 2006).  Cre plays a role in VPg uridylylation, which is the first 
step in viral RNA synthesis.  Cre contains a conserved loop motif, 
R
1NNNA
1A
2R
2NNNNNNR
3, with two adenylate residues within the consensus 
sequence 5′-AAACA-3′ being required for VPg uridylylation by 3D
pol ((Paul et al., 
2003).  It has been shown that disruption of the PV cre sequence resulted in a defect 
in positive-stranded RNA synthesis, but not in negative-stranded RNA synthesis 
(Goodfellow et al., 2003, Murray & Barton, 2003).  However, Van OoiJ et al. (2006) 
found that the CBV3 cre  plays an essential role in both positive- and negative- 
stranded RNA synthesis.  Putative cre elements were identified within the 2C gene 
of HEV71 by MFOLD software (Mathews et al., 1999, Zuker, 2003).  Interestingly, 
the predicted cre structure of HEV71-6F is similar to the PV cre (Goodfellow et al., 
2003), while the HEV71-26M cre structure more closely resembles the predicted 
structure of CBV3 cre (Van Ooij et al., 2006).  This structural difference is due to 
nucleotide variablility at position 13 of the conserved motif; U in HEV71-6F and A 
in HEV71-26M.  Further studies need to be undertaken in order to determine the 
effect of the structural differences in cre on replication efficiency and to determine if 
cre plays a role in the growth phenotype of these two strains.  This could be done by 
construction of reciprocal cre chimeras between HEV71-6F and HEV71-26M and by 
characterisation of the growth properties of the chimeric cre viruses.  Alternatively, 
as the cre function has been found to be position-independent (Yin et al., 2003), by 
using full-length cDNA clones, the cre of each virus can be disrupted and the cre 
from another virus can be inserted between the 5′ UTR and P1 region or the P1 and 
  148P2 regions.  These constructs will enable a functional analysis of HEV71-6F cre and 
HEV71-26M  cre  on viral RNA replication, without changing the amino acid 
sequence of the 2C protein of each virus.  In addition, the difference in VPg 
uridylylation efficiency between the predicted cre of these two viruses can also be 
determined by using an in vitro uridylylation assay.     
 
Evaluation of the cell culture growth properties of the parental (HEV71-26M and 
HEV71-6F) and chimeric recombinant viruses suggest that both the structural region 
(P1) and non-structural regions (P2 and P3) contribute to the growth phenotype of 
HEV71.  Phenotype expression is dependent on specific P1/P2-P3 combinations and 
is not reciprocal.  The underlying mechanisms of this finding require further 
investigation.  It is possible that there are differences at the early and the later stages 
of the virus replication cycle between these two HEV71 strains.  Experiments to 
define virus binding and cell entry into different cell lines, including neuronal and 
rodent cell lines, could provide evidence for the role of the capsid region (P1) in 
phenotypic differences.  A cell-free translation-RNA replication system could be a 
useful tool for investigating the role of P2 and P3 in replication efficiencies of the 
two strains, since this system allows the study of individual steps in the virus life 
cycle, except the early steps of virus attachment and entry.  Alternatively, luciferase 
replicons containing the firefly luciferase gene in place of the P1 region can also be 
used.  These systems have been used successfully in determination of PV translation 
and RNA replication (Franco et al., 2005, Toyoda et al., 2007).  More detailed 
mapping will need to be undertaken in order to define the role of the P2 and P3 
regions more fully.  
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IDENTIFICATION OF GENETIC DETERMINANTS OF 
MOUSE ADAPTATION AND VIRULENCE OF HEV71 
5.1 Introduction 
 
Human enterovirus 71 (HEV71), similar to the related poliovirus (PV), has a limited 
host range, with humans the only known natural host.  Although old world monkeys 
such as cynomolgous, rhesus and African green monkeys can be experimentally 
infected, other animal species including rodents are not susceptible to HEV71.  Thus, 
old world monkeys have provided the only useful animal model to elucidate HEV71 
pathogenesis; the high cost of monkeys and their maintenance precludes their 
widespread use for studies of viral pathogenesis.  A small animal model would 
provide a more economical and practical tool for studies of HEV71 pathogenesis and 
vaccine development. 
 
A recent study has reported the development of a mouse-adapted HEV71 strain.   
Seven-day-old mice infected with mouse-adapted HEV71 by oral, intramuscular 
(i.m.), intraperitoneal (i.p.) or intracerebral (i.c.) routes developed acute flaccid 
paralysis mimicking HEV71 infection in humans and monkeys, suggesting that a 
mouse model could be an alternative animal model for HEV71 study (Chen et al., 
2004, Wang et al., 2004).  Mouse-adapted HEV71 was more virulent in mice, 
exhibited larger plaque size and grew more rapidly in cell culture than the parental 
virus (Wang et al., 2004).  Potential virulence determinants of this mouse-adapted 
strain were identified; the 5′ untranslated region (four nucleotide changes), the 
capsid proteins VP2 (3 nucleotide and 1 amino acid changes), and the non-structural 
  150protein 2C (8 nucleotide and 4 amino acid changes) (Wang et al., 2004).  However, 
the role of these mutations in the virulence phenotype of the mouse-adapted strain 
was not determined.  
 
In order to establish a small animal model for studies of pathogenesis and for vaccine 
efficacy and immunogenicity testing, we have developed a HEV71 infection model 
using a mouse-adapted variant of strain HEV71-26M (Chua et al., 2008; see 
Appendix B).  To create a mouse-adapted strain, HEV71-26M virus was passaged 
six times in CHO cells.  A CHO-adapted variant of HEV71-26M (CHO-26M) was 
then passaged six times by i.c. inoculation of one-day-old BALB/c mice.  The 
mouse-adapted variant, MP-26M, was observed to have markedly increased 
virulence in newborn BALB/c mice compared to the parental HEV71-26M and 
CHO-26M.  Newborn mice infected with MP-26M by i.m., i.p. and i.c. routes 
developed fore- and/or hindlimb paralysis in an age- and dose-dependent manner, 
whereas HEV71-26M and CHO-26M infected mice did not develop clinical signs of 
infection at any virus dose or route of inoculation.  Tissue distribution studies using 
CHO-26M as a parental strain and MP-26M revealed that skeletal muscle was the 
primary site of replication in newborn mice for both viruses (Chua et al., 2008).   
 
Adaptation of HEV71-26M to CHO cells and mice has resulted in a number of 
nucleotide and deduced amino acid changes in the viral genome.  In order to 
understand the molecular mechanisms of mouse adaptation and virulence of HEV71-
26M, reverse genetics was used to generate mutant viruses processing specific amino 
acid alterations.  The construction and characterisation of mutant viruses in vitro and 
  151  152
in vivo is outlined in this chapter and the critical mutations that occur during CHO 
cell and mouse adaptation are identified. 
 
5.2  Results 
5.2.1  Comparison of nucleotide and deduced amino acid 
sequences of the mouse-adapted strain (MP-26M) and the 
CHO-adapted strain (CHO-26M) to their parental strain 
HEV71-26M and other HEV71 strains 
The whole genome sequencing of strains HEV71-26M, CHO-26M and MP-26M was 
performed by Beng Hooi Chua (Division of Virology, Telethon Institute for Child 
Health Research).  To identify molecular determinants of CHO cell and mouse 
adaptation, the complete nucleotide and deduced amino acid sequences of strains 
HEV71-26M, CHO-26M and MP-26M were compared.  Results obtained are 
presented in Table 5.1.  Comparison of HEV71-26M and CHO-26M sequences 
revealed four nucleotide differences, located in the VP2 (A
1400→T), VP1 (T
2739→C), 
2A (T
3531→C) and 3D (G
6981→A) genes.  Only one of these mutations resulted in a 
deduced amino acid change - in VP2 (K
218→I).  Three nucleotide sequence 
differences were identified between CHO-26M and MP-26M in VP1 (G
2876→A), 2C 
(A
4644→G, A
4727→G) and 3D (C
6429→A), which resulted in two deduced amino acid 
changes (VP1, G
710→E) and (2C, K
1327→R).  The amino acid changes K
218→I in 
VP2 and K
1327→R in 2C are unique to all HEV71 complete sequences available in 
GenBank, whereas the VP1 change (G
710→E) is not unique.  No nucleotide sequence 
changes were observed in the 5′ and 3′ UTRs.   Nucleotide Amino  acid   
Viral 
Proteins 
 
Nucleotide 
position  HEV71-
26M 
CHO-
26M 
MP-26M Other 
HEV71 
strains 
Amino 
acid 
position  HEV71-
26M 
CHO-
26M 
MP-26M Other 
HEV71 
strains 
 
VP2 
 
1400 
 
A 
 
T 
 
T 
 
A 
 
218 
 
K 
 
I 
 
I 
 
K 
 
VP1 
 
2739 
 
T 
 
C 
 
C 
 
C, T 
 
664 
 
G 
 
G 
 
G 
 
G 
 
2A 
 
2876 
 
G 
 
G 
 
A 
 
A, G 
 
710 
 
G 
 
G 
 
E 
 
E,G,Q,R,A 
 
2A 
 
3531 
 
T 
 
C 
 
C 
 
C, T 
 
928 
 
N 
 
N 
 
N 
 
N,S 
 
2C 
 
4644 
 
A 
 
A 
 
G 
 
A, C, T 
 
1299 
 
S 
 
S 
 
S 
 
S 
 
2C 
 
4727 
 
A 
 
A 
 
G 
 
A 
 
1327 
 
K 
 
K 
 
R 
 
K 
 
3D 
 
6429 
 
C 
 
C 
 
A 
 
A,C,G,T 
 
1894 
 
R 
 
R 
 
R 
 
R,S 
 
3D 
 
6981 
 
G 
 
A 
 
A 
 
A,G,T 
 
2078 
 
T 
 
T 
 
T 
 
T 
      
Table 5.1  Comparison of nucleotide and amino acid sequences of the wild-type HEV71-26M, CHO-adapted variant, CHO-
26M, mouse-adapted variant, MP-26M and other HEV71 strains 
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 5.2.2  Construction of recombinant viruses  
To determine which of the three amino acid mutations were responsible for the 
adaptation and virulence of HEV71-26M in mice, seven recombinant cDNA clones 
containing one, or a combination of two or three mutations (Figure 5.1 and Table 
2.8) were constructed by exchanging corresponding genomic regions of CHO-26M 
and MP-26M into the full-length clone of HEV71-26M using RT-PCR amplification 
and molecular cloning, as described in detail in section 2.2.15.  Two separate clones 
of each mutant were selected, and purified plasmid DNA was prepared for 
sequencing analysis.  Partial VP2, VP1 and 2C genes were sequenced to confirm the 
presence of appropriate mutations of each construct.  
 
To generate each of the mutant viruses, purified plasmid DNA from each of the 
seven clone constructs were co-transfected with pCMV-T7Pol into COS-7 cells 
using Lipofectamine
TM2000 (Invitrogen) as described in section 2.2.17.  Infectious 
clone-derived viruses were recovered from the transfected cells at three days post-
transfection and were passaged once on RD cells to generate working stocks for 
mouse virulence assays and for cell culture characterisation.  Clone-derived viruses 
are designated by the prefix CDV.  Partial VP2, VP1 and 2C gene RT-PCR and 
nucleotide sequencing was undertaken to ensure that the site-specific change/s 
remained present in the rescued virus populations.  Nucleotide sequencing showed 
that all mutant viruses, except CDV-26M-VP1m, retained the introduced mutation/s.  
Several attempts to rescue a CDV-26M-VP1m population that retained the VP1 
mutation (nt G
2876→A) were unsuccessful.  These included transfection of the full 
length clone, p26M-VP1m and passage of the rescued virus in Vero and CHO cells.   
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Figure 5.1  Schematic representation of recombinant cDNA clones containing one, 
or a combination of two or three mutations.  Genome maps of HEV71-26M and its 
variants are represented as an open box, with individual genes and non-coding 
regions indicated for HEV71-26M.  Amino acid mutations observed in CHO-26M 
(VP2, K
218→I) and MP-26M (VP2, K
218→I, VP1, G
710→  E, 2C, K
1327→R) are 
shown as open stars.  The approximate positions of the restriction enzyme sites used 
in clone construction are indicated on the HEV71-26M genome. 
  155Stocks of all recombinant viruses were found to be at titres of ≥10
6 TCID50/mL, 
except CDV-26M-VP1-2Cm, which had a titre at approximately 10
4 TCID50/mL.  
Similar to CDV-26M-VP1m, it was not possible to produce a high titre stock of 
CDV-26M-VP1-2Cm that had retained the VP1 mutation (nt G
2876→A).  Therefore, 
CDV-26M-VP1m and CDV-26M-VP1-2Cm were omitted from all subsequent 
analyses. 
5.2.3  Stability of introduced mutations during passage in 
mice and cell culture 
It is possible that the amino acid substitutions introduced during mouse adaptation 
may revert to that of the parental virus during cell culture passage (Jia et al., 2001).  
To determine if the amino acid substitutions in VP2, VP1 and/or 2C of mouse-
adapted virus revert to the wild-type sequence during passage in cell culture, the 
stability of these mutations was determined by examining the VP2, VP1 and 2C 
nucleotide sequences of MP-26M at increasing passage levels in cell culture.   
Infectious clone-derived MP-26M (CDV-MP-26M) was passaged five times in RD 
cells and viral RNA extracted from culture supernatants was collected at each 
passage level.  The VP2, VP1 and 2C genes were amplified by RT-PCR and their 
nucleotide sequences determined.  The VP2 (A
1400→T; K
218→I) and 2C (A
4727→G; 
K
1327→R) gene mutations were retained during the five passages on RD cells (Figure 
5.2).  By contrast, the VP1 (G
2876→A; G
710→E) gene mutation had reverted to the 
wild-type HEV71-26M/CHO-26M sequence by the second RD cell passage (Figure 
5.3).  Similar results were obtained after passaging CDV-MP-26M in Vero and CHO 
cells (data not shown).  These results indicated that there is a strong selective 
pressure being applied at this codon.  Due to instability of the VP1 mutation, only 
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(A) (B) 
(C) (D) 
VP2 mutation RD passage 1    VP2 mutation RD passage 5 
 2C mutation RD passage 1   2C mutation RD passage 5 
 
Figure 5.2  Stability of a mutation (A
1400→T; K
218→I) in the capsid protein VP2 and 
a mutation (A
4727→G; K
1327→R) in the non-structural protein 2C during cell culture 
passage.  Infectious clone-derived MP-26M was passaged five times in RD cells and 
viral RNA extracted from culture supernatants collected at each passage level.  The 
VP2 and 2C genes were amplified by RT-PCR and their nucleotide sequences 
determined.  (A) and (B) Sequence analysis of RT-PCR products of VP2 gene from 
virus stock RD cell passage 1 and 5.  (C) and (D) Sequence analysis of RT-PCR 
products of 2C gene from virus stock RD cell passage 1 and 5. 
  157virus stocks of the first RD cell passage were used for all in vitro and in vivo 
analysis. 
 
As the VP1 (G
710→E) mutation rapidly reverts to wild-type during passage in RD 
cells, it is possible that the VP2, VP1 and 2C mutations would also revert to wild-
type HEV71-26M/CHO-26M during passage in mice.  To examine the stability of 
these mutations in mice, CDV-MP-26M was serially passaged five times in seven-
day-old BALB/c mice by i.m. inoculation (10
4  TCID50) as described in section 
2.2.21.  Brain and limb muscle specimens were collected from mice showing clinical 
signs of HEV71 disease between four and five days post-infection.  RNA was 
extracted from brain and muscle homogenates obtained at each mouse passage, the 
VP1 and 2C genes were amplified by RT-PCR, and the amplicons sequenced.   
Similar to RD cell passage, the VP2 (K
218→I) and 2C (K
1327→R) mutations persisted 
during five passages in mice (data not shown).  Interestingly, the VP1 (G
710→E) 
mutation also persisted during mouse passage (Figure 5.4).  Viruses isolated from 
both brain and limb muscles retained these mutations.  
5.2.4  Identification of genetic determinants of CHO cell 
adaptation of HEV71 
It has been found that both HEV71-6F and HEV71-26M, cannot replicate well in 
CHO cells (data not shown).  After two passages in CHO cells, HEV71-26M titres 
had increased and after six passages in CHO cells had reached titres similar to those 
observed for HEV71-26M in primate (Vero, RD) cells.  In order to determine if the 
VP2 (K
218→I) mutation was responsible for the improved growth of virus in CHO 
cells, single-step growth analysis was undertaken in RD and CHO cells using 
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VP1 mutation RD passage 1
(A)
VP1 mutation RD passage 1
 
 
 
 
 
 
 
 
 
 
(B)
VP1 mutation RD passage 2
(B)
VP1 mutation RD passage 2
 
 
 
 
 
 
 
 
 
 
VP1 mutation RD passage 3
(C)
VP1 mutation RD passage 3
(C) (C)  
 
 
 
 
 
 
 
 
Figure 5.3  Stability of a mutation (G
2876→A; G
710→E) in the capsid protein VP1 
during passage in RD cells.  Sequence analysis of RT-PCR products of VP1 gene 
from virus stock RD cell passage 1  (A), passage 2  (B), and passage 3  (C). 
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Figure 5.4  Stability of a mutation (G
2876→A; G
710→E) in the capsid protein VP1 
during passage in mice.  CDV-MP-26M, was serially passaged five times in seven-
day-old BALB/c mice by intramuscular inoculation at a dosage of 10
4 TCID50.  Brain 
and limb muscle specimens were collected from mice showing clinical signs of 
HEV71 disease between four and five days post-infection.  RNA was extracted from 
brain and muscle homogenates obtained at each mouse passage, the VP1 gene was 
amplified by by RT-PCR, and the amplicons sequenced.  (A) and (B) Sequence 
analysis of RT-PCR products of VP1 gene from muscle homogenates at mouse 
passage 1 and 5.  (C) and (D) Sequence analysis of RT-PCR products of VP1 gene 
from brain homogenates at mouse passage 1 and 5.    
  160infectious clone-derived HEV71-26M and CHO-26M (CDV-26M-VP2m).  The 
results are shown in Figure 5.5.  The replication kinetics and virus yields of both 
viruses in RD cells are nearly identical.  By contrast, HEV71-26M replicates poorly 
in CHO cells, whereas CDV-26M-VP2m replicates efficiently, with maximum titers 
>100-fold higher than parental virus.  These results demonstrate that the amino acid 
substitution K
218→I in VP2 conferred the CHO cell-adapted phenotype on HEV71.   
5.2.5  Identification of genetic determinants of HEV71 mouse 
adaptation  
In order to determine which of the three amino acid changes is responsible for the 
mouse-adapted phenotype, mouse virulence assays of the parental and mutant 
viruses were undertaken by determination of the HD50 values and average survival 
times after i.m. and i.p. inoculation.  It was previously shown that newborn BALB/c 
mice were susceptible to the mouse-adapted strain, MP-26M, by three routes of 
inoculation; i.p., i.m. and i.c. in an age- and dose-dependent manner (Chua et al., 
2008).  HD50 values for MP-26M in seven-day-old BALB/cmice were 3.4x10
3, 
1.5x10
2, and 5x10
2 TCID50, after i.p., i.m. and i.c. inoculation, respectively (Chua et 
al., 2008).  Newborn mice remained susceptible to MP-26M infection until 14 days 
of age.  Seven-day-old BALB/c mice were chosen in all mouse virulence assays. 
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Figure 5.5  Growth kinetics of CDV-26M and CDV-26M-VP2m in RD  (A) and 
CHO  (B) cells.  Cell monolayers were infected at MOI of 5xTCID50/cell.  Cell 
culture supernatants were collected at the times indicated.  Samples at each time 
point were freeze-thawed three times and clarified by centrifugation prior to 
determination of virus titre by TCID50 assay.  All assays were performed in 
triplicate.  At each time point, titres are the average of three samples, with error bars 
representing the standard error of the mean. 
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5.2.5.1  Mortality profile and average survival time  
Groups of 8 or 12 BALB/c mice were inoculated intraperitoneally with 2x10
5 
TCID50  or intramuscularly with 1x10
4 TCID50  of each clone-derived virus 
population, including CDV-26M, CDV-26M-VP2m (CHO-26M), CDV-MP-26M, 
and three other mutant viruses, CDV-26M-2Cm, CDV-26M-VP2-2Cm, CDV-26M-
VP2-VP1m.  The dosages of 2x10
5 TCID50 and 1x10
4 TCID50 corresponded to 
approximately 60xHD50 of the i.p. route and 100xHD50 of the i.m. route for the wild-
type MP-26M (Chua et al., 2008).  Mice were observed daily and scored for the 
presence of clinical signs of infection, including ruffled fur, hunched body posture, 
fore-or hind-limb paralysis and failure to thrive, and the results are shown in Table 
5.2.   
 
As expected, the parental CDV-26M caused no detectable morbidity or mortality in 
infected mice, while the clone-derived mouse-adapted virus, CDV-MP-26M, caused 
100% mortality with a mean time to death 4 (±0) days by the i.p. route and 5 (±0) 
days by the i.m. route.  Clone-derived CHO-adapted virus, CDV-26M-VP2m, and 
CDV-26M-2Cm exhibited a non-virulent phenotype in mice compared to CDV-MP-
26M.  Neither virus caused observable clinical signs of infection and mortality in 
mice infected by the i.m. route, and only in 1 of 12 mice infected with CDV-26M-
VP2m by the i.p. route developed fore limb paralysis and succumbed to the 
infection, with a delayed time to death by six days compared to CDV-MP-26M. 
 
Two mutant viruses containing combinations of two amino acid substitutions, CDV-
26M-VP2-2Cm and CDV-26M-VP2-VP1m had markedly different mouse virulence 
phenotypes.  Mice infected with CDV-26M-VP2-2Cm by either the i.p. or i.m.   164
 
Mortality 
 
Average survival time (SD)# 
(days) 
 
Virus 
i.p. i.m.  i.p.  i.m. 
 
HD50 
i.m. 
(TCID50) 
 
CDV-26M 
 
0% (0/8) 
 
0% (0/8) 
 
>14 
 
>14 
 
>10
4 
CDV-26M-VP2m  8.3 (1/12)*  0% (0/8)  >14*  >14  >10
4 
CDV-26M-2Cm  0% (0/8)  0% (0/8)  >14  >14  >10
4 
CDV-26M-VP2-VP1m  100% (8/8)  100% (8/8)  4.0±(0.0)  4.9 (0.35)  1.6 
CDV-26M-VP2-2Cm  0% (0/8)  0% (8/8)  >14  >14  >10
4 
CDV-MP-26M  100% (8/8)  100% (8/8)  4.0±(0.0) 5±(0.0)  5 
*One mouse developed hindlimb paralysis and was sacrificed on day 10 post-infection. 
Table 5.2  Mortality profile, average survival time and HD50 of the parental and mutant viruses 
# Average survival time = number of days ± standard deviation 
 
 
 routes showed no clinical signs of infection.  By contrast, CDV-26M-VP2-VP1m 
exhibited a mouse virulence phenotype similar to CDV-MP-26M, causing 100% 
morbidity and mortality with a mean time to death of 4 (±0) days by the i.p. route 
and 4.9 (±0.35) days by the i.m. route.   
5.2.5.2  50% Humane end point (HD50) 
Due to similar mortality profiles and average survival times after i.p. and i.m. 
inoculation, HD50 values of each virus were determined only by the i.m. route.   
Groups of 8 to 10 BALB/c mice were inoculated intramuscularly with serial ten-fold 
dilutions of virus.  Mice were observed daily and scored for clinical signs of 
infection as described above and HD50 values calculated as described in section 
2.4.2.  The results are shown in Table 5.2.   
 
The HD50 value of the parental CDV-26M was greater than 10
4 TCID50 with no 
observed mortality at the lowest dilution of virus tested.  Virus populations without 
the VP1 (G
710→E) mutation; CDV-26M-VP2m, CDV-26M-2Cm, CDV-26M-VP2-
2Cm, had similar HD50 values (at >10
4 TCID50) to CDV-26M.  By contrast, the two 
virus populations that contained the VP1 mutation, CDV-26M-VP2-VP1m and 
CDV-MP-26M, had HD50 values of 1.6 and 5.0 TCID50, respectively.  The results of 
mouse virulence assays clearly demonstrated that a non-conservative amino acid 
substitution (G
710→E) in the capsid protein VP1 was alone sufficient to confer the 
mouse virulence phenotype on CDV-26M. 
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5.2.6  Other phenotypic characterisation of clone-derived 
viruses 
In an attempt to identify potential cell culture correlates of the difference in mouse 
virulence phenotype observed between clone-derived viruses containing the MP-
26M- VP1 mutation and other clone-derived viruses, the plaque morphology, growth 
kinetics in RD and NB41A3 (mouse neuroblastoma) cells and temperature sensitivity 
of CDV-26M, CDV-26M-VP2m, CDV-26M-VP2-2Cm, CDV-26M-VP2-VP1m and 
CDV-MP-26M in Vero and RD cells were compared.  Since CDV-26M-2Cm and 
CDV-26M-VP2-2Cm exhibited identical mouse virulence phenotypes, CDV-26M-
2Cm was omitted in the following experiments.  
 
5.2.6.1  Plaque morphology and temperature sensitivity 
Plaque size, which is considered a good indicator of the rate of viral replication 
(Flint et al., 2004), was determined on RD and Vero cells at 32˚C, 37˚C and 39˚C 
incubation.  The results are presented in Figure 5.6.  All viruses were observed to 
produce clearer plaques on Vero than on RD cells.  At 32˚C and 37˚C incubation, the 
parental CDV-26M, CHO-adapted CDV-26M-VP2m and CDV-26M-VP2-2Cm 
displayed a similar large plaque phenotype on both cell types.  Mean values of 
plaque diameter (in mm) of CDV-26M, CDV-26M-VP2m and CDV-26M-VP2-2Cm 
at 33˚C incubation were at 2.86 (±0.56), 3.28 (±0.83), 3.35 (±1.09), respectively, and 
were at 2.56 (±0.62), 3 (±0.75), 3.05 (±0.79), respectively, at 37˚C incubation.  By 
contrast, viruses containing VP1 mutation, including CDV-26M-VP2-VP1m and 
CDV-MP-26M, demonstrated a smaller plaque phenotype.  Mean values of plaque 
diameter of CDV-26M-VP2-VP1m and CDV-MP-26M at 33˚C incubation were at Figure 5.6  Plaque morphology of clone-derived viruses in Vero cells.  Ten-fold serial dilutions of virus were inoculated at 100 µL 
per well into 12-well tissue culture trays.  Infected cells were incubated for seven days at 33˚C, 37˚C or 39˚C before staining with 
crystal violet solution.                                           
167
CDV-26M-VP2m  CDV-26M-VP2-2Cm CDV-26M-VP2-VP1m  CDV-MP-26M  CDV-26M 
39˚
37˚
33˚
 1.06 (±0.32) and 1.13 (±0.43), respectively and were at 1.3 (±0.42) and 1.33 (±0.44), 
respectively, at 32˚C incubation.  All viruses exhibited a small plaque phenotype at 
39˚C incubation. 
 
The temperature sensitivity of the wild-type CDV-26M, CDV-26M-VP2m, CDV-
26M-VP2-2Cm, CDV-26M-VP2-VP1m, CDV-MP-26M was determined by 
comparing virus yields at 32˚C, 37˚C and 39˚C.  Temperature sensitivity was defined 
as logarithmic difference of the TCID50 values at 37˚C and 39˚C (Arita et al., 2005).  
The  Δ37/39˚C values from 2 to 2.75 are defined as slight temperature sensitive 
phenotype and more than 2.75 as strong temperature sensitive phenotype.  All of the 
viruses grew to similar titres at 32˚C and 37˚C (Table 5.3); growth impairment was 
detected in all virus populations when cultured at 39˚C.  However, none of the 
viruses exhibited a temperature sensitive phenotype. 
5.2.6.2  Single-step growth analysis in RD and NB41A3 cells 
The single-step growth kinetics of CDV-26M, CDV-26M-VP2m, CDV-26M-VP2-
2Cm, CDV-26M-VP2-VP1m, CDV-MP-26M were examined in RD and NB41A3 
cells over a 24 hour period.  Both RD and NB41A3 cells were infected at MOI of 
5xTCID50/cell.  In RD cells, CDV-26M, CDV-26M-VP2m and CDV-26M-VP2-
2Cm grew identically and produced maximum titres of approximately 10
7.5 
TCID50/mL at 12 hours post-infection (Figure 5.7).  Two viruses containing the VP1 
(G
710→E) mutation, CDV-26M-VP2- VP1m and CDV-MP-26M, grew poorly 
compared to the other viruses; peak titres were approximately 100-fold lower than 
for CDV-26M, CDV-26M-VP2m and CDV-26M- VP2-2Cm.  However, the 
maximal titres were also achieved at 12 h post-infection.  In NB41A3 cells (Figure 
  168Table 5.3  Temperature sensitivity of virus yields of clone-derived viruses on 
Vero cells 
 
Virus Titre (log10 PFU/mL)    
Virus  33˚C 37˚C 39˚C 
 
Δ37/39˚C 
# 
  
CDV-26M 6.9  6.8  6.4  1.06 
CDV-26M-VP2m 7.1  7.15  6.7  1.07 
CDV-26M-VP2-2Cm 7.1  7.0  6.4  1.1 
CDV-26M-VP2-VP1m 6.4  6.36  6.1  1.04 
CDV-MP-26M 6.5  6.5  6.1  1.07 
 
#Δ37/39˚C at 2.0-2.75 = slight temperature sensitive phenotype, at ≥ 2.75 = strong 
temperature sensitive phenotype (Arita et al., 2005) 
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Figure 5.7  Single step growth kinetics of clone-derived viruses in RD cells.  Cell 
monolayers were infected at a MOI of 5xTCID50/cell.  Cell culture supernatants were 
collected at the times indicated and titrated by TCID50 assay.  All assays were 
performed in triplicate.  At each time point, titres are the average of three samples; 
error bars represent the standard error of the mean.   
  170  5.8), similar growth kinetics was observed for viruses containing VP2 and 2C 
mutations, CDV-26M-VP2m and CDV-26M-VP2-2Cm, and for viruses containing 
VP1 mutations, CDV-26M-VP2-VP1m and CDV-MP-26M, while CDV-26M had a 
distinct growth pattern.  CDV-26M-VP2m and CDV-26M-VP2-2Cm viruses grew at 
approximately 10
6.5 TCID50/mL at 12 h post-infection, which was 10-fold higher 
than CDV-26M and 100-fold higher than CDV-26M-VP2-VP1m and CDV-26M-MP 
at the same time.  Maximum titres of all viruses occurred at approximately 20 h post-
infection. 
5.2.7  Predicted protein structure 
In order to locate the amino acid substitutions found in the capsid proteins VP2 and 
VP1 of CHO-26M and MP-26M, three-dimensional structures of VP2 and VP1 
proteins were predicted.  The virus most closely related to HEV71 by primary 
sequence, for which there are structural data, is bovine enterovirus (BEV).  The 
amino acid identity between HEV71 and BEV are 58% for VP2 and 41% for VP1, 
respectively.  The known crystallographic structure of bovine enterovirus capsid 
proteins (PDB number: 1BEV_2 for VP2 and 1BEV_1 for VP1) was therefore used 
to predict the location of the mutations found in VP2 and VP1 of CHO-26M and 
MP-26M.  The complete amino acid sequences of VP2 and VP1 from HEV71-26M, 
CHO-26M and MP-26M were individually submitted to an online automated protein 
homology modelling program, ESyPred3D 
(http://www.fundp.ac.be/sciences/biologie/urbm/bioinfo/esypred/), and the predicted 
three-dimensional structure of each of the proteins were viewed in RasMol 2.7 
(http://rasmol.org/).  The K
218→I mutation in VP2 was predicted to be located in the  
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Figure 5.8  Single step  growth kinetics of clone-derived viruses in mouse 
neuroblastoma (NB41A3) cells.  Monolayers were infected with viruses at MOI of 
5x TCID50/cell.  Cell culture supernatants were collected at the times indicated and 
titrated by TCID50 assay.  All assays were performed in triplicate.  At each time 
point, titres are the average of three samples; error bars represent the standard error 
of the mean. 
  172surfaced-exposed region of the EF loop and the VP1 (G
710→E) mutation was 
predicted to be located in the surface-exposed of the DE loop (Figure 5.9 and 5.10).  
 
5.3  Discussion 
Most HEV71 strains infect only primates and do not cause disease in mice.   
However, mouse-adapted strains of HEV71 can be selected by passage of virus in 
mouse brain (Arita et al., 2005, Chen et al., 2004, Chua et al., 2008, Ong et al., 
2008).  Adaptation has been described as the modification of an organism to make it 
more fit for existence within a certain environment (Domingo & Holland, 1997, 
Domingo et al., 1997).  RNA virus populations are complex and contain 
heterogeneous mixtures of related viral genomes called quasispecies (Domingo & 
Holland, 1997, Domingo et al., 1997).  This is due to high replicative error rates in 
RNA genomes, with mutation frequencies of 10
-3 and 10
-5 per nucleotide (Domingo 
& Holland, 1997, Domingo et al., 1997).  Quasispecies are thought to aid the 
survival of RNA virus populations in the presence of selective pressures (Domingo 
& Holland, 1997, Domingo et al., 1997).  Viruses with beneficial mutations are able 
to survive and adapt to a new environment, thus generating new quasispecies 
(Domingo & Holland, 1997, Domingo et al., 1997).  This explains why HEV71 
rapidly adapts to growth under the strong selective pressure of mouse passage.   
Nevertheless, the molecular mechanisms of host range adaptation by HEV71 have 
not been clarified.   
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Figure 5.9  Predicted three-dimentional structure of VP2 protein based on the known 
crystallographic structure of BEV (PDB no: 1BEV_2).  The structures were 
predicted using ESyPred3D program.  Amino acid residue 218 of VP2 was displayed 
as a spacefill model.  Each individual loop is shown in different colour; BC loop in 
green, DE loop in red, EF loop in cyan, FG loop in pink and HI loop in magenta.  
(A) the predicted HEV71-26M VP2 protein with lysine (polar and basic) at residue 
218 (K-218)  (B) the predicted CHO-26M VP2 protein with isoleucine (nonpolar and 
neutral) at residue 218 (I-218).  . 
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Figure 5.10  Predicted three-dimentional structure of VP1 protein based on the 
known crystallographic structure of BEV (PDB no: 1BEV_1).  The structures were 
predicted using ESyPred3D program.  Amino acid residue 710 of VP1 was displayed 
as a spacefill model.  Each individual loop is shown in different colour; BC loop in 
green, DE loop in red, EF loop in cyan, FG loop in pink and HI loop in magenta.  
(A) the predicted HEV71-26M VP1 protein with glycine (nonpolar and neutral) at 
residue 710 (G-710)  (B) the predicted MP-26M VP1 protein with glutamic acid 
(polar and acidic) at residue 710 (E-710).   
  175In this study, the molecular basis of mouse- and CHO cell-adaptation by HEV71 was 
identified by the use of a reverse genetic approach, a mouse HEV71 infection model 
and by in vitro characterisation.  A single amino acid change in VP2 (K
218→I) was 
identified between HEV71 strain 26M and its CHO-adapted variant, CHO-26M, and 
two additional amino acid changes in VP1 (G
710→E) and 2C (K
1327→R) were 
identified between HEV71-26M and its mouse-adapted variant, MP-26M.  In an 
attempt to specify genetic determinants of mouse adaptation and CHO cell 
adaptation of HEV71, recombinant cDNA clones containing one or a combination of 
two or three mutations were constructed by exchanging corresponding genomic 
regions of CHO-26M or MP-26M into the full-length infectious cDNA clone of 
HEV71-26M.  Clone-derived viruses were passaged once on RD cells prior to 
characterisation.  The use of clone-derived viruses with limited cell culture passage 
is likely to provide more homogenous virus population than wild-type virus.   
Furthermore, specific mutation/s can be introduced into the infectious cDNA clone. 
 
HEV71-26M is unable to replicate in CHO cells.  A CHO-adapted variant of 
HEV71-26M, CHO-26M, was selected after six passages in CHO cells.  Single-step 
growth analysis of clone-derived viruses HEV71-26M (CDV-26M) and CHO-26M 
(CDV-26M-VP2m) in CHO cells clearly demonstrated that the VP2 (K
218→I) 
mutation is responsible for the improved growth of HEV71-26M in this cell line.  
The VP2 protein of enteroviruses forms part of a deep cleft on the virion surface that 
may function as the site of virion attachment to the cellular receptor (Hogle et al., 
1985).  In the related PV, amino acid residues in VP2 located in the EF loop, a major 
neutralizing antigenic site, and residues on the inner surface of the N-terminus of 
VP2 have been shown to be responsible for mouse adaptation and virulence 
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located in the EF loop of VP2 confers a mouse-adapted phenotype of PV by allowing 
more efficient receptor-mediated conformation changes during viral uncoating and 
internalisation (Couderc et al., 1996).  
 
In this study, the amino acid substitution K
218→I of CHO-26M is predicted to be 
located in the surface exposed of EF loop of the VP2 protein.  Interestingly, this 
unique amino acid change was also identified in a mouse-adapted variant of HEV71 
(strain 4643) reported by Wang et al. (2004), in which the positively charged polar 
lysine was substituted by a non-polar leucine residue.  However, data from mouse 
virulence assays demonstrated that the K
218→I mutation in VP2 was not sufficient to 
confer the mouse virulent phenotype of HEV71-26M, but only conferred adaptation 
to improved growth in CHO cells.  Further investigation is needed to understand the 
mechanism by which the K
218→I mutation confers CHO cell adaptation.   
Transfection of viral RNA or cDNA of the parental HEV71-26M and CHO-26M 
(CDV-26M-VP2m) into CHO cells, virus binding assays and internalisation kinetics 
of these two viruses in CHO cells would help to clarify the mechanism by which this 
mutation confers CHO cell adaptation. 
 
A single amino acid substitution in protein 2C (K
1327→R) was also identified in MP-
26M (Chen et al., 2004).  This mutation is in a different location to the four amino 
acid substitutions identified in protein 2C of the mouse-adapted strain MP-4643 
(Wang et al., 2004).  Protein 2C is required for viral RNA synthesis.  It functions as 
a nucleotide triphosphatase (NTPase), as a director of viral replication complexes to 
cell membranes (Pfister & Wimmer, 1999, Teterina et al., 2001) and may also play a 
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sensitive PV mutant with a mutation in 2C has been shown to have a defect in 
uncoating.  In addition, a single amino acid change was identified in 2C of a PV 
strain resistant to hydantoin, a drug known to block virion assembly.  In our studies, 
mouse virulence assays clearly demonstrated that the 2C (K
1327→R) mutation was 
not responsible for the mouse virulence phenotype of HEV71-26M.  No differences 
in cell culture growth properties, plaque morphology or thermostability were 
identified between viruses expressing the wild-type (lysine) or mutant (arginine) 
residue at position 1327 in 2C, suggesting that this amino acid change does not affect 
viral RNA replication or virion assembly of HEV71.  In addition, the 2C (K
1327→R) 
is the conservative amino acid substitution.  Taken together, these data indicated that 
2C K
1327→R mutation did not play an important role in mouse adaptation of HEV71. 
 
In our study, only clone-derived viruses, CDV-26M-VP2-VP1m and CDV-MP-26M, 
containing the VP1 (G
710→E) mutation were virulent in seven-day-old BALB/c 
mice, indicating that the VP1 (G
710→E) change is a major genetic determinant of 
mouse virulence in our model.  Arita et al. (2008) recently demonstrated an identical 
mutation responsible for adaptation of HEV71 to growth in SCID/NOD mice.  This 
non-conservative (G
710→E) amino acid substitution is predicted to be located on the 
surface-exposed DE loop of capsid protein VP1.  In the related poliovirus, the DE 
loop of VP1 is located adjacent to the capsid canyon at the fivefold axis of symmetry 
(Hogle et al., 1985).  Amino acid mutations in the DE loop of the PV VP1 protein 
display altered heat-induced and receptor-mediated capsid conformation changes 
(Colston & Racaniello, 1995, Martin et al., 1991, Martin et al., 1988, Wien et al., 
1997).  In our study, a residue located in the DE loop of capsid protein VP1 appears 
  178to be solely responsible for the mouse virulence phenotype of HEV71.  Taken 
together, these data suggest that mouse adaptation by HEV71 may involve an early 
step in virus replication, in particular, a change in the specificity of receptor binding.  
It is likely that parental HEV71-26M is unable to infect mice due to an inability to 
bind or to enter mouse cells in order to initiate infection.  The VP1 (G
710→E) 
mutation may act directly by affecting interactions with mouse cellular receptor/s or 
a murine homologue of the human receptor.  Alternatively, this mutation may allow 
HEV71 to undergo mouse cell-specific post-binding capsid conformational changes 
or cell penetration, and thus enable HEV71 to overcome the host range restriction.  
Further investigation is needed to understand the mechanism by which this mutation 
confers mouse adaptation. 
 
Interestingly, the VP1 (G
710→E) mutation is not unique among HEV71 strains.  It is 
the most variable position in VP1, containing amino acids with different polarity and 
charge, positive charge (L-Arginine, L-Alanine), negative charge (L-glutamic acid), 
neutral polar (L-glutamine) and neutral non-polar (Glycine), and is not genotype-
specific.  HEV71 strain 6F has amino acid E at this position, but is not virulent in 
mice.  The nature of the amino acid at this position suggests that the VP1 (G
710→E) 
mutation may interact with other capsid proteins resulting in the change of the 
surface structure of the virion.  Moreover, it was not possible to obtain a stable 
HEV1-26M clone-derived virus population that contained only VP1 (G
710→E) 
mutation or VP1 (G
710→E) and 2C (K
1327→R) mutations due to reversion of VP1 
mutation to that of wild type HEV1-26M virus.  This suggests capsid protein 
interactions in which the VP2 (K
218→I) mutation may help to stabilize VP1 mutation 
via an as yet unknown interaction between these two capsid proteins.  The VP2 and 
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allows the recognition of a mouse cell receptor.  Alternatively, this interaction may 
facilitate a receptor-mediated conformational change during cell entry and virus 
uncoating.  The EF, DE, HI and BC loops interact with one another to form part of 
neutralisation-antigenic site 1 (Moss & Racaniello, 1991).  It has been hypothesised 
that interactions at this interface play a significant role in the dynamics of capsid-
associated receptor attachment and cell entry (Moss & Racaniello, 1991).  Thus, the 
mutations predicted in the EF loop of VP2 and the DE loop of VP1 of MP-26M may 
interact and regulate conformational transition of the virion during receptor 
attachment and cell entry.  
 
Clone-derived viruses containing the VP1 mutation, CDV-26M-VP2-VP1m and 
CDV-MP-26M, had a small plaque phenotype and grew to lower titres in cell culture 
compared to the other viruses and these defects appears to be linked to the effect on 
mouse virulence.  This differs from mouse-adapted HEV71 strain MP-4643 reported 
previously, which was shown to have larger plaque size and grew more rapidly in 
cell culture than the parental virus (Wang et al., 2004).  However, no mutation was 
identified in the VP1 protein of MP-4643 and there was only one mutation identified 
in VP2, indicating that the molecular basis of mouse adaptation and virulence of 
strains MP-4643 and MP-26M differ considerably.   
 
The small plaque phenotype and growth defects in cell culture of CDV-26M-VP2-
VP1m and CDV-MP-26M could possibly be due to low stability of the capsid.  The 
VP1 mutation was also found to be unstable during cell passage in primate (RD and 
Vero) and hamster (CHO) cells, but is stable during mouse passage.  These data 
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710→E) mutation has effects on conformational stability, and 
thus HEV71 is intolerant to this mutation, and under high selection pressure to revert 
to wild-type in RD, Vero and CHO cells.  The stability of the VP1 mutation in 
mouse cell lines needs to be further investigated.  
 
Interestingly, CDV-26M-VP2-VP1m and CDV-MP-26M also replicated to lower 
titres compared to other viruses in the mouse neuronal cell line, NB41A3.  By 
contrast, clone-derived viruses containing the VP2 mutation replicated more 
efficiently than the other viruses.  Studies in mice showed that skeletal muscle and/or 
connective tissue were the primary sites of replication for both CHO-26M and MP-
26M (Chua et al., 2008).  However, MP-26M replicated more efficiently than CHO-
26M in mouse limb muscle with approximatly 10-fold higher titres being detected in 
limb muscle of MP-26M-infected mice than CHO-26M-infected mice (Chua et al., 
2008).  CHO-26M caused mild pathological changes in muscles of infected mice 
whereas MP-26M induced severe myositis (Chua et al., 2008).  It has been suggested 
that the flaccid paralysis in MP-26M-infected mice is due to myositis, as inconsistent 
pathological changes were observed in the central nervous system (Chua et al., 
2008).  The VP2 and VP1 mutations of MP-26M have opposite affects on viral 
growth characteristics in the mouse neuronal cell line, NB41A3.  It is possible that 
the VP1 mutation enhances replication of MP-26M in muscle cells but not neuronal 
cells.  Single step growth analysis of clone-derived viruses in primary mouse muscle 
and neuronal cells would help clarify this issue. 
 
In conclusion, the molecular basis of CHO cell adaptation and mouse adaptation of 
HEV71 was characterised.  An amino acid substitution (K
218→I) located in the 
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non-conservative amino acid substitution (G
710→E) located in the surface exposed 
DE loop of VP1 was found to be a critical determinant of mouse adaptation and 
virulence of HEV71.  CHO cell and mouse adaptation determinants are likely to 
involve an early event in virus replication cycle; ie virus binding and entry into cells.  
Identification of viral genomic regions responsible for expanded host range and 
virulence greatly enhances our understanding of the biology of HEV71, and thus can 
advance research on viral pathogenesis and vaccine development for prevention and 
control of this important pathogen. 
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DEVELOPMENT OF A MOUSE HEV71 ORAL  
INFECTION MODEL 
6.1  Introduction 
The development of an animal model that mimics human disease is essential for the 
study of viral pathogenesis and the development of effective therapeutics and 
vaccines.  The first animal models for HEV71 infection were established in non-
human primates.  Cynomolgus, rhesus and green monkeys were found to be 
susceptible to HEV71 infection after subcutaneous (s.c.), intraspinal (i.s.), 
intracerebral (i.c.), intravenous (i.v.) or oral inoculation (Chumakov et al., 1979, 
Hashimoto & Hagiwara, 1982a, Hashimoto & Hagiwara, 1982b, Hashimoto et al., 
1978, Nagata et al., 2004).  HEV71 infection of monkeys induced neurological 
manifestations such as flaccid paralysis, tremor, ataxia and brain oedema similar to 
that seen in human cases.  Detailed pathological studies of infected cynomolgus 
monkeys revealed a widespread distribution of virus-induced lesions in both the 
pyramidal and extrapyramidal tracts of the CNS (Nagata et al., 2004).  The virus was 
found to replicate in the spinal cord, brainstem, cerebral cortex, dentate nuclei and 
cerebrum (Nagata et al., 2004).  However, the monkeys with brainstem lesions did 
not develop fatal neurogenic pulmonary oedema, a new clinical manifestation 
associated with brainstem encephalitis observed in human cases during recent large 
HFMD epidemics in Southeast Asia.  
 
Due to the prohibitive cost of primate experiments, several research groups have 
developed mouse models as an alternative tool for HEV71 pathogenesis studies, and 
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adult mice are not susceptible to HEV71 infection (Wu et al., 2002, Yu et al., 2000).  
However, newborn mice were found to be susceptible to infection with an unadapted 
HEV71 strain after i.p. inoculation at a high viral titre (Yu et al., 2000).  In all 
studies, a mouse-adapted HEV71 strain was required to consistently produce disease 
in newborn mice.  Mouse-adapted HEV71 strains have been reported to cause 
similar clinical signs of infection in mice up to 2 weeks old regardless of the route of 
inoculation (Chen et al., 2007, Chua et al., 2008, Ong et al., 2008).  The virus 
induced acute flaccid paralysis in an age-, dose-, and route-of-inoculation-dependent 
manner (Chen et al., 2007, Chua et al., 2008, Ong et al., 2008).  The amount of virus 
that constituted a 50% lethal dose (LD50) was lowest for i.m., followed by i.c., i.p. 
and oral inoculation, respectively (Chen et al., 2007, Chua et al., 2008).  The route of 
inoculation also affected disease course (Chen et al., 2007).  Mice infected 
intracranially developed flaccid paralysis in both fore and hind limbs and died one to 
two days after the onset of disease (Chen et al., 2007).  By contrast, intramuscular 
and orally infected mice always developed paralysis in the hind limbs and had longer 
lag times between the onset of paralysis and death (Chen et al., 2007).  Although 
mice were found to be resistant to infection with mouse-adapted strains beyond the 
age of 14 days, the mouse model was successfully used for testing vaccine 
candidates by passive immunization and determination of protective efficacy against 
lethal HEV71 challenge in susceptible newborn mice (Wu et al., 2002).             
          
We have developed a HEV71 infection model in newborn BALB/c mice by i.c., i.m. 
and i.p. inoculation with a mouse-adapted variant of HEV71-26M (MP-26M) (Chua 
et al., 2008).  Consistent with the studies reviewed above, our mouse-adapted strain 
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BALB/c mice.  Infectivity studies established skeletal muscle as the primary site of 
replication.  Histological studies showed intense inflammation within infected 
muscle groups.  Virus was isolated from the brain although there was no obvious 
virus-induced lesion in the CNS.  More detailed pathological studies, including 
immunohistochemistry and in situ hybridization assays will need to be carried out in 
order to provide more insight into the involvement of the CNS and the mechanism of 
virus spread.   
 
As the oral route is a natural route of HEV71 infection in human beings, a mouse 
HEV71 oral infection model would serve as the valuable tool for studying HEV71 
pathogenesis, and for vaccine or antiviral efficacy testing.  We aimed to establish a 
mouse HEV71 oral infection model for future studies, particularly for defining 
virulence determinants, and for testing of vaccine efficacy and immunogenicity.  The 
preliminary results are described in this chapter.  
 
6.2  Results  
6.2.1  Determination of stomach emptying time  
To optimise the duration of fasting prior to oral infection of suckling mice with virus 
we determined gastrointestinal transit time in newborn mice.  Stomach emptying in 
adult mice has an exponential decay constant of 74 min and gastric emptying time is 
within 6 h (Schwarz et al., 2002).  In newborn mice, however, this information is not 
known.   
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milk containing phenol red at about 20-30 µL (30 mL/kg body weight) using plastic 
feeding tubes.  Groups of two mice were sacrificed immediately (time = 0 h) and at 
1, 2, and 4 h after feeding.  Stomach and intestinal contents were observed, and 
gastric emptying time was determined using the method described in section 2.4.2.  
The extent of gastric emptying was 27%, 40% and 52% after feeding for 1, 2, and 4 
h respectively.  A fasting time of 2 hours was chosen for subsequent experiments to 
minimize physiological stress, which could affect clinical observation of HEV71 
infection in newborn mice.   
6.2.2  Effect of blue food dye on HEV71 infectivity 
To ensure that mice were cleanly inoculated via the stomach, blue food dye was used 
to visualise the virus inoculum in the stomach and to allow monitoring of virus 
deposits in other regions.  It was first necessary to detect if blue food dye inhibited 
HEV71 infectivity.  Serial virus dilutions were mixed with blue food dye at a final 
concentration of 0%, 0.1%, 0.5%, 1% or 2% (v/v), and the suspensions incubated at 
37°C for 1 h prior to determination of virus titre by TCID50 assay (see section 2.3.2).  
Blue food dye was observed to have no adverse effect on HEV71 infectivity (Table 
6.1).  Hence, blue food dye was added to each virus dilution at a final concentration 
of 1% (v/v) prior to oral inoculation of mice in all subsequent experiments.  At this 
concentration, virus inoculum could be readily observed in the stomach of mice after 
each inoculation.      
  186Table 6.1  Effect of blue food dye on HEV71 infectivity 
 
 
Concentration of blue food dye in virus 
dilution  
(% v/v) 
 
Viral titre ∗ 
(TCID50/mL) 
  
0 6.8x10
6 
0.1 4.7x10
6 
0.2 5.6x10
6 
1 1.0x10
7 
2 6.8x10
6 
 
∗Determined by TCID50 assay on Vero cells. 
  1876.2.3  Infectivity of a mouse-adapted variant of HEV71-26M 
(MP-26M) in one-day old BALB/c mice after oral infection 
Experimental infection with MP-26M via i.c., i.p. and i.m. routes caused lethal 
illness in one-day old BALB/c mice.  Infected mice developed fore- and/or hindlimb 
paralysis, hunched back, dehydration and eventual death (Chua et al., 2008).  The 
50% humane end-points (HD50) for the i.c., i.p. and i.m. routes of infection were 
5.0×10
2, 3.4×10
3 and 1.5×10
2 TCID50, respectively (Chua et al., 2008).  In order to 
develop a HEV71 oral infection model, groups of 5-6 one-day-old BALB/c mice 
were orally infected with MP-26M virus at increasing doses, ranging from 5×10
3 to 
5×10
6 TCID50 per dose, after fasting for 2 h.  Mice were observed daily for clinical 
signs of HEV71 infection; control animals were inoculated with phosphate-buffered 
saline (PBS).  Similar to other routes of inoculation, MP-26M-infected mice 
displayed fore-and/or hindlimb paralysis, hunched back, and dehydration.  Mice 
succumbed to infection 5 to 11 days after inoculation.  Oral inoculation with MP-
26M also resulted in dose-dependent mortality (Figure 6.1).  The HD50 value for the 
oral route was 5×10
5 TCID50, which was higher than the HD50 values for other routes 
of inoculation.  Experimental infection of one-day- old BALB/c mice with parental 
(unadapted) HEV71 (5×10
6 TCID50) by the oral route produced no clinical signs of 
infection. 
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Figure 6.1.  Percentage survival of one-day-old BALB/c mice after oral infection 
with MP-26M.  Groups of 5-6 one-day-old BALB/c mice were orally infected with 
MP-26M virus at increasing doses (from 5x10
3 to 5x10
6 TCID50).  Control animals 
were inoculated with phosphate-buffered saline (PBS).  Mice were observed for 14 
days post-infection and the percentage survival calculated. 
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oral infection 
In order to determine whether susceptibility of newborn mice to HEV71 infection 
after oral inoculation is age-dependent, groups of 5-8 newborn mice were infected 
orally with MP-26M at 5×10
6 TCID50 (ten times the HD50 value) at increasing ages 
(day 1, 2, 3, 5, 7, 9 and 14).  Mice were observed daily for clinical signs of infection 
and survival and mortality rates for the different age groups were recorded.  The 
results are shown in Figure 6.2.  Mice were susceptible to oral infection with MP-
26M until 14 days of age.  Similar mortality profiles were observed in mice of 1, 3 
and 5 days of age.  The first deaths occurred at 5 days post-infection, and 100% 
mortality was reached by day 6.  In mice inoculated at 9 and 11 days of age, the first 
deaths occurred on days 6 and 7 post-infection and the groups had 66.7% and 50% 
mortality, respectively. 
 
6.3  Discussion 
In this study, an oral inoculation model for HEV71 infection in mice was 
established.  Similar to previous studies (Chen et al., 2007, Chen et al., 2004, Chua et 
al., 2008, Wang et al., 2004), BALB/c mice were susceptible to MP-26M infection 
via the oral route in an age- and dose-dependent manner.  Mice orally infected with 
the parental strain HEV71-26M developed no clinically overt disease, whereas MP-
26M infected mice developed fore and/or hind limb paralysis.  Chen et al. (2004) 
found that newborn ICR mice infected orally with an unadapted HEV71 strain 
(HEV71-4643) developed skin lesions characterised as desquamation and 
cicatrisation.  However, we did not observe skin lesions in mice infected orally with 
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Figure 6.2  Age-related survival of BALB/c mice orally infected with MP-26M. 
Groups of 5-8 BALB/c mice were infected orally at the indicated ages with ten HD50 
(5x10
6 TCID50) of MP-26M.  Mice were observed for 14 days post-infection and the 
percentage survival calculated. 
  191HEV71-26M.  This discrepancy may be due to the different virus and/or host strains 
used in this study.  Generally, however, the clinical manifestations of the mouse-
adapted strain MP-26M infection we observed were consistent with previous studies 
(Chen et al., 2007, Chen et al., 2004, Chua et al., 2008, Wang et al., 2004). 
 
The HD50 for oral inoculation is much higher than that observed for other routes of 
inoculation.  This may be explained by the fact that the virus has to overcome unique 
physical barriers in the alimentary tract.  By using poliovirus receptor (PVR)-
expressing mice lacking the interferon α and β receptor (PVR-IFNAR
-/-) and 
artificial quasispecies pool of ten distinct genetically marked viruses, Kuss et al. 
(2008) demonstrated that physical barriers play a major role in limiting the spread of 
poliovirus (PV) in orally infected mice.  Three major bottleneck barriers that affect 
virus trafficking inside the host were identified, including mouth to gut, mouth to 
blood and mouth to brain.  Following oral inoculation of PVR-IFNAR
-/- with ten 
genetically marked viruses, only 16% and 19% of input viruses were present in the 
stomach, and small intestine and colon, respectively, indicating physical barriers in 
gut tissues.  In addition, only 9% and 21% of input viruses were detected in blood 
and brain, respectively.  These two bottlenecks, mouth to gut and mouth to blood, 
could be partially overcome by physical disruption of colon epithelium.   
Interestingly, the bottleneck barriers were largely absent in the PVR-IFNAR
-/- mice 
inoculated via i.m. and i.p. routes.  The physical barriers that the HEV71 virus must 
overcome in the alimentary tract might explain the high HD50 observed for oral 
inoculation compared to other routes of inoculation.  The age-related resistance to 
oral inoculation may be due to cell maturation in tissues and/or development of the 
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Roos et al., 1978).  
 
The mechanism of CNS penetration by enteroviruses remains to be elucidated.   
Virus could gain entry to the CNS via the peripheral nerves that innervate the wall of 
the alimentary tract and/or secondary infected muscles and visceral organs 
(Blinzinger & Anzil, 1974, Sabin, 1956).  Alternatively, virus could enter the 
bloodstream and then penetrate the CNS by passage across the blood-brain barrier 
(Blinzinger et al., 1969, Bodian, 1955).  Both PV and HEV71 are neurotropic 
enteroviruses and are spread by fecal-oral transmission.  In humans, PV infection is 
initiated by ingestion of the virus (Sabin, 1956).  The virus first infects and 
multiplies in the oropharyngeal and alimentary mucosa (Bodian & Horstmann, 1965, 
Sabin, 1956).  The virus then enters the deep cervical and mesenteric lymph nodes 
from where it is released into the blood, causing a transient viremia (Bodian & 
Horstmann, 1965).  Replication at extraneural sites, including brown fat, 
reticuloendothelial tissues and muscle is thought to sustain viremia (Bodian & 
Horstmann, 1965, Ren & Racaniello, 1992, Wenner & Kamitsuka, 1957).  Serum 
neutralizing antibody to PV prevents the development of poliomyelitis, suggesting 
that viremia is necessary for the spread of virus into the CNS (Bodian & Horstmann, 
1965).  Thus, the blood-brain barrier pathway is considered the primary route by 
which poliovirus disseminates to the CNS.  However, dissemination via a neural 
pathway has also been reported in several studies in humans, primates, and in the 
transgenic mouse model (Nathanson & Bodian, 1961, Nathanson & Langmuir, 1995, 
Ohka et al., 1998).  Furthermore, another neurotropic enteric virus, Reovirus 
serotype 3, spreads from the intestinal tract directly to regional nerves innervating 
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(Morrison et al., 1991).      
 
The pathway for HEV71 entry into the CNS remains unknown.  Using a murine oral 
infection model, Wang et al. (2004) showed that the virus first replicates in the 
intestine.  Virus replication was then observed in the limb muscles and spinal cord, 
followed by the brain.  Limb muscles were found to be a major site for viral 
replication and maintenance of viremia.  The authors suggested that viremia was 
necessary for the spread of virus into the CNS, because anti-HEV71 antibodies could 
protect HEV71-infected mice from developing disease.  Neuroinvasion was probably 
preceded by virus replication in extraneural tissues.  However, the pattern of spread 
of the virus from the lower to upper segments of the spinal cord also suggested a 
neural transmission pathway, such as retrograde axonal transport.  A recent study of 
a mouse model has shown that HEV71 entered the CNS via peripheral motor nerves 
after i.m. inoculation, and its spread in the CNS involved motor and other neural 
pathways (Ong et al., 2008).  To date, the route of entry into the CNS and the 
neuropathology of HEV71 infection has not been clearly defined.  More detailed 
histopathological studies will help provide more information on the pathogenesis of 
HEV71 infection.  A well-characterised mouse oral infection model could enhance 
antiviral and vaccine efficacy testing. 
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GENERAL DISCUSSION 
Since its first discovery in 1969, Human Enterovirus 71 (HEV71) has been 
associated with several large outbreaks of hand, foot and mouth disease in young 
children.  While hand, foot and mouth disease is a common clinical manifestation, 
HEV71 occasionally causes severe neurological diseases during acute infection, 
including aseptic meningitis, brainstem and/or cerebellar encephalitis, and acute 
flaccid paralysis, which may lead to permanent paralysis or death (McMinn, 2002).  
Since 1997, several large epidemics of HEV71 infection have continued to occur in 
many countries in the Asia-Pacific region including Malaysia, Taiwan, Australia, 
Vietnam, Singapore, Thailand, India, Brunei, Hong Kong and China (Cardosa et al., 
2003, Ho, 2000, Lin et al., 2006, McMinn et al., 2001b, Tu et al., 
2007)(http://www.promedmail.org, http://www.cdc.gov).  Interestingly, these recent 
outbreaks have been associated with an increasing incidence of cases with 
neurological complications.  A new severe clinical manifestation of HEV71 
infection, a fatal neurogenic pulmonary oedema associated with brainstem 
encephalitis, has also been identified (Ho, 2000, Lum et al., 1998).  HEV71 is now 
considered the leading cause of acute neurological infection in children in the Asia-
Pacific region (Daley & Dwyer, 2002, Palacios & Oberste, 2005, Wong et al., 2000).  
Due to the increase in prevalence and the severe nature of HEV71-associated 
neurological disease, investigations into the molecular genetics of virulence have 
become important areas of research.  This knowledge is essential for the 
development of vaccines for prevention and control of HEV71 infection. 
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been considerably advanced by the development of infectious cDNA clones.   
Infectious cDNA clones have been produced for a number of enteroviruses, 
including poliovirus (PV), CAV9, CBV3 and Echovirus 7 (Cello et al., 2002, Chua, 
2007, Harvala et al., 2002, Martino et al., 1999).  Such clones serve as useful tools 
for the analysis of molecular basis of enterovirus replication and virulence (Dan & 
Chantler, 2005, Harvala et al., 2002, Johnson & Sarnow, 1991), and will continue to 
provide much insight into the molecular biology of enteroviruses and the nature of 
enterovirus attenuation.  Infectious clones have also been used as the basis for the 
design and production of live-attenuated vaccines in several studies (Dan & 
Chantler, 2005, Gromeier et al., 1996, Haller et al., 1996).   
 
In this study, infectious cDNA clones of HEV71-6F (genotype C2) and HEV71-26M 
(genotype B3), two strains isolated during the 1999 Western Australian HFMD 
outbreak, were successfully constructed.  Selection of appropriate plasmid vectors 
and bacterial host strains was found to be the most critical for the construction of 
infectious cDNA clones of HEV71.  All full-length cDNA clones of HEV71-6F, 
constructed in a medium copy number plasmid pBR322 and propagated in E. coli 
strain DH5α, were found to be non-infectious.  One of the clones was fully 
sequenced and compared to the HEV71-6F sequence in order to identify the 
problem.  Sequencing revealed eight amino acid mutations located in both structural 
and non-structural proteins, and two stop codons, located in the VP3 and 2A 
proteins.  These mutations are likely to have been introduced into the viral genome 
by the bacterial host in order to decrease the expression of HEV71 proteins toxic to 
the host cell.  The medium copy number of pBR322 may have exceeded the 
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Genetic instability of the cloned cDNA has been described for several RNA viruses, 
particularly flaviviruses and coronaviruses (Masters, 1999, Mishin et al., 2001, Rice 
et al., 1989, Sumiyoshi et al., 1992), but has not been well documented for 
enteroviruses.  The instability problem encountered in the construction of HEV71-6F 
infectious cDNA clones was overcome by using a combination of low copy number 
plasmid pMC18 and bacterial host strain XL10-gold.  This protocol was also 
successfully used for generating infectious cDNA clone of HEV71-26M.  The reason 
why XL10-gold is more suitable for propagating cDNA clones of HEV71 than the 
other two strains, DH5α and DH10B, remains unclear.  Clone-derived viruses 
(CDV) of HEV71-6F and HEV71-26M were successfully obtained by transfection of 
plasmid cDNA into susceptible cells.  Analysis of the in vitro phenotype of both 
clone-derived viruses illustrates the integrity of the infectious clone system.  CDV-
6F and CDV-26M were found to display in vitro growth properties indistinguishable 
from their respective parental viruses.   
 
Interestingly, the two HEV71 strains, HEV71-6F and HEV71-26M, were found to 
have distinct cell culture growth phenotypes.  HEV71-26M replicated more 
efficiently than HEV71-6F in both human (RD) and monkey (Vero) cell lines.   
HEV71-26M exhibited a large plaque phenotype and was able to adapt to grow in 
rodent (CHO) cells.  By contrast, HEV71-6F displayed a pinpoint plaque phenotype 
and failed to adapt to grow in CHO cells.  Further study will need to be undertaken 
in order to determine temperature sensitivity and growth phenotype of these two 
strains in other cells of human origin.     
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phenotypes of the two strains.  Chimeric recombinant viruses carrying reciprocal 
exchanges of HEV71-6F and HEV71-26M 5′ UTR, structural protein genes (P1 
region) and non-structural protein genes (P2 and P3 regions) were generated and 
growth properties of the parental and chimeric viruses in cell culture were compared.  
Reciprocal 5′ UTR chimeras (6F/5′ UTR/26M and 26M/5′ UTR/6F) exhibited 
similar growth patterns to their parental backbone virus.  Secondary structures of 5′ 
UTR of these two strains were also highly similar.  In addition, the translation 
efficiencies of 5′ UTR of these two strains were not significantly different in both 
human (RD) and monkey (COS-7) cells.   Taken together, these data indicate that the 
5′ UTR is not responsible for distinct growth phenotypes between these two strains.  
Reciprocal P1 and P2-P3 chimeras displayed growth phenotypes in between that of 
the parental backbone virus, indicating that both P1 and P2-P3 genome regions 
influence the HEV71 growth phenotype in cell culture.  These results suggest that 
differences in growth characteristics between HEV71-6F and HEV71-26M may 
involve both early (binding and entry) and RNA replication steps.  Further 
investigations will need to be undertaken in order to verify this hypothesis.  A cell 
binding and viral cell entry assays may help to clarify the role of the capsid protein 
P1 in phenotypic differences.  Experiments to define viral RNA synthesis, such as 
the use of a cell-free translation-RNA replication system, the HEV71 luciferase 
replicons or quantitative real-time PCR, would help to determine the role of P2 and 
P3 in growth phenotype of these two strains.  In addition, the role of cre and 3′ UTR 
on phenotypic differences will need to be confirmed by construction of reciprocal 
cre or 3′ UTR chimeras between HEV71-6F and HEV71-26M.  This work will 
provide much insight into the molecular basis of HEV71 replication. 
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known natural host.  Non-human primate models have long been the most suitable 
animal models to study the pathogenesis of both PV and HEV71.  Since the 
identification of the cell receptor for PV, PVR (CD155), transgenic mice possessing 
the PVR have been developed (Koike et al., 1994, Ren et al., 1990).  PVR transgenic 
mice have eliminated the need for primates, and have become the definitive small 
animal model for most experimental procedures, providing new information on PV 
pathogenesis and serving as tool for vaccine testing (Koike et al., 1994, Koike et al., 
1991, Ren & Racaniello, 1992, WHO, 1998).  Unfortunately, the HEV71 cellular 
receptor has not been identified, thus no HEV71-receptor-expessing-transgenic-mice 
are available.  With limited resource of monkeys, several recent studies have 
developed a mouse model as an alternative animal model for HEV71 infection by 
using mouse-adapted variants of HEV71 (Arita et al., 2008, Chen et al., 2004, Chua 
et al., 2008, Ong et al., 2008).  A previous study by our group (Chua et al., 2008), 
has established a mouse HEV71 infection model using a mouse-adapted variant of 
HEV71-26M (MP-26M).  MP-26M was created by serial passage of HEV71-26M in 
CHO cells, and CHO-adapted virus (CHO-26M) was then serially passaged for six 
times by intracerebral inoculation of one-day-old BALB/c mice.  Despite improved 
growth in CHO cells, CHO-26M did not cause any clinical signs of infection in 
newborn BALB/c mice.  By contrast, infection of newborn mice with MP-26M 
resulted in severe disease and death in an age-, dosage- and route-dependent manner.   
 
In Chapter 5, the molecular basis of CHO cell- and mouse- adaptation was 
determined.  A single amino acid substitution within the VP2 capsid protein 
(K
218→I) was identified in CHO-26M.  Two further amino acid mutations were 
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710→E) and the 2C 
protein (K
1327→R).  No nucleotide sequence changes were observed in the 5′- and 3′-
UTRs.  By comparison with amino acid sequences of other HEV71 strains, the 
amino acid changes K
218→I in VP2 and K
1327→R in 2C are found to be unique, 
whereas the G
710→E in VP1 is not unique.  In order to study the molecular basis of 
CHO cell- and mouse- adaptation, infectious cDNA clone-derived mutant virus 
populations containing the mutations identified in CHO-26M and MP-26M were 
generated, and these clone-derived viruses (CDV) were characterised in cell culture 
and in the mouse model.  Data obtained from our study clearly demonstrated that the 
VP2 (K
218→I) mutation is responsible for the improved growth of HEV71-26M in 
CHO cells, and the VP1 (G
710→E) is a major genetic determinant of mouse 
adaptation.  Interestingly, the only capsid protein mutation identified in the mouse-
adapted virus selected by Chen et al. (2004) was located at the same position in VP2, 
with the positively charged lysine residue substituted by a non-polar leucine.   
Moreover, an identical mutation in VP1 (G
710→E) was identified in the mouse-
adapted virus selected by Arita et al. (2008).  Repeated selection at these amino acid 
positions in VP2 and VP1 strongly indicates that these amino acid residues play an 
essential role in the infection cycle of HEV71 in rodent cells, expanding host range 
of HEV71.   
 
Both amino acid substitutions in VP2 (K
218→I) and VP1 (G
710→E) are predicted to 
be located in surface exposed loops; K
218→I in the EF loop of VP2 and G
710→E in 
the DE loop of VP1.  The finding that a CDV population that contains only the 
G
710→E mutation is unstable due to reversion to the wild-type sequence after a 
single passage in RD cells suggests that the VP2 residue I
218 may help to stabilize the 
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710 via an as yet unknown interaction between these two capsid 
proteins.  The VP2 and VP1 interaction may cooperate to introduce structural change 
in the virion that either allows the recognition of a mouse cell receptor or may 
facilitate receptor-mediated conformational changes after attachment.    
 
Taken together, these data suggested that CHO cell- and mouse- adaptation 
determinants are likely to involve an early step in virus replication, particularly a 
change in the specificity of receptor binding.  Further study is needed to understand 
the mechanisms by which the amino acid mutations, VP2 (K
218→I) and VP1 
(G
710→E), confer CHO cell- and mouse- adaptation.  Cell binding assays and 
internalization kinetics of the parent HEV71-26M and CHO-26M (CDV-26M-VP2) 
in CHO cells would help to clarify the mechanism by which the VP2 (K
218→I) 
confers CHO cell adaptation.  Similarly, virus cell binding assays and internalization 
kinetics of HEV71-26M, and viruses expressing the VP1 (G
710→E) mutation in cell 
lines of mouse origin, in particular, mouse muscle and neuronal cells will need to be 
undertaken in order to determine the mechanism by which this mutation confers 
mouse adaptation. 
 
In a previous study by our research group (Herrero, 2007), identification of the 
HEV71 cell surface receptor was attempted by using Virus Overlay Protein Binding 
Assays (VOPBA) and MALDI-TOF MS.  This approach has been used successfully 
for the identification of cellular receptor for a number of viruses, such as dengue 
virus (Tio et al., 2005).  Preliminary VOPBA results showed that HEV71 bound to a 
55kDa/pI 5, 40kDa/pI 6 and 32kDa/pI 7 proteins expressed on the plasma membrane 
of RD cells (Herrero, 2007).  This method is being optimised in our research group.  
  201Preliminary analysis of these proteins by MALDI-TOF MS did not result in matches 
to any characterised proteins in the MASCOT or MS fit seach engines.  These data 
are being analysed against other search engines.  If this approach is successful in the 
identification of the HEV71 cellular receptor, it will be useful to identify mouse 
homologue receptors of HEV71 in future studies.  Experiments can be carried out by 
performing VOPBA and MALDI-TOF MS using mouse cell lines, particularly 
muscle and neuronal cells, and mouse-adapted virus MP-26M.   
 
Although a mouse model is not as good as a monkey model for studying HEV71 
pathogenesis due to the need to select mouse-adapted strains for infection of mice, it 
is, however, currently the most convenient animal model and has served as a useful 
tool for testing of vaccine efficacy and immunogenicity.  For example, Yu et al. 
(2000) has shown that passive immunization with inactivated HEV71 was able to 
protect newborn mice against HEV71 infection.  In addition, Wu et al. (2007) 
demonstrated that active immunization with avirulent HEV71 or CAV16 by the oral 
route could protect newborn mice against infection with virulent HEV71.   
Furthermore, a recent study by Ong et al. (2008) has shown that a model of HEV71 
infection in 2 week-old mice can be used to study pathogenesis of HEV71 infection, 
particularly in viral transmission pathways and mechanisms of neuronal damage. 
 
The natural route of HEV71 infection in human is the oral route.  Given that a well-
characterised mouse infection model will provide more information on the 
pathogenesis of HEV71 infection and provide a useful tool for development of 
vaccines, we thus aimed to establish a mouse HEV71 oral infection model and the 
preliminary results are described in Chapter 6.  BALB/c mice orally infected with a 
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other routes of inoculation.  Mice were also susceptible to MP-26M infection via an 
oral route in an age- and dose-dependent manner.  This mouse oral infection model 
will need to be thoroughly characterised pathologically in a future study. 
 
In summary, the work described in this thesis has contributed to the understanding of 
the molecular biology of HEV71.  A reverse genetic system developed in this study 
has proven to be an invaluable tool for the study of molecular mechanisms of 
replication and virulence.  Infectious cDNA clones can be used for further study on 
viral genetic elements that control viral translation and replication processes.  The 
impact of these processes and the role of viral genetic elements on determination of 
viral neurovirulence can therefore be determined.  This information will provide a 
genetic basis for the development of a live, attenuated vaccines for control of this 
important neurotropic virus. 
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  226APPENDIX 
Full length sequence HEV71-6F (DQ381846) 
TTAAAACAGCCTGTGGGTTGCACCCACCCACAGGGCCTACTGGGCGCTAGCACTCTGGCACTGAGGTACC 
TTTGTGCGCCTGTTTTGACTTCCCTTCCCCGAAGTAACTTAGAAGCTGTAAATCAACGATCAATAGTAGG 
TGTGACACACCAGTCATATCTTGATCAAGCACTTCTGTTTCCCCGGACTGAGTATCAATAGGCTGCTCGC 
GCGGCTGAAGGAGAAAACGTTCGTTACCCGACCAACTACTTCGAGAAGCTTAGTACCACCATGAACGAGG 
CAGAGTGTTTCGTTCAGCACAACCCCAGTGTAGATCAGGCTGATGAGCCACTGCAACCCCCATGGGCGAC 
CATGGCAGTGGCTGCGTTGGCGGCCTGCCCATGGAGAAATCCATGGGACGCTCTAATTCTGACATGGTGT 
GAAGAGCCTATTGAGCTAGCTGGTAGTCCTCCGGCCCCTGAATGCGGCTAATCCTAACTGCGGAGCACAT 
GCTCACAAACCAGTGGGTGGTGTGTCGTAACGGGCAACTCTGCAGCGGAACCGACTACTTTGGGTGTCCG 
TGTTTCCTTTTATTCTTATATTGGCTGCTTATGGTGACAATCAAAGAATTGTTACCATATAGCTATTGGA 
TTGGCCATCCGGTGTGCAACAGAGCAATTGTTTACCTATTTATTGGTTTTGTACCATTATCACTGAAGTC 
TGTGATCACTCTCAAATTCATTTTGACCCTCAACACAACCAAATATGGGCTCACAGGTGTCCACACAACG 
CTCCGGTTCGCATGAAAACTCTAACTCAGCTACCGAGGGTTCCACTATAAATTATACTACCATTAATTAC 
TATAAAGACTCCTATGCCGCCACAGCAGGTAAACAGAGTCTCAAGCAAGACCCAGACAAGTTTGCAAATC 
CCGTCAAAGACATCTTCACTGAAATGGCGGCGCCATTAAAATCTCCATCCGCTGAGGCATGTGGTTACAG 
CGATCGGGTAGCACAATTAACTATTGGCAACTCTACCATCACTACACAAGAAGCAGCAAACATCATAGTT 
GGCTATGGTGAGTGGCCTTCCTACTGCTCGGATTCTGACGCTACAGCGGTGGACAAACCAACGCGCCCAG 
ATGTTTCGGTGAATAGGTTTTACACATTGGACACTAAACTGTGGGAGAAATCATCCAAGGGGTGGTACTG 
GAAATTCCCGGATGTGTTAACTGAAACCGGGGTCTTTGGTCAAAATGCGCAGTTCCACTACCTCTATCGG 
TCAGGGTTCTGCATTCACGTGCAGTGCAATGCTAGTAAGTTCCACCAAGGAGCACTCCTAGTCGCTGTCC 
TCCCAGAGTATGTCATTGGGACAGTAGCAGGTGGCACAGGGACGGAGGATAGCCACCCTCCTTACAAGCA 
GACTCAACCCGGTGCTGATGGCTTCGAGCTGCAACACCCGTACGTGCTTGATGCTGGCGTTCCAATATCA 
CAATTAACAGTGTGCCCACATCAGTGGATTAATTTGAGGACTAACAATTGTGCCACAATAATAGTACCGT 
ACATAAACGCACTACCCTTTGATTCTGCCTTGAACCATTGTAACTTTGGTCTGCTGGTTGTGCCTATTAG 
CCCGTTAGATTATGACCAAGGTGCGACGCCAGTGATCCCCATTACTATCACCCTGGCCCCAATGTGTTCT 
GAATTTGCAGGCCTTAGACAAGCAGTTACGCAAGGGTTTCCTACTGAGCTGAAACCTGGCACAAACCAAT 
TTTTAACCACTGACGATGGCGTCTCAGCACCCATTCTGCCAAACTTCCACCCCACCCCGTGTATCCATAT 
ACCCGGTGAAGTTAGAAACTTGCTAGAGCTATGCCAGGTGGAGACCATTTTAGAGGTCAACAATGTACCC 
ACGAATGCCACTAGCTTAATGGAGAGATTGCGCTTCCCGGTCTCAGCCCAAGCCGGAAAAGGTGAATTAT 
GTGCAGTGTTCAGAGCTGACCCCGGGCGAAGTGGACCATGGCAGTCCACCTTGTTGGGCCAGTTGTGCGG 
GTACTACACCCAATGGTCAGGATCACTGGAAGTCACCTTCATGTTCACTGGGTCCTTTATGGCTACCGGC 
AAGATGCTCATAGCATACACACCACCAGGAGGTCCCTTACCCAAGGACCGGGCGACCGCCATGTTGGGTA 
CGCACGTCATCTGGGACTTTGGGCTGCAATCGTCTGTCACCCTTGTAATACCATGGATCAGCAACACTCA 
CTACAGAGCGCACGCTCGAGATGGTGTGTTTGACTACTACACTACAGGTTTGGTTAGCATATGGTACCAG 
ACGAATTACGTGGTTCCAATTGGGGCACCCAATACAGCCTATATAATAGCATTGGCGGCAGCCCAGAAGA 
ATTTCACCATGAAGTTGTGCAAGGATGCTAGTGATATCCTACAGACAGGCACTATCCAGGGAGATAGGGT 
GGCAGATGTGATTGAGAGTTCTATAGGGGACAGTGTGAGCAGAGCCCTCACCCGAGCTCTACCGGCACCT 
ACAGGTCAAGATACGCAGGTAAGTAGCCATCGATTGGATACTGGTAAAGTTCCAGCACTCCAAGCCGCTG 
AAATTGGAGCATCATCAAATGCTAGTGATGAGAGCATGATTGAGACGCGATGTGTTCTTAATTCACATAG 
CACAGCTGAGACCACTCTTGATAGCTTCTTCAGCAGAGCAGGATTAGTTGGAGAGATAGACCTTCCTCTT 
AAAGGCACAACCAACCCGAATGGGTATGCAAACTGGGACATAGACATAACAGGTTACGCGCAAATGCGTA 
GAAAGGTGGAGTTGTTCACCTACATGCGTTTTGACGCAGAGTTCACCTTTGTTGCATGCACGCCTACCGG 
GGAAGTTGTCCCGCAATTGCTCCAGTATATGTTTGTACCACCCGGAGCCCCCAAACCAGACTCCAGAGAA 
TCTCTCGTATGGCAGACTGCCACTAATCCCTCAGTCTTTGTGAAGCTGTCAGACCCCCCAGCACAGGTTT 
CAGTACCATTCATGTCACCTGCAAGCGCCTATCAATGGTTCTATGACGGGTATCCCACATTCGGTGAACA 
CAAGCAGGAGAAAGACCTTGAATACGGGGCATGCCCAAATAACATGATGGGTACGTTTTCAGTGCGGACT 
GTAGGAACCTCGAAGTCCAAGTACCCATTGGTGATCAGGATTTACATGAGGATGAAGCATGTCAGGGCGT 
GGATACCTCGCCCAATGCGCAACCAAAACTATCTATTCAAAGCCAACCCAAATTATGCTGGCAACTCCAT 
TAAACCAACTGGTGCCAGTCGCACAGCTATCACCACCCTCGGGAAATTTGGACAACAGTCCGGGGCCATC 
TACGTGGGCAACTTCAGAGTGGTCAACCGCCATCTTGCTACTCATAACGACTGGGCAAACCTTGTTTGGG 
AGGACAGCTCCCGCGATTTGCTCGTATCATCTACCACTGCCCAAGGTTGTGACACAATTGCTCGTTGCAA 
TTGCCAGACAGGAGTGTACTATTGTAACTCAATGAGAAAACACTATCCTGTCAGTTTCTCGAAACCCAGC 
TTGATCTTCGTAGAGGCCAGTGAGTATTACCCGGCTAGATACCAGTCACACCTCATGCTTGCAGTGGGTC 
ACTCAGAACCAGGGGATTGCGGTGGCATTCTTAGATGCCAACACGGCGTCGTAGGGATAGTTTCCACCGG 
GGGAAACGGCCTGGTGGGATTCGCCGATGTGAGGGATCTTCTGTGGTTGGATGATGAGGCTATGGAGCAG 
GGCGTGTCTGATTACATCAAAGGGCTTGGAGATGCTTTTGGCATGGGGTTTACAGACGCAGTGTCAAGAG 
AAGTTGAAGCATTAAAAAATCACTTGATCGGCTCAGAGGGTGCCGTGGAGAAGATTCTTAAGAACTTAGT 
CAAACTCATCTCTGCGCTCGTCATTGTCATCAGGAGTGATTATGACATGGTCACATTAACGGCAACACTT 
GCCCTGATCGGGTGCCACGGGAGCCCTTGGGCCTGGGTTAAATCGAAGACAGCATCAATTTTGGGCATAC 
CGATGGCTCAGAAGCAGAGTGCCTCTTGGTTAAAGAAGTTCAACGATGCGGCGAGTGCCGCTAAGGGGCT 
  227TGAGTGGATCTCCAACAAAATCAGCAAATTTATCGATTGGCTCAAGGAGAAAATCATTCCGGCTGCTAAA 
GAGAAAGTCGAGTTTCTAAACAATCTAAAGCAACTCCCCTTATTGGAGAACCAAATTTCCAATCTCGAAC 
AGTCAGCAGCTTCGCAGGAGGACCTTGAAGCGATGTTTGGCAACGTGTCTTATCTGGCCCACTTCTGCCG 
CAAATTCCAACCCCTCTATGCCACAGAAGCGAAGAGGGTGTACGCCCTAGAAAAGAGAATGAATAATTAC 
ATGCAGTTCAAGAGCAAACACCGTATTGAACCTGTATGCCTAATCATTAGAGGCTCGCCTGGTACTGGGA 
AGTCCTTGGCAACAGGGATTATTGCTAGAGCTATAGCAGACAAGTACCACTCCAGTGTGTATTCCTTACC 
TCCGGACCCAGACCACTTTGACGGATACAAACAACAGATCGTCACTGTTATGGACGACCTATGCCAAAAC 
CCAGACGGGAAAGACATGTCACTATTTTGTCAGATGGTCTCCACAGTGGATTTTATACCGCCTATGGCAT 
CTCTGGAGGAGAAGGGAGTCTCATTTACCTCCAAGTTTGTGATCGCCTCCACAAACGCCAGTAACATCAT 
AGTGCCAACAGTCTCGGATTCAGATGCCATCCGTCGTCGGTTCTTTATGGACTGTGATATTGAGGTAACT 
GATTCCTATAAGACAGAGCTGGGCAGGCTTGATGCAGGGAGAGCAGCTAGGCTGTGCTCTGAGAACAACA 
CTGCTAACTTTAAACGGTGCAGTCCATTGGTCTGTGGGAAAGCAATCCAGCTTAGGGATAGGAAGTCCAA 
GGTGAGATACAGTGTGGACACGGTAGTGAGTGAGCTTGTCAGGGAGTATAACAACAGATCAGTTATTGGG 
AACACCATTGAAGCTCTTTTCCAAGGGCCCCCTAAATTTAGACCGATAAGGATTAGCCTAGAGGAGAAGC 
CCGCACCTGATGCTATTAGTGACCTATTAGCTAGTGTCGATAGTGAAGAGGTTCGCCAATACTGTAGAGA 
TCAGGGATGGATTGTACCTGACTCTCCCACCAACGTTGAGCGCCACTTAAACAGAGCTGTCTTGATTATG 
CAATCTGTAGCCACCGTGGTAGCGGTTGTGTCCCTTGTTTACGTTATCTACAAGTTGTTCGCCGGTTTTC 
AAGGAGCATACTCCGGCGCCCCCAAGCAAACACTCAAGAAACCAGTGCTGCGCACGGCAACTGTGCAGGG 
GCCGAGCTTGGACTTCGCCCTATCTCTACTTAGGAGGAACATTAGGCAGGTCCAAACCGACCAGGGCCAC 
TTTACAATGTTAGGAGTGCGAGACCATTTGGCTGTGCTCCCCAGGCACTCCCAACCAGGAAAGACCATCT 
GGGTTGAACACAAGTTAGTGAAGGTCGTAGATGCTGTGGAGCTAGTAGATGAACAAGGGGTTAACCTAGA 
GCTCACACTGGTAACGCTTGACACCAACGAAAAATTTAGAGACATCACAAGATTCATACCAGAAACAATT 
AGTCCTGCTAGTGATGCCACTTTAGTTATAAATACTGAACATATGCCCAGTATGTTTGTGCCAGTTGGAG 
ATGTGGTCCAGTATGGATTTTTGAACCTTAGTGGTAAGCCCACTCACAGGACTATGATGTACAATTTTCC 
AACAAAAGCAGGACAGTGTGGTGGAGTTGTGACTGCCGTGGGTAAGGTGATTGGGATCCACATTGGTGGC 
AACGGTAGGCAAGGTTTCTGCGCTGCCCTGAAGAGGGGATACTTTTGCAGTGAACAAGGTGAGATCCAAT 
GGATGAAGCCCAACAAAGAAACTGGCAGGTTGAACATCAACGGACCTACTCGCACTAAGCTTGAACCAAG 
TGTCTTTCACGATGTGTTCGAGGGCACTAAAGAGCCAGCAGTGCTGACTAGTAAAGACCCAAGGCTGGAA 
GTTGACTTTGAACAGGCTCTTTTTTCAAAATACGTGGGAAACACGCTTCATGAACCCGACGAGTTTGTCA 
AGGAGGCGGCCTTACATTATGCCAACCAACTCAAGCAGTTAGATATTAAGACCACCAAGATGAGCATGGA 
GGATGCTTGTTACGGTACAGAGAACCTGGAAGCTATAGATCTTCACACAAGTGCAGGATATCCATATAGT 
GCACTAGGCATCAAGAAAAGGGATATTTTGGACCCAACAACTCGTGATGTCAGCAAAATGAAATCCTACA 
TGGACAAGTATGGGTTGGATCTACCGTACTCTACTTATGTTAAAGATGAACTCAGGGCCATCGACAAGAT 
CAAGAAAGGAAAGTCTCGTCTCATAGAAGCAAGCAGTCTAAATGACTCAGTGTACTTGAGAATGACATTT 
GGGCACCTTTATGAAGCCTTTCACGCCAATCCAGGTACAGTCACTGGTTCAGCTGTTGGATGCAACCCAG 
ATGTGTTCTGGAGTAAGTTACCAATTCTACTTCCAGGATCGCTTTTTGCGTTTGACTACTCGGGGTATGA 
CGCTAGTCTCAGCCCAGTGTGGTTCAGGGCGCTGGAGATAGTCCTGCGGGAAATTGGATACTCTGAGGAC 
GCACTGTCTCTCATAGAAGGGATCAATCATACCCACCATGTGTACCGCAATAAAACTTATTGTGTTCTTG 
GGGGAATGCCCTCAGGTTGCTCAGGCACCTCCATTTTCAACTCGATGATCAACAACATTATTATTAGGAC 
ACTCCTGATTAAAACATTCAAAGGGATAGATCTAGATGAATTGAACATGGTGGCCTACGGGGATGATGTG 
TTGGCTAGTTACCCCTTCCCAATTGACTGTCTAGAATTGGCGAGAACAGGCAAGGAGTATGGTTTAACTA 
TGACCCCTGCCGACAAGTCACCCTGCTTTAATGAAGTCACATGGGAGAATGCCACTTTCTTGAAGAGAGG 
ATTCTTGCCTGATCATCAATTCCCGTTCCTCATCCACCCTACGATGCCAATGAGGGAGATTCACGAGTCC 
ATTCGTTGGACCAAAGATGCACGAAGTACCCAAGATCATGTGCGCTCCCTCTGCTTATTAGCATGGCACA 
ACGGGAAAGAGGAGTATGAAAAATTTGTGAGTACAATCAGATCAGTTCCAATTGGAAAAGCATTGGCTAT 
ACCAAATTTTGAGAACCTGAGAAGAAATTGGCTCGAATTGTTTTAAATTTACAGTTCATAACTGAACCCC 
ACCAGTAATCTGGTCGTGTTAATGACTGGTGGGGGTAAATTTGTTATAACCAGAATAGC 
 
 
 
 
  228Full length sequence of HEV71-26M (EU364841) 
TTAAAACAGCCTGTGGGTTGCACCCACTCACAGGGCCCACGTGGCGCTAGCACTCTGATTCTACGGAATC 
TTTGTGCGCCTGTTTTACAACCCCCCCCCAATTTGCAACTTAGAAGCAATACACAACACTGATCAACAGC 
AGGCATGGCGCACCAGCCATGTCTTGATCAAGCACTTCTGTTTCCCCGGACTGAGTATCAATAGACTGCT 
CACGCGGTTGAAGGAGAAAGCGTCCGTTATCCGGCTAACTACTTCGAGAAACCTAGTAGCACCATTGAAG 
CTGCGGAGTGTTTCGCTCGGCACTTCCCCCGTGTAGATCAGGCCGATGAGTCACTGCAATCCCCACGGGC 
GACCGTGGCAGTGGCTGCGCTGGCGGCCTGCCTATGGGGCAACCCATAGGACGCTCTAATGTGGACATGG 
TGCGAAGAGTCTATTGAGCTAGTTAGTAGTCCTCCGGCCCCTGAATGCGGCTAATCCTAACTGCGGAGCA 
CATGCCCTCAACCCAGAGGGTAGTGTGTCGTAACGGGCAACTCTGCAGCGGAACCGACTACTTTGGGTGT 
CCGTGTTTCCTTTTATTCTTACATTGGCTGCTTATGGTGACAATCACAGAATTGTTACCATATAGCTATT 
GGATTGGCCATCCGGTGTGCAATAGAGCTATTATACACCTATTTGTTGGCTTTGTACCACTAACCTTAAA 
ATCTATAACCACCCTCAACTTTATATTAACTCTCAATACAGTCAAACATGGGCTCACAAGTGTCTACTCA 
GCGATCCGGCTCCCACGAGAACTCCAATTCAGCTACGGAAGGCTCTACCATTAATTACACTACCATCAAC 
TATTACAAAGACTCCTATGCTGCAACAGCAGGCAAACAGAGCCTCAAACAAGACCCTGATAAGTTTGCTA 
ACCCTGTCAAGGATATTTTCACTGAAATGGCTGCGCCACTGAAGTCTCCATCCGCTGAAGCTTGTGGTTA 
TAGTGATCGTGTGGCACAACTCACCATTGGAAACTCCACCATTACTACACAGGAGGCGGCAAACATCATA 
GTCGGTTATGGTGAGTGGCCCTCATATTGCTCTGATGACGATGCTACAGCGGTGGATAAACCAACGCGCC 
CAGATGTGTCAGTGAATAGGTTTTATACATTGGACACCAAACTGTGGGAAAAATCATCTAAGGGGTGGTA 
TTGGAAGTTTCCTGATGTTTTGACTGAGACCGGAGTCTTTGGCCAGAACGCACAGTTTCACTATTTATAT 
AGATCAGGGTTTTGCATTCATGTGCAATGTAATGCTAGCAAGTTCCATCAAGGAGCGCTGTTAGTCGCTA 
TTCTTCCAGAGTATGTTATAGGGACAGTGGCAGGCGGCACAGGTACAGAGGACAGCCACCCTCCTTACAA 
ACAAACGCAACCTGGCGCTGATGGTTTTGAGCTGCAGCACCCGTACGTGCTCGATGCTGGGATTCCTATA 
TCACAACTGACGGTGTGCCCCCATCAATGGATTAATCTGCGGACCAATAACTGTGCCACGATAATAGTGC 
CATATATGAACACACTGCCTTTCGACTCTGCCCTGAACCATTGCAATTTTGGGCTGTTGGTAGTGCCCAT 
TAGCCCATTAGATTTTGACCAAGGGGCAACTCCGGTTATCCCTATTACAATCACTCTAGCTCCAATGTGC 
TCTGAGTTTGCAGGTCTCAGACAGGCAGTCACTCAAGGCTTCCCTACTGAGCCAAAACCAGGAACAAATC 
AATTTTTGACCACCGATGACGGCGTCTCAGCACCCATTCTACCAAATTTCCACCCCACTCCATGTATTCA 
CATACCCGGTGAAGTCAGAAACCTGCTTGAGTTGTGTCAAGTGGAGACTATTCTTGAGGTTAACAACGTA 
CCCACCAATGATACCAGTTTGATGGAAAGGCTACGATTCCCAGTGTCTGCGCAAGCGGGGAAAGGTGAAT 
TGTGTGCCGTGTTTAGGGCCGACCCTGGAAGGGACGGTCCATGGCAATCAACAATGCTGGGCCAGCTGTG 
TGGATACTACACCCAGTGGTCAGGGTCACTGGAGGTCACTTTTATGTTTACCGGGTCTTTTATGGCCACG 
GGTAAAATGCTCATAGCCTATACACCTCCTGGTGGCCCCTTACCTAAAGACCGGGCCACAGCAATGCTGG 
GCACGCATGTTATCTGGGATTTTGGGTTACAATCATCTGTCACCCTTGTGATACCATGGATCAGTAACAC 
CCACTACAGAGCGCATGCCCGGGACGGAGTGTTCGATTACTATACCACAGGACTGGTCAGTATCTGGTAT 
CAAACAAACTACGTAGTTCCAATTGGGGCACCCAATACAGCTTACATAATAGCACTAGCGGCAGCCCAGA 
AGAACTTTACCATGAAACTGTGCAAAGACACTAGTCACATATTACAGACAGCCTCCATTCAGGGAGATAG 
GGTGGCAGATGTGATCGAGAGCTCTATAGGAGATAGTGTGAGTAGAGCACTTACCCAGGCCCTGCCAGCA 
CCCACAGGTCAAAACACACAGGTGAGCAGTCATCGACTAGACACTGGCGAAGTTCCAGCGCTTCAAGCTG 
CTGAAATTGGGGCATCGTCAAATACTAGTGATGAGAGTATGATTGAAACACGGTGCGTTCTTAACTCACA 
CAGCACAGCAGAAACCACCTTGGATAGCTTCTTCAGTAGGGCAGGTTTGGTAGGGGAGATAGATCTCCCT 
CTTGAGGGTACTACTAATCCGAATGGTTATGCCAACTGGGATATAGACATAACTGGTTACGCACAGATGC 
GCAGGAAAGTGGAGTTGTTCACCTACATGCGCTTTGATGCGGAATTCACTTTTGTTGCGTGCACTCCCAC 
CGGCGGGGTTGTTCCACAATTACTCCAGTATATGTTTGTTCCCCCTGGTGCTCCCAAACCAGAATCTAGA 
GAATCACTTGCTTGGCAAACAGCCACAAACCCCTCAGTTTTTGTCAAGTTGACTGATCCCCCAGCACAGG 
TCTCAGTTCCATTCATGTCACCTGCGAGCGCTTACCAGTGGTTTTACGACGGGTACCCCACGTTTGGAGA 
ACATAAACAGGAGAAAGACCTTGAATATGGAGCGTGTCCTAATAACATGATGGGCACTTTCTCGGTGCGA 
AATGTGGGGTCATCAAAGTCCAAGTACCCTCTGGTTGTCAGAATATATATGAGAATGAAGCATGTCAGGG 
CATGGATACCTCGCCCGATGCGCAACCAAAACTACTTGTTCAAAGCCAATCCGAACTACGCTGGCAACTC 
CATTAAGCCGACCGGCACTAGCCGTACTGCCATTACTACCCTTGGAAAGTTCGGCCAGCAATCTGGGGCC 
ATCTACGTGGGCAACTTCAGAGTGGTTAATCGTCACCTCGCTACTCATAATGACTGGGCGAATCTCGTCT 
GGGAAGACAGCTCCCGCGACCTACTAGTGTCGTCTACCACTGCCCAGGGCTGTGATACAATTGCACGTTG 
TGACTGTCAAACAGGAGTGTACTATTGTAATTCTAAGAGAAAGCACTATCCAGTCAGCTTCTCTAAACCT 
AGCCTCATTTATGTGGAAGCTAGCGAGTATTACCCTGCTAGATACCAGTCTCATCTCATGCTTGCGGCGG 
GCCATTCTGAACCAGGAGATTGTGGTGGCATCCTTAGGTGCCAGCACGGTGTTGTCGGCATTGTGTCCAC 
TGGTGGCAATGGGCTTGTTGGCTTTGCAGATGTCAGGGATCTCCTATGGTTGGATGAAGAAGCAATGGAG 
CAGGGTGTGTCCGACTACATTAAGGGACTTGGTGATGCGTTTGGAACTGGCTTCACCGATGCAGTTTCCA 
GAGAAGTTGAGGCTCTTAAGAACCACCTTATTGGGTCTGAGGGAGCTGTCGAGAAGATCCTAAAGAATTT 
GATCAAATTAATCTCTGCTTTAGTCATCGTGATTAGGAGTGATTATGACATGGTCACTCTCACAGCAACT 
TTAGCTCTGATAGGGTGCCACGGTAGTCCCTGGGCATGGATTAAAGCAAAAACAGCTTCCATTCTAGGCA 
TCCCTATTGCCCAGAAGCAAAGTGCGTCCTGGCTTAAAAAGTTTAACGATATGGCCAACGCCGCCAAGGG 
GTTAGAGTGGATCTCCAGTAAGATTAGTAAATTCATCGATTGGCTCAAAGAGAAAATCATACCAGCGGCT 
AGGGAGAAGGTGGAGTTTCTGAACAACTTAAAACAGTTGCCGTTGTTGGAGAATCAGATCTCAAATCTAG 
AGCAGTCTGCTGCTTCACAAGAAGATCTTGAAGCCATGTTCGGAAATGTGTCGTACCTAGCTCACTTCTG 
CCGCAAATTCCAACCACTGTACGCTACAGAAGCCAAAAGGGTCTATGCTTTGGAGAAAAGAATGAACAAC 
  229TACATGCAGTTCAAGAGCAAACACCGAATTGAACCTGTATGTCTTATTATTAGGGGTTCTCCGGGCACCG 
GGAAATCACTAGCAACTGGCATCATTGCTCGGGCAATAGCAGACAAGTATCACTCAAGTGTGTACTCACT 
CCCACCAGACCCGGATCACTTTGATGGATACAAACAGCAGGTGGTCACGGTCATGGATGACTTATGTCAG 
AATCCTGATGGCAAAGATATGTCATTGTTCTGCCAGATGGTGTCCACAGTGGATTTCATCCCACCAATGG 
CTTCCCTAGAAGAGAAAGGAGTTTCTTTCACATCTAAATTTGTCATTGCATCTACCAATTCCAGCAACAT 
CATAGTACCAACAGTGTCTGATTCTGATGCAATTCGCCGTAGGTTCTATATGGATTGTGATATCGAAGTC 
ACGGATTCATATAAAACGGACTTGGGTAGGTTAGATGCTGGGCGAGCCGCCAAATTGTGCTCTGAGAATA 
ACACAGCAAATTTCAAGCGTTGTAGCCCACTAGTGTGTGGGAAGGCCATTCAGCTGAGAGATAGAAAGTC 
CAAGGTCAGGTACAGTGTGGACACGGTGGTTTCTGAGCTCATAAGGGAATACAACAACAGGTCTGCTATT 
GGTAACACAATTGAAGCACTATTCCAAGGTCCGCCTAAGTTTAGACCCATAAGGATCAGTCTTGAAGAAA 
AGCCAGCCCCAGACGCCATTAGTGACCTTCTTGCTAGTGTGGATAGCGAGGAGGTACGCCAGTACTGTAG 
AGATCAAGGTTGGATCATACCAGAGACTCCTACAAATGTTGAACGGCACCTCAACAGAGCTGTGCTAGTC 
ATGCAATCCATCGCTACAGTTGTGGCAGTCGTTTCACTGGTGTATGTCATCTACAAGCTCTTCGCTGGAT 
TCCAAGGCGCGTACTCTGGTGCTCCCAAGCAGATACTTAAGAAACCCGTTCTCCGCACGGCAACAGTACA 
GGGTCCAAGTCTCGATTTCGCTCTGTCTCTACTGAGGAGGAATATCAGGCAAGTGCAAACAGATCAAGGA 
CATTTCACCATGCTGGGTGTCAGGGACCGTTTGGCTGTTCTTCCACGCCACTCCCAGCCCGGCAAAACAA 
TCTGGGTAGAGCACAAACTCGTAAACATTCTGGACGCTGTTGAACTGGTGGATGAACAAGGGGTTAATTT 
GGAGCTAACCCTAATCACCCTTGACACTAATGAGAAATTCAGAGACATTACTAAGTTCATCCCAGAGAGC 
ATCAGCGCTGCAAGCGATGCTACCCTAGTGATCAACACAGAGCACATGCCCTCAATGTTTGTGCCGGTGG 
GAGACGTTGTGCAATATGGTTTTCTCAACCTCAGTGGAAAGCCAACCCACCGTACCATGATGTACAACTT 
TCCCACCAAGGCAGGGCAGTGTGGAGGGGTGGTGACATCAGTTGGAAAGGTCATTGGTATACACATAGGT 
GGTAACGGCAGACAAGGTTTCTGTGCGGGACTTAAGAGGAGCTACTTCGCCAGCGAGCAAGGAGAGATCC 
AGTGGGTCAAGCCCAATAAAGAAACTGGGAGACTCAACATCAATGGGCCAACTCGCACTAAGCTCGAACC 
CAGTGTATTTCATGATGTTTTTGAGGGAAACAAGGAGCCAGCAGTTCTACACAGTAAAGATCCCCGCCTC 
GAGGTGGATTTTGAGCAGGCTTTGTTCTCCAAGTACGTAGGGAATACACTATATGAGCCTGATGAGTACA 
TTAAGGAGGCAGCTCTTCACTATGCAAATCAGTTGAAACAGCTAGACATTGACACCTCCCAGATGAGCAT 
GGAGGAAGCCTGTTACGGCACTGAGAACCTTGAGGCCATTGACCTTCACACTAGTGCAGGCTACCCATAC 
AGTGCTCTAGGAATAAAGAAAAGAGACATCCTAGATTCTACTACTAGGGATGTGAGCAAGATGAAATTTT 
ATATGGACAAGTATGGCTTGGACCTTCCCTACTCCACCTATGTCAAGGATGAGCTACGCTCGATAGATAA 
GATCAAGAAGGGGAAGTCTCGTTTGATTGAAGCCAGCAGCTTAAATGATTCTGTGTACCTTAGGATGACT 
TTTGGGCACCTTTATGAAACCTTCCATGCAAACCCTGGAACTGTGACCGGCTCGGCCGTGGGATGCAATC 
CGGATACATTCTGGAGTAAACTACCCATCTTACTCCCTGGCTCACTCTTTGCTTTCGACTATTCAGGATA 
TGATGCTAGTCTTAGCCCTGTCTGGTTCAGAGCATTGGAATTAGTTCTTAGGGAAATAGGCTACAGTGAG 
GAAGCAGTTTCACTTGTTGAGGGGATCAATCACACACACCATGTATACCGCAACAAAACTTACTGTGTGC 
TTGGTGGCATGCCCTCTGGTTGCTCAGGAACATCCATATTCAATTCAATGATCAATAACATTATTATTAG 
AGCACTGCTCATCAAAACGTTCAAGGGCATTGATTTAGACGAGCTCAACATGGTTGCCTACGGGGATGAT 
GTGCTTGCCAGTTACCCTTTTCCAATTGACTGTTTGGAGTTGGCAAGAACGGGCAAGGAGTACGGTTTAA 
CCATGACTCCTGCAGACAAATCCCCATGCTTCAATGAAGTCAATTGGGATAACGCAACCTTTCTCAAAAG 
AGGCTTCTTGCCCGATGAACAATTTCCATTCCTTATCCACCCTACCATGCCAATGAAAGAAATCCACGAG 
TCCATACGGTGGACCAAGGACGCGCGAAATACCCAAGATCACGTGCGGTCCTTGTGCCTTCTGGCATGGC 
ACAATGGTAAACAGGAATATGAAAAGTTTGTGAGCGCAATTAGATCAGTACCAGTAGGAAAAGCATTGGC 
TATTCCAAATTATGAGAATCTGAGACGCAATTGGCTCGAACTATTCTAGAGGTTAAGTATATACCTCAAC 
CCCACCAGGAATCTGGTCGTGAACATGACTGGTGGGGGTAAATTTGTTATAACCAGAATAGC 
 
 
 
  230